ID EPHA3_HUMAN Reviewed; 983 AA. AC P29320; Q9H2V3; Q9H2V4; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 240. DE RecName: Full=Ephrin type-A receptor 3; DE EC=2.7.10.1; DE AltName: Full=EPH-like kinase 4; DE Short=EK4; DE Short=hEK4; DE AltName: Full=HEK; DE Short=Human embryo kinase; DE AltName: Full=Tyrosine-protein kinase TYRO4; DE AltName: Full=Tyrosine-protein kinase receptor ETK1; DE Short=Eph-like tyrosine kinase 1; DE Flags: Precursor; GN Name=EPHA3; Synonyms=ETK, ETK1, HEK, TYRO4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-924. RX PubMed=1311845; DOI=10.1073/pnas.89.5.1611; RA Wicks I.P., Wilkinson D., Salvaris E., Boyd A.W.; RT "Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase RT expressed by human lymphoid tumor cell lines."; RL Proc. Natl. Acad. Sci. U.S.A. 89:1611-1615(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Melanoma; RX PubMed=10987298; RA Chiari R., Hames G., Stroobant V., Texier C., Maillere B., Boon T., RA Coulie P.G.; RT "Identification of a tumor-specific shared antigen derived from an Eph RT receptor and presented to CD4 T cells on HLA class II molecules."; RL Cancer Res. 60:4855-4863(2000). RN [3] RP PROTEIN SEQUENCE OF 21-29 AND 840-860, AND CHARACTERIZATION. RX PubMed=1737782; DOI=10.1016/s0021-9258(19)50725-6; RA Boyd A.W., Ward L.D., Wicks I.P., Simpson R.J., Salvaris E., Wilks A., RA Welch K., Loudovaris M., Rockman S., Busmanis I.; RT "Isolation and characterization of a novel receptor-type protein tyrosine RT kinase (hek) from a human pre-B cell line."; RL J. Biol. Chem. 267:3262-3267(1992). RN [4] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [5] RP FUNCTION IN CELL-CELL ADHESION, EFNA5-BINDING, SUBCELLULAR LOCATION RP (ISOFORM 1), INTERACTION WITH CRK, AND PHOSPHORYLATION AT TYR-596; TYR-602 RP AND TYR-779. RX PubMed=11870224; DOI=10.1242/jcs.115.5.1059; RA Lawrenson I.D., Wimmer-Kleikamp S.H., Lock P., Schoenwaelder S.M., Down M., RA Boyd A.W., Alewood P.F., Lackmann M.; RT "Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing RT 293T and melanoma cells by CrkII and Rho-mediated signalling."; RL J. Cell Sci. 115:1059-1072(2002). RN [6] RP FUNCTION. RX PubMed=12794130; DOI=10.4049/jimmunol.170.12.6024; RA Sharfe N., Freywald A., Toro A., Roifman C.M.; RT "Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation RT in T cells."; RL J. Immunol. 170:6024-6032(2003). RN [7] RP INVOLVEMENT IN CRC. RX PubMed=12738854; DOI=10.1126/science.1082596; RA Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., RA Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Mutational analysis of the tyrosine kinome in colorectal cancers."; RL Science 300:949-949(2003). RN [8] RP EPHRIN LIGAND-BINDING, OLIGOMERIZATION, MUTAGENESIS OF VAL-133 AND PHE-152, RP AND INTERACTION WITH CRK. RX PubMed=14660665; DOI=10.1074/jbc.m309326200; RA Smith F.M., Vearing C., Lackmann M., Treutlein H., Himanen J., Chen K., RA Saul A., Nikolov D., Boyd A.W.; RT "Dissecting the EphA3/Ephrin-A5 interactions using a novel functional RT mutagenesis screen."; RL J. Biol. Chem. 279:9522-9531(2004). RN [9] RP IDENTIFICATION IN A COMPLEX WITH ADAM10 AND EFNA5. RX PubMed=16239146; DOI=10.1016/j.cell.2005.08.014; RA Janes P.W., Saha N., Barton W.A., Kolev M.V., Wimmer-Kleikamp S.H., RA Nievergall E., Blobel C.P., Himanen J.P., Lackmann M., Nikolov D.B.; RT "Adam meets Eph: an ADAM substrate recognition module acts as a molecular RT switch for ephrin cleavage in trans."; RL Cell 123:291-304(2005). RN [10] RP EFNA5 LIGAND-BINDING. RX PubMed=15901737; DOI=10.1074/jbc.m504972200; RA Day B., To C., Himanen J.P., Smith F.M., Nikolov D.B., Boyd A.W., RA Lackmann M.; RT "Three distinct molecular surfaces in ephrin-A5 are essential for a RT functional interaction with EphA3."; RL J. Biol. Chem. 280:26526-26532(2005). RN [11] RP INTERACTION WITH PTPN1, PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN1, AND RP SUBCELLULAR LOCATION (ISOFORM 2). RX PubMed=21135139; DOI=10.1083/jcb.201005035; RA Nievergall E., Janes P.W., Stegmayer C., Vail M.E., Haj F.G., Teng S.W., RA Neel B.G., Bastiaens P.I., Lackmann M.; RT "PTP1B regulates Eph receptor function and trafficking."; RL J. Cell Biol. 191:1189-1203(2010). RN [12] RP X-RAY CRYSTALLOGRAPHY (1.07 ANGSTROMS) OF 577-947 IN COMPLEX WITH ATP RP ANALOG, IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT TYR-596; RP TYR-602 AND TYR-701, AND MUTAGENESIS OF TYR-596; TYR-602; TYR-742 AND RP SER-768. RX PubMed=18547520; DOI=10.1016/j.str.2008.03.008; RA Davis T.L., Walker J.R., Loppnau P., Butler-Cole C., Allali-Hassani A., RA Dhe-Paganon S.; RT "Autoregulation by the juxtamembrane region of the human ephrin receptor RT tyrosine kinase A3 (EphA3)."; RL Structure 16:873-884(2008). RN [13] RP VARIANTS [LARGE SCALE ANALYSIS] LYS-37; SER-85; LEU-621 AND ASN-806. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [14] RP VARIANTS LYS-660 AND MET-933. RX PubMed=16941478; DOI=10.1002/humu.9452; RA Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M., RA Riggins G.J., Wang T.L., Yan H., Gazdar A., Kern S.E., Pennacchio L., RA Kinzler K.W., Vogelstein B., Velculescu V.E.; RT "Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers."; RL Hum. Mutat. 27:1060-1061(2006). RN [15] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-229; PHE-449; LEU-518; VAL-564; RP SER-568; PRO-590; GLU-766; GLY-777; HIS-914 AND ARG-924. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [16] RP VARIANT ASN-207. RX PubMed=20838624; DOI=10.1371/journal.pone.0012653; RA Corbo V., Ritelli R., Barbi S., Funel N., Campani D., Bardelli A., RA Scarpa A.; RT "Mutational profiling of kinases in human tumours of pancreatic origin RT identifies candidate cancer genes in ductal and ampulla of vater RT carcinomas."; RL PLoS ONE 5:E12653-E12653(2010). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane- CC bound ephrin family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling (PubMed:11870224, PubMed:12794130). CC Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5 CC (By similarity). Upon activation by EFNA5 regulates cell-cell adhesion, CC cytoskeletal organization and cell migration (PubMed:11870224). Also CC activated by EFNA1, inhibiting epithelial-to-mesenchymal transition of CC cardiac cells and playing a role in heart development CC (PubMed:12794130). Involved in the retinotectal mapping of neurons. May CC also control the segregation but not the guidance of motor and sensory CC axons during neuromuscular circuit development (By similarity). CC {ECO:0000250|UniProtKB:P29319, ECO:0000269|PubMed:11870224, CC ECO:0000269|PubMed:12794130}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses. Forms a ternary CC EFNA5-EPHA3-ADAM10 complex mediating EFNA5 extracellular domain CC shedding by ADAM10 which regulates the EFNA5-EPHA3 complex CC internalization and function. Interacts with NCK1 (via SH2 domain); CC mediates EFNA5-EPHA3 signaling (By similarity). Interacts CC (phosphorylated) with PTPN1; dephosphorylates EPHA3 and may regulate CC its trafficking and function. Interacts (phosphorylated) with CRK; CC mediates EFNA5-EPHA3 signaling through RHOA GTPase activation. CC {ECO:0000250, ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:14660665, CC ECO:0000269|PubMed:16239146, ECO:0000269|PubMed:18547520, CC ECO:0000269|PubMed:21135139}. CC -!- INTERACTION: CC P29320; P29317: EPHA2; NbExp=3; IntAct=EBI-1641575, EBI-702104; CC P29320; Q15375: EPHA7; NbExp=4; IntAct=EBI-1641575, EBI-1383428; CC P29320; Q13485: SMAD4; NbExp=6; IntAct=EBI-1641575, EBI-347263; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane CC {ECO:0000269|PubMed:11870224}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted CC {ECO:0000269|PubMed:21135139}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P29320-1; Sequence=Displayed; CC Name=2; CC IsoId=P29320-2; Sequence=VSP_002995, VSP_002996; CC -!- TISSUE SPECIFICITY: Widely expressed. Highest level in placenta. CC -!- PTM: Autophosphorylates upon activation by EFNA5. Phosphorylation on CC Tyr-602 mediates interaction with NCK1. Dephosphorylated by PTPN1. CC {ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:18547520, CC ECO:0000269|PubMed:21135139}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12738854}. Note=The gene CC represented in this entry may be involved in disease pathogenesis. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40463/EPHA3"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M83941; AAA58633.1; -; mRNA. DR EMBL; AF213459; AAG43576.1; -; mRNA. DR EMBL; AF213460; AAG43577.1; -; mRNA. DR CCDS; CCDS2922.1; -. [P29320-1] DR CCDS; CCDS46875.1; -. [P29320-2] DR PIR; A38224; A38224. DR RefSeq; NP_005224.2; NM_005233.5. [P29320-1] DR RefSeq; NP_872585.1; NM_182644.3. [P29320-2] DR PDB; 2GSF; X-ray; 1.77 A; A=577-947. DR PDB; 2QO2; X-ray; 1.60 A; A=577-947. DR PDB; 2QO7; X-ray; 1.60 A; A=577-947. DR PDB; 2QO9; X-ray; 1.55 A; A=577-947. DR PDB; 2QOB; X-ray; 1.65 A; A=609-947. DR PDB; 2QOC; X-ray; 1.25 A; A=609-947. DR PDB; 2QOD; X-ray; 1.15 A; A=577-947. DR PDB; 2QOF; X-ray; 1.20 A; A=577-947. DR PDB; 2QOI; X-ray; 1.25 A; A=577-947. DR PDB; 2QOK; X-ray; 1.20 A; A=577-947. DR PDB; 2QOL; X-ray; 1.07 A; A=577-947. DR PDB; 2QON; X-ray; 1.79 A; A=577-947. DR PDB; 2QOO; X-ray; 1.25 A; A=577-947. DR PDB; 2QOQ; X-ray; 1.60 A; A=577-947. DR PDB; 3DZQ; X-ray; 1.75 A; A=609-947. DR PDB; 3FXX; X-ray; 1.70 A; A=577-947. DR PDB; 3FY2; X-ray; 1.80 A; A=577-947. DR PDB; 4G2F; X-ray; 1.70 A; A=609-947. DR PDB; 4GK2; X-ray; 2.20 A; A=609-947. DR PDB; 4GK3; X-ray; 1.90 A; A=609-947. DR PDB; 4GK4; X-ray; 2.10 A; A=609-947. DR PDB; 4L0P; X-ray; 2.26 A; A=29-201. DR PDB; 4P4C; X-ray; 1.60 A; A=609-947. DR PDB; 4P5Q; X-ray; 1.35 A; A=606-947. DR PDB; 4P5Z; X-ray; 2.00 A; A=606-947. DR PDB; 4TWN; X-ray; 1.71 A; A=609-947. DR PDB; 4TWO; X-ray; 2.05 A; A=609-947. DR PDB; 6IN0; X-ray; 1.50 A; A=612-904. DR PDBsum; 2GSF; -. DR PDBsum; 2QO2; -. DR PDBsum; 2QO7; -. DR PDBsum; 2QO9; -. DR PDBsum; 2QOB; -. DR PDBsum; 2QOC; -. DR PDBsum; 2QOD; -. DR PDBsum; 2QOF; -. DR PDBsum; 2QOI; -. DR PDBsum; 2QOK; -. DR PDBsum; 2QOL; -. DR PDBsum; 2QON; -. DR PDBsum; 2QOO; -. DR PDBsum; 2QOQ; -. DR PDBsum; 3DZQ; -. DR PDBsum; 3FXX; -. DR PDBsum; 3FY2; -. DR PDBsum; 4G2F; -. DR PDBsum; 4GK2; -. DR PDBsum; 4GK3; -. DR PDBsum; 4GK4; -. DR PDBsum; 4L0P; -. DR PDBsum; 4P4C; -. DR PDBsum; 4P5Q; -. DR PDBsum; 4P5Z; -. DR PDBsum; 4TWN; -. DR PDBsum; 4TWO; -. DR PDBsum; 6IN0; -. DR AlphaFoldDB; P29320; -. DR SMR; P29320; -. DR BioGRID; 108356; 115. DR DIP; DIP-40307N; -. DR FunCoup; P29320; 1027. DR IntAct; P29320; 85. DR MINT; P29320; -. DR STRING; 9606.ENSP00000337451; -. DR BindingDB; P29320; -. DR ChEMBL; CHEMBL4954; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P29320; -. DR GuidetoPHARMACOLOGY; 1823; -. DR GlyCosmos; P29320; 5 sites, No reported glycans. DR GlyGen; P29320; 7 sites, 3 N-linked glycans (3 sites). DR iPTMnet; P29320; -. DR MetOSite; P29320; -. DR PhosphoSitePlus; P29320; -. DR SwissPalm; P29320; -. DR BioMuta; EPHA3; -. DR DMDM; 116241351; -. DR CPTAC; CPTAC-1774; -. DR CPTAC; CPTAC-3202; -. DR CPTAC; CPTAC-3203; -. DR jPOST; P29320; -. DR MassIVE; P29320; -. DR PaxDb; 9606-ENSP00000337451; -. DR PeptideAtlas; P29320; -. DR ProteomicsDB; 54536; -. [P29320-1] DR ProteomicsDB; 54537; -. [P29320-2] DR ABCD; P29320; 1 sequenced antibody. DR Antibodypedia; 4182; 558 antibodies from 41 providers. DR DNASU; 2042; -. DR Ensembl; ENST00000336596.7; ENSP00000337451.2; ENSG00000044524.12. [P29320-1] DR Ensembl; ENST00000452448.6; ENSP00000399926.2; ENSG00000044524.12. [P29320-2] DR GeneID; 2042; -. DR KEGG; hsa:2042; -. DR MANE-Select; ENST00000336596.7; ENSP00000337451.2; NM_005233.6; NP_005224.2. DR UCSC; uc003dqx.2; human. [P29320-1] DR AGR; HGNC:3387; -. DR ClinPGx; PA27819; -. DR CTD; 2042; -. DR DisGeNET; 2042; -. DR GeneCards; EPHA3; -. DR HGNC; HGNC:3387; EPHA3. DR HPA; ENSG00000044524; Tissue enhanced (prostate). DR MalaCards; EPHA3; -. DR MIM; 114500; phenotype. DR MIM; 179611; gene. DR OpenTargets; ENSG00000044524; -. DR VEuPathDB; HostDB:ENSG00000044524; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000157088; -. DR HOGENOM; CLU_000288_141_3_1; -. DR InParanoid; P29320; -. DR OMA; GNTKCAK; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29320; 8 GO annotations based on evolutionary models. DR PhylomeDB; P29320; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29320; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29320; -. DR SIGNOR; P29320; -. DR Agora; ENSG00000044524; -. DR BioGRID-ORCS; 2042; 12 hits in 1194 CRISPR screens. DR ChiTaRS; EPHA3; human. DR EvolutionaryTrace; P29320; -. DR GeneWiki; EPH_receptor_A3; -. DR GenomeRNAi; 2042; -. DR Pharos; P29320; Tchem. DR PRO; PR:P29320; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P29320; protein. DR Bgee; ENSG00000044524; Expressed in ganglionic eminence and 159 other cell types or tissues. DR ExpressionAtlas; P29320; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IDA:HPA. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0031965; C:nuclear membrane; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005003; F:ephrin receptor activity; IDA:ARUK-UCL. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; IBA:GO_Central. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0097156; P:fasciculation of motor neuron axon; ISS:UniProtKB. DR GO; GO:0097155; P:fasciculation of sensory neuron axon; ISS:UniProtKB. DR GO; GO:0045806; P:negative regulation of endocytosis; IDA:UniProtKB. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; ISS:UniProt. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB. DR GO; GO:0022407; P:regulation of cell-cell adhesion; IDA:UniProt. DR GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:UniProtKB. DR GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IDA:UniProtKB. DR CDD; cd10481; EphR_LBD_A3; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR FunFam; 1.10.150.50:FF:000046; ephrin type-A receptor 3; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 1.10.510.10:FF:000019; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034266; EphA3_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF12; EPHRIN TYPE-A RECEPTOR 3; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF07647; SAM_2; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Direct protein sequencing; Glycoprotein; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Secreted; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..20 FT /evidence="ECO:0000269|PubMed:1737782" FT CHAIN 21..983 FT /note="Ephrin type-A receptor 3" FT /id="PRO_0000016802" FT TOPO_DOM 21..541 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 542..565 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 566..983 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 29..207 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 325..435 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 436..531 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 621..882 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 911..975 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 981..983 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 746 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 628..633 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 653 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 700..706 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 750..751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 596 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11870224, FT ECO:0000269|PubMed:18547520" FT MOD_RES 602 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11870224, FT ECO:0000269|PubMed:18547520" FT MOD_RES 701 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18547520" FT MOD_RES 779 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11870224" FT MOD_RES 937 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:P29319" FT CARBOHYD 232 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 337 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 391 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 404 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 493 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 532..539 FT /note="SFSISGES -> CMYYFNAV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10987298" FT /id="VSP_002995" FT VAR_SEQ 540..983 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10987298" FT /id="VSP_002996" FT VARIANT 37 FT /note="T -> K (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036086" FT VARIANT 85 FT /note="N -> S (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036087" FT VARIANT 207 FT /note="K -> N (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation; dbSNP:rs200567888)" FT /evidence="ECO:0000269|PubMed:20838624" FT /id="VAR_068853" FT VARIANT 229 FT /note="S -> Y (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042126" FT VARIANT 449 FT /note="S -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042127" FT VARIANT 518 FT /note="G -> L (in a lung squamous cell carcinoma sample; FT somatic mutation; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042128" FT VARIANT 564 FT /note="I -> V (in dbSNP:rs55712516)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042129" FT VARIANT 568 FT /note="C -> S (in dbSNP:rs56077781)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042130" FT VARIANT 590 FT /note="L -> P (in dbSNP:rs56081642)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042131" FT VARIANT 621 FT /note="I -> L (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1414714315)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036088" FT VARIANT 660 FT /note="T -> K (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16941478" FT /id="VAR_065831" FT VARIANT 766 FT /note="G -> E (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042132" FT VARIANT 777 FT /note="A -> G (in dbSNP:rs34437982)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042133" FT VARIANT 806 FT /note="D -> N (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2107553474)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036089" FT VARIANT 914 FT /note="R -> H (in dbSNP:rs17801309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_027919" FT VARIANT 924 FT /note="W -> R (in dbSNP:rs35124509)" FT /evidence="ECO:0000269|PubMed:1311845, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042134" FT VARIANT 933 FT /note="T -> M (in a lung carcinoma sample; somatic FT mutation; dbSNP:rs372594677)" FT /evidence="ECO:0000269|PubMed:16941478" FT /id="VAR_065832" FT MUTAGEN 133 FT /note="V->E: Loss of EFNA5-binding ability and function." FT /evidence="ECO:0000269|PubMed:14660665" FT MUTAGEN 152 FT /note="F->L: Loss of EFNA5-binding ability and function." FT /evidence="ECO:0000269|PubMed:14660665" FT MUTAGEN 596 FT /note="Y->F: 10-fold suppression of kinase activity; when FT associated with F-602. Full kinase activity; when FT associated with F-602 and F-742. Full kinase activity; when FT associated with F-602 and A-768." FT /evidence="ECO:0000269|PubMed:18547520" FT MUTAGEN 602 FT /note="Y->F: 10-fold suppression of kinase activity; when FT associated with F-596. Full kinase activity; when FT associated with F-596 and F-742. Full kinase activity; when FT associated with F-596 and A-768." FT /evidence="ECO:0000269|PubMed:18547520" FT MUTAGEN 742 FT /note="Y->F: Full kinase activity; when associated with F- FT 596 and F-602." FT /evidence="ECO:0000269|PubMed:18547520" FT MUTAGEN 768 FT /note="S->A: Full kinase activity; when associated with F- FT 596 and F-602." FT /evidence="ECO:0000269|PubMed:18547520" FT CONFLICT 911 FT /note="T -> S (in Ref. 1; AAA58633)" FT /evidence="ECO:0000305" FT STRAND 29..34 FT /evidence="ECO:0007829|PDB:4L0P" FT TURN 38..41 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 45..48 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 51..58 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 64..71 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 80..83 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:4L0P" FT HELIX 106..108 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 117..128 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:4L0P" FT HELIX 137..139 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 141..147 FT /evidence="ECO:0007829|PDB:4L0P" FT HELIX 154..159 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:4L0P" FT STRAND 176..200 FT /evidence="ECO:0007829|PDB:4L0P" FT TURN 610..612 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 621..629 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 631..641 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 647..654 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 661..674 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 685..689 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 691..694 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 696..700 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 707..712 FT /evidence="ECO:0007829|PDB:2QOL" FT TURN 713..716 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 720..739 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 749..751 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 752..754 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 760..762 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 765..768 FT /evidence="ECO:0007829|PDB:4TWN" FT HELIX 788..790 FT /evidence="ECO:0007829|PDB:2QOD" FT HELIX 793..798 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 803..818 FT /evidence="ECO:0007829|PDB:2QOL" FT TURN 819..821 FT /evidence="ECO:0007829|PDB:2QO9" FT TURN 824..827 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 830..838 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 851..860 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 865..867 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 871..883 FT /evidence="ECO:0007829|PDB:2QOL" FT HELIX 885..889 FT /evidence="ECO:0007829|PDB:2QOL" FT STRAND 890..892 FT /evidence="ECO:0007829|PDB:4G2F" FT STRAND 898..903 FT /evidence="ECO:0007829|PDB:2QOC" SQ SEQUENCE 983 AA; 110131 MW; BE04DBF958245424 CRC64; MDCQLSILLL LSCSVLDSFG ELIPQPSNEV NLLDSKTIQG ELGWISYPSH GWEEISGVDE HYTPIRTYQV CNVMDHSQNN WLRTNWVPRN SAQKIYVELK FTLRDCNSIP LVLGTCKETF NLYYMESDDD HGVKFREHQF TKIDTIAADE SFTQMDLGDR ILKLNTEIRE VGPVNKKGFY LAFQDVGACV ALVSVRVYFK KCPFTVKNLA MFPDTVPMDS QSLVEVRGSC VNNSKEEDPP RMYCSTEGEW LVPIGKCSCN AGYEERGFMC QACRPGFYKA LDGNMKCAKC PPHSSTQEDG SMNCRCENNY FRADKDPPSM ACTRPPSSPR NVISNINETS VILDWSWPLD TGGRKDVTFN IICKKCGWNI KQCEPCSPNV RFLPRQFGLT NTTVTVTDLL AHTNYTFEID AVNGVSELSS PPRQFAAVSI TTNQAAPSPV LTIKKDRTSR NSISLSWQEP EHPNGIILDY EVKYYEKQEQ ETSYTILRAR GTNVTISSLK PDTIYVFQIR ARTAAGYGTN SRKFEFETSP DSFSISGESS QVVMIAISAA VAIILLTVVI YVLIGRFCGY KSKHGADEKR LHFGNGHLKL PGLRTYVDPH TYEDPTQAVH EFAKELDATN ISIDKVVGAG EFGEVCSGRL KLPSKKEISV AIKTLKVGYT EKQRRDFLGE ASIMGQFDHP NIIRLEGVVT KSKPVMIVTE YMENGSLDSF LRKHDAQFTV IQLVGMLRGI ASGMKYLSDM GYVHRDLAAR NILINSNLVC KVSDFGLSRV LEDDPEAAYT TRGGKIPIRW TSPEAIAYRK FTSASDVWSY GIVLWEVMSY GERPYWEMSN QDVIKAVDEG YRLPPPMDCP AALYQLMLDC WQKDRNNRPK FEQIVSILDK LIRNPGSLKI ITSAAARPSN LLLDQSNVDI TTFRTTGDWL NGVWTAHCKE IFTGVEYSSC DTIAKISTDD MKKVGVTVVG PQKKIISSIK ALETQSKNGP VPV // ID ERBB4_HUMAN Reviewed; 1308 AA. AC Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 251. DE RecName: Full=Receptor tyrosine-protein kinase erbB-4; DE EC=2.7.10.1; DE AltName: Full=Proto-oncogene-like protein c-ErbB-4; DE AltName: Full=Tyrosine kinase-type cell surface receptor HER4; DE AltName: Full=p180erbB4; DE Contains: DE RecName: Full=ERBB4 intracellular domain; DE Short=4ICD; DE Short=E4ICD; DE AltName: Full=s80HER4; DE Flags: Precursor; GN Name=ERBB4; Synonyms=HER4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1), FUNCTION AS CELL SURFACE RP RECEPTOR, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=8383326; DOI=10.1073/pnas.90.5.1746; RA Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W., RA Foy L., Neubauer M.G., Shoyab M.; RT "Ligand-specific activation of HER4/p180erbB4, a fourth member of the RT epidermal growth factor receptor family."; RL Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), TISSUE RP SPECIFICITY, FUNCTION AS CELL SURFACE RECEPTOR FOR NRG1 AND BTC, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND PROTEOLYTIC PROCESSING. RC TISSUE=Fetal brain; RX PubMed=9334263; DOI=10.1074/jbc.272.42.26761; RA Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D., RA Klagsbrun M.; RT "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific RT tissue distribution and differential processing in response to phorbol RT ester."; RL J. Biol. Chem. 272:26761-26768(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B CYT-1; RP JM-A CYT-2 AND JM-B CYT-2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A CYT-2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7689552; DOI=10.1016/s0021-9258(17)46636-1; RA Culouscou J.-M., Plowman G.D., Carlton G.W., Green J.M., Shoyab M.; RT "Characterization of a breast cancer cell differentiation factor that RT specifically activates the HER4/p180erbB4 receptor."; RL J. Biol. Chem. 268:18407-18410(1993). RN [6] RP INTERACTION WITH NRG1, AND AUTOPHOSPHORYLATION. RX PubMed=7902537; DOI=10.1038/366473a0; RA Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W., Rothwell V.M., RA Buckley S.; RT "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4."; RL Nature 366:473-475(1993). RN [7] RP FUNCTION AS NRG1 RECEPTOR IN REGULATION OF CELL PROLIFERATION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT RP TYR-1056; TYR-1188 AND TYR-1242, AND INTERACTION WITH EGFR; SHC1 AND RP PIK3R1. RX PubMed=8617750; DOI=10.1074/jbc.271.9.4813; RA Cohen B.D., Green J.M., Foy L., Fell H.P.; RT "HER4-mediated biological and biochemical properties in NIH 3T3 cells. RT Evidence for HER1-HER4 heterodimers."; RL J. Biol. Chem. 271:4813-4818(1996). RN [8] RP INTERACTION WITH BTC, AND AUTOPHOSPHORYLATION. RX PubMed=8570211; RA Riese D.J. II, Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D., RA Stern D.F.; RT "Betacellulin activates the epidermal growth factor receptor and erbB-4, RT and induces cellular response patterns distinct from those stimulated by RT epidermal growth factor or neuregulin-beta."; RL Oncogene 12:345-353(1996). RN [9] RP FUNCTION AS HBEGF RECEPTOR; IN CELL MIGRATION; CELL PROLIFERATION AND IN RP ACTIVATION OF PIK3R1, INTERACTION WITH HBEGF AND PIK3R1, AND RP AUTOPHOSPHORYLATION. RX PubMed=9135143; DOI=10.1093/emboj/16.6.1268; RA Elenius K., Paul S., Allison G., Sun J., Klagsbrun M.; RT "Activation of HER4 by heparin-binding EGF-like growth factor stimulates RT chemotaxis but not proliferation."; RL EMBO J. 16:1268-1278(1997). RN [10] RP INTERACTION WITH NRG2, FUNCTION AS NRG2 RECEPTOR, AND PHOSPHORYLATION. RX PubMed=9168115; DOI=10.1038/387512a0; RA Carraway K.L. III, Weber J.L., Unger M.J., Ledesma J., Yu N., Gassmann M., RA Lai C.; RT "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases."; RL Nature 387:512-516(1997). RN [11] RP INTERACTION WITH EREG, AND AUTOPHOSPHORYLATION. RX PubMed=9419975; DOI=10.1038/sj.onc.1201458; RA Komurasaki T., Toyoda H., Uchida D., Morimoto S.; RT "Epiregulin binds to epidermal growth factor receptor and ErbB-4 and RT induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB- RT 2, ErbB-3 and ErbB-4."; RL Oncogene 15:2841-2848(1997). RN [12] RP INTERACTION WITH NRG3, AND AUTOPHOSPHORYLATION. RX PubMed=9275162; DOI=10.1073/pnas.94.18.9562; RA Zhang D., Sliwkowski M.X., Mark M., Frantz G., Akita R., Sun Y., Hillan K., RA Crowley C., Brush J., Godowski P.J.; RT "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and RT activates ErbB4."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9562-9567(1997). RN [13] RP INTERACTION WITH GRB7. RX PubMed=9516479; DOI=10.1074/jbc.273.13.7717; RA Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H., RA Wallasch C., Daly R.J.; RT "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals RT a novel target selectivity for erbB3."; RL J. Biol. Chem. 273:7717-7724(1998). RN [14] RP INTERACTION WITH ERBB2, AND FUNCTION IN ACTIVATION OF STAT5A. RX PubMed=10358079; DOI=10.1074/jbc.274.24.17209; RA Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.; RT "ErbB receptor-induced activation of stat transcription factors is mediated RT by Src tyrosine kinases."; RL J. Biol. Chem. 274:17209-17218(1999). RN [15] RP ALTERNATIVE SPLICING, FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PIK3R1, RP INTERACTION WITH NRG1 AND PIKR3R1, AUTOPHOSPHORYLATION, AND TISSUE RP SPECIFICITY. RX PubMed=10353604; DOI=10.1038/sj.onc.1202612; RA Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., Klagsbrun M.; RT "Characterization of a naturally occurring ErbB4 isoform that does not bind RT or activate phosphatidyl inositol 3-kinase."; RL Oncogene 18:2607-2615(1999). RN [16] RP FUNCTION AS NRG4 RECEPTOR IN ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1 AND IN RP CELL PROLIFERATION, INTERACTION WITH NRG4, AND SUBCELLULAR LOCATION. RX PubMed=10348342; DOI=10.1038/sj.onc.1202631; RA Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., RA Yarden Y.; RT "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor RT tyrosine kinase."; RL Oncogene 18:2681-2689(1999). RN [17] RP FUNCTION AS NRG1 RECEPTOR IN CELL PROLIFERATION; MIGRATION; SURVIVAL AND IN RP PHOSPHORYLATION OF SHC1; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND RP ALTERNATIVE SPLICING. RX PubMed=10722704; DOI=10.1074/jbc.275.12.8641; RA Kainulainen V., Sundvall M., Maatta J.A., Santiestevan E., Klagsbrun M., RA Elenius K.; RT "A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase RT mediates proliferation but not survival or chemotaxis."; RL J. Biol. Chem. 275:8641-8649(2000). RN [18] RP PROTEOLYTIC PROCESSING. RX PubMed=10744726; DOI=10.1074/jbc.275.14.10379; RA Rio C., Buxbaum J.D., Peschon J.J., Corfas G.; RT "Tumor necrosis factor-alpha-converting enzyme is required for cleavage of RT erbB4/HER4."; RL J. Biol. Chem. 275:10379-10387(2000). RN [19] RP FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2 AND MAPK3/ERK1, INTERACTION WITH RP PIK3R1; GRB2; SHC1; BTC; NRG1; NRG2 AND NRG3, AND LIGAND-SPECIFIC RP AUTOPHOSPHORYLATION. RX PubMed=10867024; DOI=10.1074/jbc.c901015199; RA Sweeney C., Lai C., Riese D.J. II, Diamonti A.J., Cantley L.C., RA Carraway K.L. III; RT "Ligand discrimination in signaling through an ErbB4 receptor homodimer."; RL J. Biol. Chem. 275:19803-19807(2000). RN [20] RP INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2. RX PubMed=10725395; DOI=10.1073/pnas.97.7.3596; RA Garcia R.A., Vasudevan K., Buonanno A.; RT "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at RT neuronal synapses."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000). RN [21] RP FUNCTION AS NRG1 RECEPTOR AND IN ACTIVATION OF MAP KINASES, RP AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=11178955; DOI=10.1006/bbrc.2001.4302; RA Egeblad M., Mortensen O.H., van Kempen L.C., Jaattela M.; RT "BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at RT different concentrations in intact cells."; RL Biochem. Biophys. Res. Commun. 281:25-31(2001). RN [22] RP MUTAGENESIS OF LYS-751, AND FUNCTION IN PROMOTING CELL DIFFERENTIATION AND RP INHIBITING CELL PROLIFERATION. RX PubMed=11390655; DOI=10.1128/mcb.21.13.4265-4275.2001; RA Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E., Caskey L., RA Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III; RT "Her4 mediates ligand-dependent antiproliferative and differentiation RT responses in human breast cancer cells."; RL Mol. Cell. Biol. 21:4265-4275(2001). RN [23] RP FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION WITH RP YAP1, AND MUTAGENESIS OF TYR-1301. RX PubMed=12807903; DOI=10.1074/jbc.m305597200; RA Komuro A., Nagai M., Navin N.E., Sudol M.; RT "WW domain-containing protein YAP associates with ErbB-4 and acts as a co- RT transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that RT translocates to the nucleus."; RL J. Biol. Chem. 278:33334-33341(2003). RN [24] RP INTERACTION WITH MUC1. RX PubMed=12939402; RA Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.; RT "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent RT on the DF3/MUC1 oncoprotein."; RL Mol. Cancer Res. 1:765-775(2003). RN [25] RP INTERACTION WITH STAT5A, SUBCELLULAR LOCATION, FUNCTION IN NUCLEAR RP LOCALIZATION OF STAT5A, DNA-BINDING, AND MUTAGENESIS OF 681-LYS--ARG-684. RX PubMed=15534001; DOI=10.1083/jcb.200403155; RA Williams C.C., Allison J.G., Vidal G.A., Burow M.E., Beckman B.S., RA Marrero L., Jones F.E.; RT "The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by RT functioning as a STAT5A nuclear chaperone."; RL J. Cell Biol. 167:469-478(2004). RN [26] RP INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND TYR-1301. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [27] RP FUNCTION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF VAL-675. RX PubMed=15746097; DOI=10.1074/jbc.m412457200; RA Vidal G.A., Naresh A., Marrero L., Jones F.E.; RT "Presenilin-dependent gamma-secretase processing regulates multiple RT ERBB4/HER4 activities."; RL J. Biol. Chem. 280:19777-19783(2005). RN [28] RP FUNCTION IN PROMOTING APOPTOSIS, SUBCELLULAR LOCATION, AND INTERACTION WITH RP BCL2. RX PubMed=16778220; DOI=10.1158/0008-5472.can-05-2368; RA Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., RA Tovey S., Cooke T.G., Bartlett J.M., Jones F.E.; RT "The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting RT apoptosis of breast cancer cells."; RL Cancer Res. 66:6412-6420(2006). RN [29] RP INTERACTION WITH CBFA2T3. RX PubMed=16815842; DOI=10.1074/jbc.m603998200; RA Linggi B., Carpenter G.; RT "ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional RT repression."; RL J. Biol. Chem. 281:25373-25380(2006). RN [30] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=16251361; DOI=10.1091/mbc.e05-05-0402; RA Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J., RA Egeblad M., Elenius K.; RT "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 RT isoform promote ligand-independent survival and cancer cell growth."; RL Mol. Biol. Cell 17:67-79(2006). RN [31] RP FUNCTION IN DIFFERENTIATION OF MAMMARY EPITHELIUM, PROTEOLYTIC PROCESSING, RP AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION WITH STAT5A. RX PubMed=16837552; DOI=10.1091/mbc.e06-02-0101; RA Muraoka-Cook R.S., Sandahl M., Husted C., Hunter D., Miraglia L., RA Feng S.M., Elenius K., Earp H.S. III; RT "The intracellular domain of ErbB4 induces differentiation of mammary RT epithelial cells."; RL Mol. Biol. Cell 17:4118-4129(2006). RN [32] RP MUTAGENESIS OF GLN-646, AND PHOSPHORYLATION AT TYR-1056. RX PubMed=17120616; DOI=10.3727/000000006783981134; RA Pitfield S.E., Bryant I., Penington D.J., Park G., Riese D.J. II; RT "Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling RT to inhibition of colony formation by human mammary cell lines."; RL Oncol. Res. 16:179-193(2006). RN [33] RP FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING, SUBCELLULAR RP LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN, AND MUTAGENESIS OF RP VAL-675; LYS-751; ARG-992; LEU-995 AND ASP-1000. RX PubMed=17638867; DOI=10.1158/0008-5472.can-06-4145; RA Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A., RA Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.; RT "HER4 D-box sequences regulate mitotic progression and degradation of the RT nuclear HER4 cleavage product s80HER4."; RL Cancer Res. 67:6582-6590(2007). RN [34] RP INTERACTION WITH ERBB2, MUTAGENESIS OF ASP-843, AND AUTOPHOSPHORYLATION IN RP TRANS. RX PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020; RA Li Z., Mei Y., Liu X., Zhou M.; RT "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor RT heterodimer partners."; RL Cell. Signal. 19:466-471(2007). RN [35] RP FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND RP MUTAGENESIS OF LYS-751. RX PubMed=17486069; DOI=10.1038/sj.onc.1210501; RA Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I., Savisalo M., RA Silvennoinen O., Yarden Y., Elenius K.; RT "Differential nuclear localization and kinase activity of alternative ErbB4 RT intracellular domains."; RL Oncogene 26:6905-6914(2007). RN [36] RP PHOSPHORYLATION AT TYR-875; TYR-1035; TYR-1056; TYR-1150; TYR-1162; RP TYR-1188; TYR-1202; TYR-1242; TYR-1258 AND TYR-1284, INTERACTION WITH RP PIK3R1 AND STAT1, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=18721752; DOI=10.1016/j.chembiol.2008.07.006; RA Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G.; RT "System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation RT that are unusually selective in their recruitment properties."; RL Chem. Biol. 15:808-817(2008). RN [37] RP INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF E4ICD1. RX PubMed=19193720; DOI=10.1096/fj.08-121947; RA Zeng F., Xu J., Harris R.C.; RT "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK RT II cells."; RL FASEB J. 23:1935-1945(2009). RN [38] RP FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS, INTERACTION WITH ERBB2, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, PHOSPHORYLATION BY ERBB2, ACTIVITY RP REGULATION, AND MUTAGENESIS OF VAL-721; ALA-773; ARG-782; GLU-810; PRO-854; RP ASP-861; GLU-872 AND THR-926. RX PubMed=19098003; DOI=10.1074/jbc.m805438200; RA Tvorogov D., Sundvall M., Kurppa K., Hollmen M., Repo S., Johnson M.S., RA Elenius K.; RT "Somatic mutations of ErbB4: selective loss-of-function phenotype affecting RT signal transduction pathways in cancer."; RL J. Biol. Chem. 284:5582-5591(2009). RN [39] RP INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301. RX PubMed=19561640; DOI=10.1038/onc.2009.162; RA Li Y., Zhou Z., Alimandi M., Chen C.; RT "WW domain containing E3 ubiquitin protein ligase 1 targets the full-length RT ErbB4 for ubiquitin-mediated degradation in breast cancer."; RL Oncogene 28:2948-2958(2009). RN [40] RP INTERACTION WITH TXNL4A; DDX23; MATR3; RBM15; ILF3; TRIM28; U5S1; U2SURP; RP ITCH; HNRNPU; AP2A1; NULC; LEO1; WWP2; MDM2; HXK1 AND SRRT, FUNCTION, RP SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042; RA Gilmore-Hebert M., Ramabhadran R., Stern D.F.; RT "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage RT response pathways."; RL Mol. Cancer Res. 8:1388-1398(2010). RN [41] RP ACTIVITY REGULATION. RX PubMed=21439954; DOI=10.1016/j.yexcr.2011.03.015; RA Carrasco-Garcia E., Saceda M., Grasso S., Rocamora-Reverte L., Conde M., RA Gomez-Martinez A., Garcia-Morales P., Ferragut J.A., Martinez-Lacaci I.; RT "Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting RT with erbB3 and erbB4 in glioblastoma cell lines."; RL Exp. Cell Res. 317:1476-1489(2011). RN [42] RP REVIEW ON ROLE IN BREAST AND NEURAL DEVELOPMENT. RX PubMed=14504474; RA Jones F.E., Golding J.P., Gassmann M.; RT "ErbB4 signaling during breast and neural development: novel genetic models RT reveal unique ErbB4 activities."; RL Cell Cycle 2:555-559(2003). RN [43] RP REVIEW. RX PubMed=15944951; DOI=10.14670/hh-20.1005; RA Zaczek A., Brandt B., Bielawski K.P.; RT "The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase RT receptors and the consequences for therapeutic approaches."; RL Histol. Histopathol. 20:1005-1015(2005). RN [44] RP REVIEW ON ROLE IN MAMMARY GLAND DEVELOPMENT. RX PubMed=18437540; DOI=10.1007/s10911-008-9080-x; RA Muraoka-Cook R.S., Feng S.M., Strunk K.E., Earp H.S. III; RT "ErbB4/HER4: role in mammary gland development, differentiation and growth RT inhibition."; RL J. Mammary Gland Biol. Neoplasia 13:235-246(2008). RN [45] RP REVIEW ON ROLE OF THE ERBB4 INTRACELLULAR DOMAIN. RX PubMed=18473151; DOI=10.1007/s10911-008-9076-6; RA Jones F.E.; RT "HER4 intracellular domain (4ICD) activity in the developing mammary gland RT and breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:247-258(2008). RN [46] RP REVIEW ON LIGAND SPECIFICITY AND SIGNALING. RX PubMed=18454307; DOI=10.1007/s10911-008-9079-3; RA Sundvall M., Iljin K., Kilpinen S., Sara H., Kallioniemi O.P., Elenius K.; RT "Role of ErbB4 in breast cancer."; RL J. Mammary Gland Biol. Neoplasia 13:259-268(2008). RN [47] RP REVIEW ON ROLE IN NRG1 SIGNALING AND CARDIOVASCULAR HEALTH. RX PubMed=20933198; DOI=10.1016/s1054-3589(10)59002-1; RA Xu Y., Li X., Liu X., Zhou M.; RT "Neuregulin-1/ErbB signaling and chronic heart failure."; RL Adv. Pharmacol. 59:31-51(2010). RN [48] RP REVIEW ON ALTERNATIVE SPLICING AND PROTEOLYTIC PROCESSING; TISSUE RP SPECIFICITY; SIGNALING AND ROLE IN DISEASE. RX PubMed=21811097; DOI=10.4161/cc.10.16.17194; RA Veikkolainen V., Vaparanta K., Halkilahti K., Iljin K., Sundvall M., RA Elenius K.; RT "Function of ERBB4 is determined by alternative splicing."; RL Cell Cycle 10:2647-2657(2011). RN [49] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND RP GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473; RP ASN-495 AND ASN-576. RX PubMed=16203964; DOI=10.1073/pnas.0507591102; RA Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.; RT "The extracellular region of ErbB4 adopts a tethered conformation in the RT absence of ligand."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 690-999 IN COMPLEX WITH INHIBITOR, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LEU-710; RP MET-766; LEU-864 AND ILE-947. RX PubMed=18287036; DOI=10.1073/pnas.0708281105; RA Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., RA Caferro T.R., Dickerson S.H., Dickson H.D., Donaldson K.H., Gaul M., RA Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., RA Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., RA Waterson A.G., Williams J.D., White W.L., Uehling D.E.; RT "6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as RT tunable covalent modifiers of ErbB kinases."; RL Proc. Natl. Acad. Sci. U.S.A. 105:2773-2778(2008). RN [51] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 702-1029 OF APOPROTEIN AND IN RP COMPLEX WITH LAPATINIB, CATALYTIC ACTIVITY, ACTIVITY REGULATION, RP AUTOPHOSPHORYLATION, AND SUBUNIT. RX PubMed=18334220; DOI=10.1016/j.str.2007.12.016; RA Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., RA Pal A., Bornmann W.G., Lemmon M.A., Cole P.A., Leahy D.J.; RT "Mechanism of activation and inhibition of the HER4/ErbB4 kinase."; RL Structure 16:460-467(2008). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [53] RP VARIANTS ALS19 GLN-927 AND TRP-1275, AND CHARACTERIZATION OF VARIANTS ASL19 RP GLN-927 AND TRP-1275. RX PubMed=24119685; DOI=10.1016/j.ajhg.2013.09.008; RA Takahashi Y., Fukuda Y., Yoshimura J., Toyoda A., Kurppa K., Moritoyo H., RA Belzil V.V., Dion P.A., Higasa K., Doi K., Ishiura H., Mitsui J., Date H., RA Ahsan B., Matsukawa T., Ichikawa Y., Moritoyo T., Ikoma M., Hashimoto T., RA Kimura F., Murayama S., Onodera O., Nishizawa M., Yoshida M., Atsuta N., RA Sobue G., Fifita J.A., Williams K.L., Blair I.P., Nicholson G.A., RA Gonzalez-Perez P., Brown R.H. Jr., Nomoto M., Elenius K., Rouleau G.A., RA Fujiyama A., Morishita S., Goto J., Tsuji S., Nakamura R., Watanabe H., RA Izumi Y., Kaji R., Morita M., Ogaki K., Taniguchi A., Aiba I., RA Mizoguchi K., Okamoto K., Hasegawa K., Aoki M., Kawata A., Nakano I., RA Abe K., Oda M., Konagaya M., Imai T., Nakagawa M., Fujita T., Sasaki H., RA Nishizawa M.; RT "ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause RT amyotrophic lateral sclerosis type 19."; RL Am. J. Hum. Genet. 93:900-905(2013). CC -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell CC surface receptor for neuregulins and EGF family members and regulates CC development of the heart, the central nervous system and the mammary CC gland, gene transcription, cell proliferation, differentiation, CC migration and apoptosis. Required for normal cardiac muscle CC differentiation during embryonic development, and for postnatal CC cardiomyocyte proliferation. Required for normal development of the CC embryonic central nervous system, especially for normal neural crest CC cell migration and normal axon guidance. Required for mammary gland CC differentiation, induction of milk proteins and lactation. Acts as CC cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and CC the EGF family members BTC, EREG and HBEGF. Ligand binding triggers CC receptor dimerization and autophosphorylation at specific tyrosine CC residues that then serve as binding sites for scaffold proteins and CC effectors. Ligand specificity and signaling is modulated by alternative CC splicing, proteolytic processing, and by the formation of heterodimers CC with other ERBB family members, thereby creating multiple combinations CC of intracellular phosphotyrosines that trigger ligand- and context- CC specific cellular responses. Mediates phosphorylation of SHC1 and CC activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CC CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the CC activation of phosphatidylinositol 3-kinase and AKT1 and protect cells CC against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate CC reorganization of the actin cytoskeleton and promote cell migration in CC response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the CC phosphotyrosine that mediates interaction with PIK3R1, and hence do not CC phosphorylate PIK3R1, do not protect cells against apoptosis, and do CC not promote reorganization of the actin cytoskeleton and cell CC migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM- CC A CYT-2 gives rise to the corresponding soluble intracellular domains CC (4ICD) that translocate to the nucleus, promote nuclear import of CC STAT5A, activation of STAT5A, mammary epithelium differentiation, cell CC proliferation and activation of gene expression. The ERBB4 soluble CC intracellular domains (4ICD) colocalize with STAT5A at the CSN2 CC promoter to regulate transcription of milk proteins during lactation. CC The ERBB4 soluble intracellular domains can also translocate to CC mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, CC ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, CC ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9334263}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:18287036, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750}; CC -!- ACTIVITY REGULATION: Binding of a cognate ligand leads to dimerization CC and activation by autophosphorylation on tyrosine residues. In vitro CC kinase activity is increased by Mg(2+). Inhibited by PD153035, CC lapatinib, gefitinib (iressa, ZD1839), AG1478 and BIBX1382BS. CC {ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:18334220, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:21439954, CC ECO:0000269|PubMed:8617750}. CC -!- SUBUNIT: Monomer in the absence of bound ligand. Homodimer or CC heterodimer with another ERBB family member upon ligand binding, thus CC forming heterotetramers. Interacts with EGFR and ERBB2. Interacts with CC CBFA2T3 (By similarity). Interacts with DLG2 (via its PDZ domain), DLG3 CC (via its PDZ domain), DLG4 (via its PDZ domain) and SNTB2 (via its PDZ CC domain). Interacts with MUC1. Interacts (via its PPxy motifs) with CC WWOX. Interacts (via the PPxY motif 3 of isoform JM-A CYT-2) with YAP1 CC (via the WW domain 1 of isoform 1). Interacts (isoform JM-A CYT-1 and CC isoform JM-B CYT-1) with WWP1. Interacts (via its intracellular domain) CC with TRIM28. Interacts (via the intracellular domains of both CYT-1 and CC CYT-2 isoforms) with KAP1; the interaction does not phosphorylate KAP1 CC but represses ERBB4-mediated transcriptional activity. Interacts with CC PRPU, DDX23, MATR3, RBM15, ILF3, KAP1, U5S1, U2SURP, ITCH, HNRNPU, CC AP2A1, NULC, LEO1, WWP2, IGHG1, HXK1, GRB7 and SRRT. Interacts CC (phosphorylated isoform JM-A CYT-1 and isoform JM-B CYT-1) with PIK3R1. CC Interacts with SHC1. Interacts with GRB2. Interacts (soluble CC intracellular domain) with STAT5A. Interacts (soluble intracellular CC domain) with BCL2. Interacts (phosphorylated) with STAT1. {ECO:0000250, CC ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, CC ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10725395, CC ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:12939402, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16815842, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:16978839, ECO:0000269|PubMed:18287036, CC ECO:0000269|PubMed:18334220, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:19561640, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:7689552, ECO:0000269|PubMed:7902537, CC ECO:0000269|PubMed:8570211, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, CC ECO:0000269|PubMed:9275162, ECO:0000269|PubMed:9419975, CC ECO:0000269|PubMed:9516479}. CC -!- INTERACTION: CC Q15303; P42684: ABL2; NbExp=4; IntAct=EBI-80371, EBI-1102694; CC Q15303; Q13895: BYSL; NbExp=3; IntAct=EBI-80371, EBI-358049; CC Q15303; Q12959: DLG1; NbExp=4; IntAct=EBI-80371, EBI-357481; CC Q15303; Q15700: DLG2; NbExp=3; IntAct=EBI-80371, EBI-80426; CC Q15303; Q92796: DLG3; NbExp=4; IntAct=EBI-80371, EBI-80440; CC Q15303; P78352: DLG4; NbExp=9; IntAct=EBI-80371, EBI-80389; CC Q15303; P00533: EGFR; NbExp=4; IntAct=EBI-80371, EBI-297353; CC Q15303; P04626: ERBB2; NbExp=5; IntAct=EBI-80371, EBI-641062; CC Q15303; P21860: ERBB3; NbExp=4; IntAct=EBI-80371, EBI-720706; CC Q15303; P62993: GRB2; NbExp=7; IntAct=EBI-80371, EBI-401755; CC Q15303; Q99075: HBEGF; NbExp=2; IntAct=EBI-80371, EBI-7211558; CC Q15303; P08238: HSP90AB1; NbExp=2; IntAct=EBI-80371, EBI-352572; CC Q15303; Q96J02-2: ITCH; NbExp=3; IntAct=EBI-80371, EBI-6672198; CC Q15303; Q96JA1: LRIG1; NbExp=3; IntAct=EBI-80371, EBI-2865191; CC Q15303; Q86UL8: MAGI2; NbExp=2; IntAct=EBI-80371, EBI-311035; CC Q15303; Q02297-6: NRG1; NbExp=3; IntAct=EBI-80371, EBI-15651799; CC Q15303; Q06124: PTPN11; NbExp=2; IntAct=EBI-80371, EBI-297779; CC Q15303; P26447: S100A4; NbExp=4; IntAct=EBI-80371, EBI-717058; CC Q15303; P29353: SHC1; NbExp=6; IntAct=EBI-80371, EBI-78835; CC Q15303; Q12815: TROAP; NbExp=3; IntAct=EBI-80371, EBI-2349743; CC Q15303; P46937: YAP1; NbExp=3; IntAct=EBI-80371, EBI-1044059; CC Q15303; P62258: YWHAE; NbExp=2; IntAct=EBI-80371, EBI-356498; CC Q15303-3; Q96J02-2: ITCH; NbExp=2; IntAct=EBI-15692884, EBI-6672198; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10348342, CC ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, CC ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, CC ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19193720, CC ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:16251361, CC ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720, ECO:0000269|PubMed:20858735, CC ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:9334263}. Note=In CC response to NRG1 treatment, the activated receptor is internalized. CC -!- SUBCELLULAR LOCATION: [ERBB4 intracellular domain]: Nucleus CC {ECO:0000269|PubMed:17486069}. Mitochondrion CC {ECO:0000269|PubMed:17486069}. Note=Following proteolytical processing CC E4ICD (E4ICD1 or E4ICD2 generated from the respective isoforms) is CC translocated to the nucleus. Significantly more E4ICD2 than E4ICD1 is CC found in the nucleus. E4ICD2 colocalizes with YAP1 in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=JM-A CYT-1; CC IsoId=Q15303-1; Sequence=Displayed; CC Name=JM-B CYT-1; CC IsoId=Q15303-2; Sequence=VSP_002895; CC Name=JM-A CYT-2; CC IsoId=Q15303-3; Sequence=VSP_022148; CC Name=JM-B CYT-2; CC IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148; CC -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart, CC kidney, in addition to skeletal muscle, parathyroid, cerebellum, CC pituitary, spleen, testis and breast. Lower levels in thymus, lung, CC salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform JM-B CYT-1 CC are expressed in cerebellum, but only the isoform JM-B is expressed in CC the heart. {ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:8383326, CC ECO:0000269|PubMed:9334263}. CC -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 are processed by ADAM17. CC Proteolytic processing in response to ligand or 12-O- CC tetradecanoylphorbol-13-acetate stimulation results in the production CC of 120 kDa soluble receptor forms and intermediate membrane-anchored 80 CC kDa fragments (m80HER4), which are further processed by a presenilin- CC dependent gamma-secretase to release a cytoplasmic intracellular domain CC (E4ICD; E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2, depending on the isoform). CC Membrane-anchored 80 kDa fragments of the processed isoform JM-A CYT-1 CC are more readily degraded by the proteasome than fragments of isoform CC JM-A CYT-2, suggesting a prevalence of E4ICD2 over E4ICD1. Isoform JM-B CC CYT-1 and isoform JM-B CYT-2 lack the ADAM17 cleavage site and are not CC processed by ADAM17, precluding further processing by gamma-secretase. CC {ECO:0000269|PubMed:10744726, ECO:0000269|PubMed:12807903, CC ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16837552, CC ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:9334263}. CC -!- PTM: Autophosphorylated on tyrosine residues in response to ligand CC binding. Autophosphorylation occurs in trans, i.e. one subunit of the CC dimeric receptor phosphorylates tyrosine residues on the other subunit. CC Ligands trigger phosphorylation at specific tyrosine residues, thereby CC creating binding sites for scaffold proteins and effectors. CC Constitutively phosphorylated at a basal level when overexpressed in CC heterologous systems; ligand binding leads to increased CC phosphorylation. Phosphorylation at Tyr-1035 is important for CC interaction with STAT1. Phosphorylation at Tyr-1056 is important for CC interaction with PIK3R1. Phosphorylation at Tyr-1242 is important for CC interaction with SHC1. Phosphorylation at Tyr-1188 may also contribute CC to the interaction with SHC1. Isoform JM-A CYT-2 is constitutively CC phosphorylated on tyrosine residues in a ligand-independent manner. CC E4ICD2 but not E4ICD1 is phosphorylated on tyrosine residues. CC {ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:17120616, CC ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:18721752, CC ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:8617750, CC ECO:0000269|PubMed:9168115}. CC -!- PTM: Ubiquitinated. During mitosis, the ERBB4 intracellular domain is CC ubiquitinated by the APC/C complex and targeted to proteasomal CC degradation. Isoform JM-A CYT-1 and isoform JM-B CYT-1 are CC ubiquitinated by WWP1. The ERBB4 intracellular domain (E4ICD1) is CC ubiquitinated, and this involves NEDD4. {ECO:0000269|PubMed:17638867, CC ECO:0000269|PubMed:19193720}. CC -!- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A CC neurodegenerative disorder affecting upper motor neurons in the brain CC and lower motor neurons in the brain stem and spinal cord, resulting in CC fatal paralysis. Sensory abnormalities are absent. The pathologic CC hallmarks of the disease include pallor of the corticospinal tract due CC to loss of motor neurons, presence of ubiquitin-positive inclusions CC within surviving motor neurons, and deposition of pathologic CC aggregates. The etiology of amyotrophic lateral sclerosis is likely to CC be multifactorial, involving both genetic and environmental factors. CC The disease is inherited in 5-10% of the cases. CC {ECO:0000269|PubMed:24119685}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform JM-A CYT-1]: Proteolytical processing generates CC E4ICD1 (s80Cyt1). CC -!- MISCELLANEOUS: [Isoform JM-A CYT-2]: Proteolytical processing generates CC E4ICD2 (s80Cyt2). {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Conflicting reports about the role of ERBB4 in mediating CC apoptosis, differentiation, or tumor cell proliferation may be CC explained by the opposite functions of the different isoforms and their CC intracellular fragments, and by the formation of heterodimers with CC other EGF receptor family members (PubMed:18454307, PubMed:21811097). CC Thus, heterodimer formation of a kinase-dead ERBB4 mutant with ERBB2 is CC sufficient for the activation of AKT1, MAPK1/ERK2 and MAPK3/ERK1 CC (PubMed:19098003). {ECO:0000305|PubMed:19098003}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L07868; AAB59446.1; -; mRNA. DR EMBL; BC112199; AAI12200.1; -; mRNA. DR EMBL; BC143741; AAI43742.1; -; mRNA. DR EMBL; BC143747; AAI43748.1; -; mRNA. DR EMBL; BC143749; AAI43750.1; -; mRNA. DR EMBL; AB209697; BAD92934.1; -; mRNA. DR CCDS; CCDS2394.1; -. [Q15303-1] DR CCDS; CCDS42811.1; -. [Q15303-3] DR PIR; A47253; A47253. DR RefSeq; NP_001036064.1; NM_001042599.2. [Q15303-3] DR RefSeq; NP_001425934.1; NM_001439005.1. [Q15303-2] DR RefSeq; NP_001425935.1; NM_001439006.1. [Q15303-4] DR RefSeq; NP_005226.1; NM_005235.3. [Q15303-1] DR PDB; 2AHX; X-ray; 2.40 A; A/B=26-641. DR PDB; 2L2T; NMR; -; A/B=642-685. DR PDB; 2LCX; NMR; -; A/B=642-685. DR PDB; 2R4B; X-ray; 2.40 A; A/B=690-999. DR PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029. DR PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029. DR PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029. DR PDB; 3U2P; X-ray; 2.57 A; A=26-522. DR PDB; 3U7U; X-ray; 3.03 A; A/B/C/D/E/F=26-640. DR PDB; 3U9U; X-ray; 3.42 A; E/F=26-650. DR PDB; 8U4I; EM; 3.38 A; A/B=26-635. DR PDB; 8U4J; EM; 3.70 A; A/B=26-635. DR PDB; 8U4K; EM; 4.27 A; A=26-634. DR PDB; 8U4L; EM; 3.31 A; A=26-634. DR PDBsum; 2AHX; -. DR PDBsum; 2L2T; -. DR PDBsum; 2LCX; -. DR PDBsum; 2R4B; -. DR PDBsum; 3BBT; -. DR PDBsum; 3BBW; -. DR PDBsum; 3BCE; -. DR PDBsum; 3U2P; -. DR PDBsum; 3U7U; -. DR PDBsum; 3U9U; -. DR PDBsum; 8U4I; -. DR PDBsum; 8U4J; -. DR PDBsum; 8U4K; -. DR PDBsum; 8U4L; -. DR AlphaFoldDB; Q15303; -. DR EMDB; EMD-41883; -. DR EMDB; EMD-41884; -. DR EMDB; EMD-41885; -. DR EMDB; EMD-41886; -. DR SMR; Q15303; -. DR BioGRID; 108378; 183. DR CORUM; Q15303; -. DR DIP; DIP-29650N; -. DR ELM; Q15303; -. DR FunCoup; Q15303; 1593. DR IntAct; Q15303; 146. DR MINT; Q15303; -. DR STRING; 9606.ENSP00000342235; -. DR BindingDB; Q15303; -. DR ChEMBL; CHEMBL3009; -. DR DrugBank; DB08916; Afatinib. DR DrugBank; DB12267; Brigatinib. DR DrugBank; DB05424; Canertinib. DR DrugBank; DB12744; CGI-1842. DR DrugBank; DB11963; Dacomitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12325; Idasanutlin. DR DrugBank; DB15035; Zanubrutinib. DR DrugCentral; Q15303; -. DR GuidetoPHARMACOLOGY; 1799; -. DR TCDB; 8.A.23.1.17; the basigin (basigin) family. DR GlyCosmos; Q15303; 11 sites, No reported glycans. DR GlyGen; Q15303; 11 sites, 6 N-linked glycans (4 sites). DR iPTMnet; Q15303; -. DR PhosphoSitePlus; Q15303; -. DR BioMuta; ERBB4; -. DR DMDM; 3913590; -. DR jPOST; Q15303; -. DR MassIVE; Q15303; -. DR PaxDb; 9606-ENSP00000342235; -. DR PeptideAtlas; Q15303; -. DR ProteomicsDB; 60520; -. [Q15303-1] DR ProteomicsDB; 60521; -. [Q15303-2] DR ProteomicsDB; 60522; -. [Q15303-3] DR ProteomicsDB; 60523; -. [Q15303-4] DR Pumba; Q15303; -. DR ABCD; Q15303; 1 sequenced antibody. DR Antibodypedia; 1602; 1464 antibodies from 47 providers. DR DNASU; 2066; -. DR Ensembl; ENST00000260943.11; ENSP00000260943.7; ENSG00000178568.16. [Q15303-4] DR Ensembl; ENST00000342788.9; ENSP00000342235.4; ENSG00000178568.16. [Q15303-1] DR Ensembl; ENST00000436443.5; ENSP00000403204.1; ENSG00000178568.16. [Q15303-3] DR GeneID; 2066; -. DR KEGG; hsa:2066; -. DR MANE-Select; ENST00000342788.9; ENSP00000342235.4; NM_005235.3; NP_005226.1. DR UCSC; uc002veg.2; human. [Q15303-1] DR AGR; HGNC:3432; -. DR CIViC; 2066; 9 evidence items across 8 molecular profiles. DR ClinPGx; PA27847; -. DR CTD; 2066; -. DR DisGeNET; 2066; -. DR GeneCards; ERBB4; -. DR HGNC; HGNC:3432; ERBB4. DR HPA; ENSG00000178568; Tissue enhanced (brain, fallopian tube). DR MalaCards; ERBB4; -. DR MIM; 600543; gene. DR MIM; 615515; phenotype. DR OpenTargets; ENSG00000178568; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000178568; -. DR eggNOG; KOG1025; Eukaryota. DR GeneTree; ENSGT00940000154695; -. DR InParanoid; Q15303; -. DR OMA; VCHSECL; -. DR OrthoDB; 6219513at2759; -. DR PAN-GO; Q15303; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q15303; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15303; -. DR Reactome; R-HSA-1227986; Signaling by ERBB2. DR Reactome; R-HSA-1236394; Signaling by ERBB4. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250342; PI3K events in ERBB4 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. DR Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. DR Reactome; R-HSA-9018519; Estrogen-dependent gene expression. DR Reactome; R-HSA-9620244; Long-term potentiation. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR SignaLink; Q15303; -. DR SIGNOR; Q15303; -. DR Agora; ENSG00000178568; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 2066; 33 hits in 1186 CRISPR screens. DR ChiTaRS; ERBB4; human. DR EvolutionaryTrace; Q15303; -. DR GeneWiki; ERBB4; -. DR GenomeRNAi; 2066; -. DR Pharos; Q15303; Tclin. DR PRO; PR:Q15303; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15303; protein. DR Bgee; ENSG00000178568; Expressed in endothelial cell and 154 other cell types or tissues. DR ExpressionAtlas; Q15303; baseline and differential. DR GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:MGI. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005006; F:epidermal growth factor receptor activity; IEA:Ensembl. DR GO; GO:0005154; F:epidermal growth factor receptor binding; IPI:UniProtKB. DR GO; GO:0050811; F:GABA receptor binding; IEA:Ensembl. DR GO; GO:0038131; F:neuregulin receptor activity; IDA:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IMP:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0061026; P:cardiac muscle tissue regeneration; ISS:UniProtKB. DR GO; GO:0045165; P:cell fate commitment; IEA:Ensembl. DR GO; GO:0016477; P:cell migration; IDA:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB. DR GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl. DR GO; GO:0021551; P:central nervous system morphogenesis; ISS:UniProtKB. DR GO; GO:0009880; P:embryonic pattern specification; ISS:UniProtKB. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central. DR GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl. DR GO; GO:0038130; P:ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0038138; P:ERBB4-ERBB4 signaling pathway; IDA:MGI. DR GO; GO:0072046; P:establishment of planar polarity involved in nephron morphogenesis; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007595; P:lactation; IMP:UniProtKB. DR GO; GO:0060749; P:mammary gland alveolus development; ISS:UniProtKB. DR GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISS:UniProtKB. DR GO; GO:0043653; P:mitochondrial fragmentation involved in apoptotic process; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:2001223; P:negative regulation of neuron migration; IEA:Ensembl. DR GO; GO:0007399; P:nervous system development; ISS:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central. DR GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl. DR GO; GO:0021889; P:olfactory bulb interneuron differentiation; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IBA:GO_Central. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:UniProtKB. DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IMP:UniProtKB. DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0030334; P:regulation of cell migration; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0007416; P:synapse assembly; IEA:Ensembl. DR CDD; cd00064; FU; 3. DR CDD; cd05110; PTKc_HER4; 1. DR CDD; cd12092; TM_ErbB4; 1. DR FunFam; 2.10.220.10:FF:000001; Receptor protein-tyrosine kinase; 1. DR FunFam; 2.10.220.10:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.30.200.20:FF:000044; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000003; Receptor protein-tyrosine kinase; 1. DR FunFam; 3.80.20.20:FF:000004; Receptor protein-tyrosine kinase; 1. DR FunFam; 1.10.510.10:FF:002828; Receptor tyrosine-protein kinase erbB-2; 1. DR Gene3D; 6.10.250.880; -; 1. DR Gene3D; 2.10.220.10; Hormone Receptor, Insulin-like Growth Factor Receptor 1, Chain A, domain 2; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.20.20; Receptor L-domain; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR006211; Furin-like_Cys-rich_dom. DR InterPro; IPR006212; Furin_repeat. DR InterPro; IPR032778; GF_recep_IV. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR000494; Rcpt_L-dom. DR InterPro; IPR036941; Rcpt_L-dom_sf. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR049328; TM_ErbB1. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt. DR PANTHER; PTHR24416:SF90; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00757; Furin-like; 1. DR Pfam; PF14843; GF_recep_IV; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF01030; Recep_L_domain; 2. DR Pfam; PF21314; TM_ErbB1; 1. DR PIRSF; PIRSF000619; TyrPK_EGF-R; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00261; FU; 5. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 2. DR SUPFAM; SSF52058; L domain-like; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; KW Amyotrophic lateral sclerosis; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Disease variant; Disulfide bond; Glycoprotein; KW Kinase; Lactation; Membrane; Mitochondrion; Neurodegeneration; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Transcription; KW Transcription regulation; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..25 FT /evidence="ECO:0000255" FT CHAIN 26..1308 FT /note="Receptor tyrosine-protein kinase erbB-4" FT /id="PRO_0000016674" FT CHAIN 676..1308 FT /note="ERBB4 intracellular domain" FT /evidence="ECO:0000250" FT /id="PRO_0000396797" FT TOPO_DOM 26..651 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 652..675 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 676..1308 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 718..985 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1117..1150 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 676..684 FT /note="Nuclear localization signal" FT MOTIF 1032..1035 FT /note="PPxY motif 1" FT MOTIF 1053..1056 FT /note="PPxY motif 2" FT MOTIF 1298..1301 FT /note="PPxY motif 3" FT MOTIF 1306..1308 FT /note="PDZ-binding" FT ACT_SITE 843 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 724..732 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 751 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 797..799 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 843..848 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 875 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1035 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1056 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:17120616, FT ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:8617750" FT MOD_RES 1150 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1162 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1188 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1202 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1242 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752, FT ECO:0000269|PubMed:8617750" FT MOD_RES 1258 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT MOD_RES 1284 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:18721752" FT CARBOHYD 138 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 181 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 253 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 358 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 473 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 495 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 548 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 576 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16203964" FT CARBOHYD 620 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 29..56 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 156..186 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 189..197 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 193..205 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 213..221 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 217..229 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 230..238 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 234..246 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 249..258 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 262..289 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 293..304 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 308..323 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 326..330 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 503..512 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 507..520 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 523..532 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 536..552 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 555..569 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 559..577 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 580..589 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 593..614 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 617..625 FT /evidence="ECO:0000269|PubMed:16203964" FT DISULFID 621..633 FT /evidence="ECO:0000269|PubMed:16203964" FT VAR_SEQ 626..648 FT /note="NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD (in isoform FT JM-B CYT-1 and isoform JM-B CYT-2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:9334263" FT /id="VSP_002895" FT VAR_SEQ 1046..1061 FT /note="Missing (in isoform JM-A CYT-2 and isoform JM-B CYT- FT 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4" FT /id="VSP_022148" FT VARIANT 140 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042113" FT VARIANT 303 FT /note="S -> Y (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs1484791833)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042114" FT VARIANT 927 FT /note="R -> Q (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514262)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070810" FT VARIANT 1275 FT /note="R -> W (in ALS19; reduces autophosphorylation upon FT NRG1 stimulation; dbSNP:rs397514263)" FT /evidence="ECO:0000269|PubMed:24119685" FT /id="VAR_070811" FT MUTAGEN 646 FT /note="Q->C: Constitutively activated kinase." FT /evidence="ECO:0000269|PubMed:17120616" FT MUTAGEN 675 FT /note="V->A: Abolishes proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:15746097, FT ECO:0000269|PubMed:17638867" FT MUTAGEN 681..684 FT /note="KKKR->EIMG: Abolishes nuclear localization of the FT ERBB4 intracellular domain." FT /evidence="ECO:0000269|PubMed:15534001" FT MUTAGEN 710 FT /note="L->N: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 721 FT /note="V->I: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 751 FT /note="K->R: Abolishes kinase activity. Abolishes FT phosphorylation, proteolytic processing and nuclear FT localization." FT /evidence="ECO:0000269|PubMed:11390655, FT ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867" FT MUTAGEN 766 FT /note="M->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 773 FT /note="A->S: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 782 FT /note="R->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 810 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 843 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:16978839" FT MUTAGEN 854 FT /note="P->Q: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 861 FT /note="D->Y: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 864 FT /note="L->R: Strongly reduced autophosphorylation." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 872 FT /note="E->K: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 926 FT /note="T->M: No effect on kinase activity." FT /evidence="ECO:0000269|PubMed:19098003" FT MUTAGEN 947 FT /note="I->R: Constitutively autophosphorylated." FT /evidence="ECO:0000269|PubMed:18287036" FT MUTAGEN 992 FT /note="R->A: Abolishes APC/C-mediated degradation; when FT associated with A-995 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 995 FT /note="L->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-1000." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1000 FT /note="D->A: Abolishes APC/C-mediated degradation; when FT associated with A-992 and A-995." FT /evidence="ECO:0000269|PubMed:17638867" FT MUTAGEN 1035 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1301." FT /evidence="ECO:0000269|PubMed:16061658" FT MUTAGEN 1056 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination. Promotes nuclear translocation of ERBB4 FT intracellular domain E4ICD1." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1056 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1301." FT /evidence="ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: Abolishes interaction with NEDD4 and impairs FT ubiquitination." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->A: No effect on interaction with WWOX. Abolishes FT interaction with WWOX; when associated with A-1035. Loss of FT interaction with YAP1 and stimulation of transcription." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT MUTAGEN 1301 FT /note="Y->F: Abolishes interaction with WWP1; when FT associated with F-1056." FT /evidence="ECO:0000269|PubMed:12807903, FT ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:19561640" FT STRAND 28..30 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 38..41 FT /evidence="ECO:0007829|PDB:3U7U" FT HELIX 42..53 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 75..79 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 82..85 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 87..91 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 158..160 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 163..165 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 167..169 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 173..175 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 176..178 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 191..193 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 197..201 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 202..204 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 226..228 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 234..242 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 245..254 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 257..261 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 265..269 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 270..273 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 274..277 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 283..285 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 288..292 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 298..300 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 303..307 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 312..317 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 320..325 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 327..329 FT /evidence="ECO:0007829|PDB:3U2P" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 340..342 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 350..352 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 360..364 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 366..368 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 370..374 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 377..379 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 386..394 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 397..400 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 402..405 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 415..417 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 425..427 FT /evidence="ECO:0007829|PDB:8U4L" FT STRAND 432..438 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 455..461 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 469..471 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 474..476 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 479..482 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 489..491 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:2AHX" FT TURN 498..500 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 512..516 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 519..528 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 531..534 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 537..543 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 545..548 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 551..554 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 568..573 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 576..585 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 588..592 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 595..608 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 612..616 FT /evidence="ECO:0007829|PDB:2AHX" FT STRAND 625..629 FT /evidence="ECO:0007829|PDB:2AHX" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:8U4L" FT HELIX 651..676 FT /evidence="ECO:0007829|PDB:2L2T" FT HELIX 715..717 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 718..729 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 731..737 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 740..743 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 746..752 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 762..773 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 778..780 FT /evidence="ECO:0007829|PDB:3BBT" FT STRAND 783..787 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 789..791 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 793..797 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 804..810 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 812..814 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 817..836 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 846..848 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 849..853 FT /evidence="ECO:0007829|PDB:2R4B" FT STRAND 856..859 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 864..869 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 889..893 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 899..914 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 920..923 FT /evidence="ECO:0007829|PDB:2R4B" FT TURN 926..928 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 929..934 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 947..955 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 961..963 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 967..977 FT /evidence="ECO:0007829|PDB:2R4B" FT HELIX 981..983 FT /evidence="ECO:0007829|PDB:2R4B" SQ SEQUENCE 1308 AA; 146808 MW; 5E4AE80985D88761 CRC64; MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV // ID GUC2F_HUMAN Reviewed; 1108 AA. AC P51841; Q9UJF1; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 02-NOV-2010, sequence version 2. DT 28-JAN-2026, entry version 220. DE RecName: Full=Retinal guanylyl cyclase 2; DE Short=RETGC-2 {ECO:0000303|PubMed:7777544}; DE EC=4.6.1.2 {ECO:0000269|PubMed:7777544}; DE AltName: Full=Guanylate cyclase 2F, retinal {ECO:0000312|HGNC:HGNC:4691}; DE AltName: Full=Guanylate cyclase F; DE Short=GC-F; DE AltName: Full=Rod outer segment membrane guanylate cyclase 2; DE Short=ROS-GC2; DE Flags: Precursor; GN Name=GUCY2F; Synonyms=GUC2F, RETGC2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANT GLN-296, TISSUE SPECIFICITY, ACTIVITY RP REGULATION, AND CATALYTIC ACTIVITY. RC TISSUE=Retina; RX PubMed=7777544; DOI=10.1073/pnas.92.12.5535; RA Lowe D.G., Dizhoor A.M., Liu K., Gu Q., Spencer M., Laura R., Lu L., RA Hurley J.B.; RT "Cloning and expression of a second photoreceptor-specific membrane retina RT guanylyl cyclase (RetGC), RetGC-2."; RL Proc. Natl. Acad. Sci. U.S.A. 92:5535-5539(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [3] RP VARIANT [LARGE SCALE ANALYSIS] PRO-10. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-40; ASN-160; TRP-230; PRO-284; GLN-305; RP CYS-308; HIS-380; ARG-434; ASP-568; GLN-628; LEU-677; LYS-794; VAL-1010; RP ARG-1052 AND ASP-1055. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP VARIANT ASP-872. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [6] RP ACTIVITY REGULATION. RX PubMed=29515371; DOI=10.3389/fnmol.2018.00052; RA Wimberg H., Janssen-Bienhold U., Koch K.W.; RT "Control of the Nucleotide Cycle in Photoreceptor Cell Extracts by Retinal RT Degeneration Protein 3."; RL Front. Mol. Neurosci. 11:52-52(2018). CC -!- FUNCTION: Responsible for the synthesis of cyclic GMP (cGMP) in rods CC and cones of photoreceptors (PubMed:7777544). Plays an essential role CC in phototransduction, by mediating cGMP replenishment (By similarity). CC May also participate in the trafficking of membrane-associated proteins CC to the photoreceptor outer segment membrane (By similarity). CC {ECO:0000250|UniProtKB:Q5SDA5, ECO:0000269|PubMed:7777544}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP = 3',5'-cyclic GMP + diphosphate; Xref=Rhea:RHEA:13665, CC ChEBI:CHEBI:33019, ChEBI:CHEBI:37565, ChEBI:CHEBI:57746; EC=4.6.1.2; CC Evidence={ECO:0000269|PubMed:7777544}; CC -!- ACTIVITY REGULATION: Activated by GUCA1B when free calcium ions CC concentration is low, and inhibited by GUCA1B when free calcium ions CC concentration is high (PubMed:15772651). Inhibited by RD3 CC (PubMed:29515371). {ECO:0000269|PubMed:15772651, CC ECO:0000269|PubMed:29515371}. CC -!- SUBUNIT: Homodimer (By similarity). Interacts with RD3; promotes the CC exit of GUCY2F from the endoplasmic reticulum and its trafficking to CC the photoreceptor outer segments (By similarity). CC {ECO:0000250|UniProtKB:P51842, ECO:0000250|UniProtKB:Q5SDA5}. CC -!- SUBCELLULAR LOCATION: Photoreceptor outer segment membrane CC {ECO:0000250|UniProtKB:O02740}; Single-pass type I membrane protein CC {ECO:0000255}. CC -!- TISSUE SPECIFICITY: Retina. Localized exclusively in the outer nuclear CC layer and inner segments of the rod and cone photoreceptor cells. CC {ECO:0000269|PubMed:7777544}. CC -!- DOMAIN: The protein kinase domain is predicted to be catalytically CC inactive. CC -!- PTM: There are 9 conserved cysteine residues in sensory guanylate CC cyclases, 6 in the extracellular domain, which may be involved in CC intra- or interchain disulfide bonds. CC -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase CC family. {ECO:0000255|PROSITE-ProRule:PRU00099}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L37378; AAA74451.1; -; mRNA. DR EMBL; AL031387; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS14545.1; -. DR PIR; I59385; I59385. DR RefSeq; NP_001513.2; NM_001522.3. DR AlphaFoldDB; P51841; -. DR SMR; P51841; -. DR BioGRID; 109241; 6. DR FunCoup; P51841; 179. DR IntAct; P51841; 6. DR MINT; P51841; -. DR STRING; 9606.ENSP00000218006; -. DR iPTMnet; P51841; -. DR PhosphoSitePlus; P51841; -. DR BioMuta; GUCY2F; -. DR DMDM; 311033391; -. DR jPOST; P51841; -. DR MassIVE; P51841; -. DR PaxDb; 9606-ENSP00000218006; -. DR PeptideAtlas; P51841; -. DR ProteomicsDB; 56431; -. DR Antibodypedia; 29460; 108 antibodies from 18 providers. DR DNASU; 2986; -. DR Ensembl; ENST00000218006.3; ENSP00000218006.2; ENSG00000101890.5. DR GeneID; 2986; -. DR KEGG; hsa:2986; -. DR MANE-Select; ENST00000218006.3; ENSP00000218006.2; NM_001522.3; NP_001513.2. DR UCSC; uc065aqx.1; human. DR AGR; HGNC:4691; -. DR ClinPGx; PA29071; -. DR CTD; 2986; -. DR DisGeNET; 2986; -. DR GeneCards; GUCY2F; -. DR HGNC; HGNC:4691; GUCY2F. DR HPA; ENSG00000101890; Tissue enriched (retina). DR MIM; 300041; gene. DR OpenTargets; ENSG00000101890; -. DR VEuPathDB; HostDB:ENSG00000101890; -. DR eggNOG; KOG1023; Eukaryota. DR GeneTree; ENSGT00940000162146; -. DR HOGENOM; CLU_001072_1_0_1; -. DR InParanoid; P51841; -. DR OMA; QDSQSMR; -. DR OrthoDB; 1890790at2759; -. DR PAN-GO; P51841; 5 GO annotations based on evolutionary models. DR PhylomeDB; P51841; -. DR BRENDA; 4.6.1.2; 2681. DR PathwayCommons; P51841; -. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR SignaLink; P51841; -. DR BioGRID-ORCS; 2986; 10 hits in 794 CRISPR screens. DR ChiTaRS; GUCY2F; human. DR GenomeRNAi; 2986; -. DR Pharos; P51841; Tbio. DR PRO; PR:P51841; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P51841; protein. DR Bgee; ENSG00000101890; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 14 other cell types or tissues. DR GO; GO:0005640; C:nuclear outer membrane; TAS:ProtInc. DR GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0120200; C:rod photoreceptor outer segment; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW. DR GO; GO:0004383; F:guanylate cyclase activity; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0001653; F:peptide receptor activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IEA:InterPro. DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0006182; P:cGMP biosynthetic process; IBA:GO_Central. DR GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl. DR GO; GO:0050908; P:detection of light stimulus involved in visual perception; IEA:Ensembl. DR GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IBA:GO_Central. DR GO; GO:0022400; P:regulation of opsin-mediated signaling pathway; TAS:Reactome. DR GO; GO:0007601; P:visual perception; TAS:ProtInc. DR CDD; cd07302; CHD; 1. DR CDD; cd06371; PBP1_sensory_GC_DEF-like; 1. DR FunFam; 1.10.510.10:FF:000404; Guanylate cyclase; 1. DR FunFam; 3.30.70.1230:FF:000013; Guanylate cyclase; 1. DR FunFam; 3.40.50.2300:FF:000114; Guanylate cyclase; 1. DR Gene3D; 3.40.50.2300; -; 2. DR Gene3D; 3.30.70.1230; Nucleotide cyclase; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR001054; A/G_cyclase. DR InterPro; IPR018297; A/G_cyclase_CS. DR InterPro; IPR001828; ANF_lig-bd_rcpt. DR InterPro; IPR050401; Cyclic_nucleotide_synthase. DR InterPro; IPR011645; HNOB_dom_associated. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR029787; Nucleotide_cyclase. DR InterPro; IPR028082; Peripla_BP_I. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR PANTHER; PTHR11920; GUANYLYL CYCLASE; 1. DR PANTHER; PTHR11920:SF349; RETINAL GUANYLYL CYCLASE 2; 1. DR Pfam; PF01094; ANF_receptor; 1. DR Pfam; PF00211; Guanylate_cyc; 1. DR Pfam; PF07701; HNOBA; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00044; CYCc; 1. DR SUPFAM; SSF55073; Nucleotide cyclase; 1. DR SUPFAM; SSF53822; Periplasmic binding protein-like I; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1. DR PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW Cell projection; cGMP biosynthesis; Disulfide bond; GTP-binding; Lyase; KW Membrane; Nucleotide-binding; Proteomics identification; KW Reference proteome; Sensory transduction; Signal; Transmembrane; KW Transmembrane helix; Vision. FT SIGNAL 1..50 FT /evidence="ECO:0000255" FT CHAIN 51..1108 FT /note="Retinal guanylyl cyclase 2" FT /id="PRO_0000012386" FT TOPO_DOM 51..467 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 468..490 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 491..1108 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 532..812 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 884..1014 FT /note="Guanylate cyclase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00099" FT DISULFID 104..132 FT /evidence="ECO:0000250" FT DISULFID 452 FT /note="Interchain" FT /evidence="ECO:0000250" FT DISULFID 460 FT /note="Interchain" FT /evidence="ECO:0000250" FT VARIANT 10 FT /note="R -> P (in a breast cancer sample; somatic mutation; FT dbSNP:rs755991142)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036419" FT VARIANT 40 FT /note="S -> C (in dbSNP:rs34228145)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042233" FT VARIANT 160 FT /note="I -> N (in dbSNP:rs33971675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042234" FT VARIANT 230 FT /note="R -> W (in dbSNP:rs33973457)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042235" FT VARIANT 284 FT /note="L -> P (in dbSNP:rs12008095)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_009136" FT VARIANT 296 FT /note="R -> Q (in dbSNP:rs502209)" FT /evidence="ECO:0000269|PubMed:7777544" FT /id="VAR_009137" FT VARIANT 305 FT /note="R -> Q (in dbSNP:rs55966326)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042236" FT VARIANT 308 FT /note="Y -> C (in dbSNP:rs16985750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030633" FT VARIANT 380 FT /note="Q -> H (in dbSNP:rs2272925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030634" FT VARIANT 434 FT /note="G -> R (in dbSNP:rs56293008)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042237" FT VARIANT 568 FT /note="G -> D (in a glioblastoma multiforme sample; somatic FT mutation; dbSNP:rs779221554)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042238" FT VARIANT 628 FT /note="R -> Q (in dbSNP:rs7883913)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_030635" FT VARIANT 677 FT /note="V -> L (in dbSNP:rs35474112)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042239" FT VARIANT 794 FT /note="E -> K (in dbSNP:rs35726803)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042240" FT VARIANT 872 FT /note="G -> D (in dbSNP:rs148663380)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069424" FT VARIANT 1010 FT /note="A -> V (in dbSNP:rs55735218)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042241" FT VARIANT 1052 FT /note="K -> R (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042242" FT VARIANT 1055 FT /note="E -> D (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042243" SQ SEQUENCE 1108 AA; 124850 MW; B047BBF1A3C009F9 CRC64; MFLGLGRFSR LVLWFAAFRK LLGHHGLASA KFLWCLCLLS VMSLPQQVWT LPYKIGVVGP WACDSLFSKA LPEVAARLAI ERINRDPSFD LSYSFEYVIL NEDCQTSRAL SSFISHHQMA SGFIGPTNPG YCEAASLLGN SWDKGIFSWA CVNYELDNKI SYPTFSRTLP SPIRVLVTVM KYFQWAHAGV ISSDEDIWVH TANRVASALR SHGLPVGVVL TTGQDSQSMR KALQRIHQAD RIRIIIMCMH SALIGGETQM HLLECAHDLK MTDGTYVFVP YDALLYSLPY KHTPYRVLRN NPKLREAYDA VLTITVESQE KTFYQAFTEA AARGEIPEKL EFDQVSPLFG TIYNSIYFIA QAMNNAMKEN GQAGAASLVQ HSRNMQFHGF NQLMRTDSNG NGISEYVILD TNLKEWELHS TYTVDMEMEL LRFGGTPIHF PGGRPPRADA KCWFAEGKIC HGGIDPAFAM MVCLTLLIAL LSINGFAYFI RRRINKIQLI KGPNRILLTL EDVTFINPHF GSKRGSRASV SFQITSEVQS GRSPRLSFSS GSLTPATYEN SNIAIYEGDW VWLKKFSLGD FGDLKSIKSR ASDVFEMMKD LRHENINPLL GFFYDSGMFA IVTEFCSRGS LEDILTNQDV KLDWMFKSSL LLDLIKGMKY LHHREFVHGR LKSRNCVVDG RFVLKVTDYG FNDILEMLRL SEEESSMEEL LWTAPELLRA PRGSRLGSFA GDVYSFAIIM QEVMVRGTPF CMMDLPAQEI INRLKKPPPV YRPVVPPEHA PPECLQLMKQ CWAEAAEQRP TFDEIFNQFK TFNKGKKTNI IDSMLRMLEQ YSSNLEDLIR ERTEELEIEK QKTEKLLTQM LPPSVAESLK KGCTVEPEGF DLVTLYFSDI VGFTTISAMS EPIEVVDLLN DLYTLFDAII GSHDVYKVET IGDAYMVASG LPKRNGSRHA AEIANMSLDI LSSVGTFKMR HMPEVPVRIR IGLHSGPVVA GVVGLTMPRY CLFGDTVNTA SRMESTGLPY RIHVSLSTVT ILQNLSEGYE VELRGRTELK GKGTEETFWL IGKKGFMKPL PVPPPVDKDG QVGHGLQPVE IAAFQRRKAE RQLVRNKP // ID KPCL_HUMAN Reviewed; 683 AA. AC P24723; B4DJN5; Q16246; Q8NE03; DT 01-MAR-1992, integrated into UniProtKB/Swiss-Prot. DT 15-DEC-2009, sequence version 4. DT 28-JAN-2026, entry version 232. DE RecName: Full=Protein kinase C eta type; DE EC=2.7.11.13 {ECO:0000269|PubMed:34593629}; DE AltName: Full=PKC-L; DE AltName: Full=nPKC-eta; GN Name=PRKCH; Synonyms=PKCL, PRKCL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RC TISSUE=Lung; RX PubMed=1986216; DOI=10.1128/mcb.11.1.126-133.1991; RA Bacher N., Zisman Y., Berent E., Livneh E.; RT "Isolation and characterization of PKC-L, a new member of the protein RT kinase C-related gene family specifically expressed in lung, skin, and RT heart."; RL Mol. Cell. Biol. 11:126-133(1991). RN [2] RP ERRATUM OF PUBMED:1986216, AND SEQUENCE REVISION. RX PubMed=1545821; DOI=10.1128/mcb.12.3.1404-.1992; RA Bacher N., Zisman Y., Berent E., Livneh E.; RL Mol. Cell. Biol. 12:1404-1404(1992). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Thalamus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 438-539 (ISOFORM 1). RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [8] RP FUNCTION. RX PubMed=11112424; DOI=10.1006/bbrc.2000.3903; RA Akkaraju G.R., Basu A.; RT "Overexpression of protein kinase C-eta attenuates caspase activation and RT tumor necrosis factor-alpha-induced cell death."; RL Biochem. Biophys. Res. Commun. 279:103-107(2000). RN [9] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=10806212; DOI=10.1074/jbc.m003203200; RA Hussaini I.M., Karns L.R., Vinton G., Carpenter J.E., Redpath G.T., RA Sando J.J., VandenBerg S.R.; RT "Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific RT proliferative response in astrocytic tumor cells."; RL J. Biol. Chem. 275:22348-22354(2000). RN [10] RP FUNCTION. RX PubMed=11772428; DOI=10.1093/neuonc/4.1.9; RA Hussaini I.M., Carpenter J.E., Redpath G.T., Sando J.J., Shaffrey M.E., RA Vandenberg S.R.; RT "Protein kinase C-eta regulates resistance to UV- and gamma-irradiation- RT induced apoptosis in glioblastoma cells by preventing caspase-9 RT activation."; RL Neuro-oncol. 4:9-21(2002). RN [11] RP FUNCTION IN CELL PROLIFERATION. RX PubMed=15489897; DOI=10.1038/sj.onc.1208093; RA Aeder S.E., Martin P.M., Soh J.W., Hussaini I.M.; RT "PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR RT signaling pathways."; RL Oncogene 23:9062-9069(2004). RN [12] RP INTERACTION WITH DGKQ. RX PubMed=15632189; DOI=10.1074/jbc.m409301200; RA van Baal J., de Widt J., Divecha N., van Blitterswijk W.J.; RT "Translocation of diacylglycerol kinase theta from cytosol to plasma RT membrane in response to activation of G protein-coupled receptors and RT protein kinase C."; RL J. Biol. Chem. 280:9870-9878(2005). RN [13] RP FUNCTION. RX PubMed=17146445; DOI=10.1038/sj.onc.1210090; RA Uht R.M., Amos S., Martin P.M., Riggan A.E., Hussaini I.M.; RT "The protein kinase C-eta isoform induces proliferation in glioblastoma RT cell lines through an ERK/Elk-1 pathway."; RL Oncogene 26:2885-2893(2007). RN [14] RP FUNCTION IN B-CELL SIGNALING. RX PubMed=18780722; DOI=10.1093/intimm/dxn101; RA Oda A., Ono T., Yamamoto M., Goitsuka R., Kitamura D.; RT "PKC eta directs induction of IRF-4 expression and Ig kappa gene RT rearrangement in pre-BCR signaling pathway."; RL Int. Immunol. 20:1417-1426(2008). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [16] RP INDUCTION. RX PubMed=19797084; DOI=10.1128/mcb.01044-09; RA Raveh-Amit H., Maissel A., Poller J., Marom L., Elroy-Stein O., Shapira M., RA Livneh E.; RT "Translational control of protein kinase Ceta by two upstream open reading RT frames."; RL Mol. Cell. Biol. 29:6140-6148(2009). RN [17] RP FUNCTION IN PHOSPHORYLATION OF OCLN. RX PubMed=19114660; DOI=10.1073/pnas.0802741106; RA Suzuki T., Elias B.C., Seth A., Shen L., Turner J.R., Giorgianni F., RA Desiderio D., Guntaka R., Rao R.; RT "PKC eta regulates occludin phosphorylation and epithelial tight junction RT integrity."; RL Proc. Natl. Acad. Sci. U.S.A. 106:61-66(2009). RN [18] RP FUNCTION. RX PubMed=20558593; DOI=10.1124/mol.110.064394; RA Lee H.K., Yeo S., Kim J.S., Lee J.G., Bae Y.S., Lee C., Baek S.H.; RT "Protein kinase C-eta and phospholipase D2 pathway regulates foam cell RT formation via regulator of G protein signaling 2."; RL Mol. Pharmacol. 78:478-485(2010). RN [19] RP FUNCTION. RX PubMed=21820409; DOI=10.1016/j.bbrc.2011.07.090; RA Raveh-Amit H., Hai N., Rotem-Dai N., Shahaf G., Gopas J., Livneh E.; RT "Protein kinase C? activates NF-?B in response to camptothecin-induced DNA RT damage."; RL Biochem. Biophys. Res. Commun. 412:313-317(2011). RN [20] RP REVIEW. RX PubMed=12473186; DOI=10.1093/oxfordjournals.jbchem.a003297; RA Kashiwagi M., Ohba M., Chida K., Kuroki T.; RT "Protein kinase C eta (PKC eta): its involvement in keratinocyte RT differentiation."; RL J. Biochem. 132:853-857(2002). RN [21] RP FUNCTION. RX PubMed=22304920; DOI=10.1016/j.cell.2012.01.016; RA Lau E., Kluger H., Varsano T., Lee K., Scheffler I., Rimm D.L., Ideker T., RA Ronai Z.A.; RT "PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while RT blocking its apoptotic function at mitochondria."; RL Cell 148:543-555(2012). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-656, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH PRKCH UPSTREAM RP OPEN READING FRAME 2, AND PHOSPHORYLATION AT THR-656 AND SER-675. RX PubMed=34593629; DOI=10.1073/pnas.2018899118; RA Jayaram D.R., Frost S., Argov C., Liju V.B., Anto N.P., Muraleedharan A., RA Ben-Ari A., Sinay R., Smoly I., Novoplansky O., Isakov N., Toiber D., RA Keasar C., Elkabets M., Yeger-Lotem E., Livneh E.; RT "Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor RT of PKCs."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [25] RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 1-138, PHOSPHORYLATION AT SER-28 RP AND SER-32, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=16973127; DOI=10.1016/j.bbrc.2006.08.160; RA Littler D.R., Walker J.R., She Y.-M., Finerty P.J. Jr., Newman E.M., RA Dhe-Paganon S.; RT "Structure of human protein kinase C eta (PKCeta) C2 domain and RT identification of phosphorylation sites."; RL Biochem. Biophys. Res. Commun. 349:1182-1189(2006). RN [26] RP ASSOCIATION OF VARIANT ILE-374 WITH ISCHSTR, AND CHARACTERIZATION OF RP VARIANT ILE-374. RX PubMed=17206144; DOI=10.1038/ng1945; RA Kubo M., Hata J., Ninomiya T., Matsuda K., Yonemoto K., Nakano T., RA Matsushita T., Yamazaki K., Ohnishi Y., Saito S., Kitazono T., Ibayashi S., RA Sueishi K., Iida M., Nakamura Y., Kiyohara Y.; RT "A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of RT cerebral infarction."; RL Nat. Genet. 39:212-217(2007). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-19; ARG-65; GLN-149; GLN-359; ILE-374; RP ALA-575; ILE-594 AND SER-612. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-independent, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in the CC regulation of cell differentiation in keratinocytes and pre-B cell CC receptor, mediates regulation of epithelial tight junction integrity CC and foam cell formation, and is required for glioblastoma proliferation CC and apoptosis prevention in MCF-7 cells. In keratinocytes, binds and CC activates the tyrosine kinase FYN, which in turn blocks epidermal CC growth factor receptor (EGFR) signaling and leads to keratinocyte CC growth arrest and differentiation. Associates with the cyclin CCNE1- CC CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 CC dephosphorylation and thereby G1 arrest in keratinocytes. In CC association with RALA activates actin depolymerization, which is CC necessary for keratinocyte differentiation. In the pre-B cell receptor CC signaling, functions downstream of BLNK by up-regulating IRF4, which in CC turn activates L chain gene rearrangement. Regulates epithelial tight CC junctions (TJs) by phosphorylating occludin (OCLN) on threonine CC residues, which is necessary for the assembly and maintenance of TJs. CC In association with PLD2 and via TLR4 signaling, is involved in CC lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell CC formation. Upon PMA stimulation, mediates glioblastoma cell CC proliferation by activating the mTOR pathway, the PI3K/AKT pathway and CC the ERK1-dependent phosphorylation of ELK1. Involved in the protection CC of glioblastoma cells from irradiation-induced apoptosis by preventing CC caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates CC NF-kappa-B upstream signaling by activating IKBKB, and confers CC protection against DNA damage-induced apoptosis. Promotes oncogenic CC functions of ATF2 in the nucleus while blocking its apoptotic function CC at mitochondria. Phosphorylates ATF2 which promotes its nuclear CC retention and transcriptional activity and negatively regulates its CC mitochondrial localization. {ECO:0000269|PubMed:10806212, CC ECO:0000269|PubMed:11112424, ECO:0000269|PubMed:11772428, CC ECO:0000269|PubMed:15489897, ECO:0000269|PubMed:17146445, CC ECO:0000269|PubMed:18780722, ECO:0000269|PubMed:19114660, CC ECO:0000269|PubMed:20558593, ECO:0000269|PubMed:21820409, CC ECO:0000269|PubMed:22304920}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:34593629}; CC -!- ACTIVITY REGULATION: Novel PKCs (PRKCD, PRKCE, PRKCH and PRKCQ) are CC calcium-insensitive, but activated by diacylglycerol (DAG) and CC phosphatidylserine. Three specific sites; Thr-513 (activation loop of CC the kinase domain), Thr-656 (turn motif) and Ser-675 (hydrophobic CC region), need to be phosphorylated for its full activation. Inhibited CC by PRKCH upstream open reading frame 2 (PubMed:34593629). CC {ECO:0000269|PubMed:34593629}. CC -!- SUBUNIT: Interacts with FYN (By similarity). Interacts with RALA (By CC similarity). Interacts with DGKQ (PubMed:15632189). Interacts with CC PRKCH upstream open reading frame 2; the interaction leads to CC inhibition of kinase activity (PubMed:34593629). CC {ECO:0000250|UniProtKB:P23298, ECO:0000269|PubMed:15632189, CC ECO:0000269|PubMed:34593629}. CC -!- INTERACTION: CC P24723; Q16625-1: OCLN; NbExp=2; IntAct=EBI-2865850, EBI-16115673; CC P24723; Q28269: OCLN; Xeno; NbExp=2; IntAct=EBI-2865850, EBI-16222162; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P24723-1; Sequence=Displayed; CC Name=2; CC IsoId=P24723-2; Sequence=VSP_056572; CC -!- TISSUE SPECIFICITY: Most abundant in lung, less in heart and skin. CC {ECO:0000269|PubMed:1986216}. CC -!- INDUCTION: By stress conditions caused by amino acid starvation (at CC protein level). {ECO:0000269|PubMed:19797084}. CC -!- DOMAIN: The C1 domain, containing the phorbol ester/DAG-type region 1 CC (C1A) and 2 (C1B), is the diacylglycerol sensor and the C2 domain is a CC non-calcium binding domain. CC -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an acute CC neurologic event leading to death of neural tissue of the brain and CC resulting in loss of motor, sensory and/or cognitive function. Ischemic CC strokes, resulting from vascular occlusion, is considered to be a CC highly complex disease consisting of a group of heterogeneous disorders CC with multiple genetic and environmental risk factors. CC {ECO:0000269|PubMed:17206144}. Note=Disease susceptibility is CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M55284; AAA60100.1; -; mRNA. DR EMBL; AK290183; BAF82872.1; -; mRNA. DR EMBL; AK296158; BAG58897.1; -; mRNA. DR EMBL; AL138996; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL355916; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL359220; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471061; EAW80800.1; -; Genomic_DNA. DR EMBL; CH471061; EAW80801.1; -; Genomic_DNA. DR EMBL; BC037268; AAH37268.1; -; mRNA. DR EMBL; S74620; AAB32724.1; -; mRNA. DR CCDS; CCDS9752.1; -. [P24723-1] DR PIR; A39666; A39666. DR RefSeq; NP_006246.2; NM_006255.4. [P24723-1] DR RefSeq; XP_024305429.1; XM_024449661.2. [P24723-2] DR RefSeq; XP_024305430.1; XM_024449662.2. [P24723-2] DR RefSeq; XP_054232364.1; XM_054376389.1. [P24723-2] DR RefSeq; XP_054232365.1; XM_054376390.1. [P24723-2] DR PDB; 2FK9; X-ray; 1.75 A; A=1-138. DR PDB; 3TXO; X-ray; 2.05 A; A=333-683. DR PDB; 8FP1; X-ray; 1.85 A; A=333-683. DR PDB; 8FP3; X-ray; 2.30 A; A=333-683. DR PDBsum; 2FK9; -. DR PDBsum; 3TXO; -. DR PDBsum; 8FP1; -. DR PDBsum; 8FP3; -. DR AlphaFoldDB; P24723; -. DR SMR; P24723; -. DR BioGRID; 111569; 31. DR DIP; DIP-44588N; -. DR FunCoup; P24723; 864. DR IntAct; P24723; 14. DR MINT; P24723; -. DR STRING; 9606.ENSP00000329127; -. DR BindingDB; P24723; -. DR ChEMBL; CHEMBL3616; -. DR DrugCentral; P24723; -. DR GuidetoPHARMACOLOGY; 1487; -. DR GlyGen; P24723; 3 sites, 3 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P24723; -. DR PhosphoSitePlus; P24723; -. DR BioMuta; PRKCH; -. DR DMDM; 281185512; -. DR CPTAC; CPTAC-3187; -. DR CPTAC; CPTAC-3188; -. DR jPOST; P24723; -. DR MassIVE; P24723; -. DR PaxDb; 9606-ENSP00000329127; -. DR PeptideAtlas; P24723; -. DR ProteomicsDB; 4395; -. DR ProteomicsDB; 54223; -. [P24723-1] DR Pumba; P24723; -. DR Antibodypedia; 24422; 309 antibodies from 34 providers. DR DNASU; 5583; -. DR Ensembl; ENST00000332981.11; ENSP00000329127.5; ENSG00000027075.18. [P24723-1] DR Ensembl; ENST00000555082.6; ENSP00000450981.1; ENSG00000027075.18. [P24723-2] DR GeneID; 5583; -. DR KEGG; hsa:5583; -. DR MANE-Select; ENST00000332981.11; ENSP00000329127.5; NM_006255.5; NP_006246.2. DR UCSC; uc001xfn.4; human. [P24723-1] DR AGR; HGNC:9403; -. DR ClinPGx; PA33767; -. DR CTD; 5583; -. DR DisGeNET; 5583; -. DR GeneCards; PRKCH; -. DR HGNC; HGNC:9403; PRKCH. DR HPA; ENSG00000027075; Low tissue specificity. DR MalaCards; PRKCH; -. DR MIM; 601367; phenotype. DR MIM; 605437; gene. DR OpenTargets; ENSG00000027075; -. DR VEuPathDB; HostDB:ENSG00000027075; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000158220; -. DR HOGENOM; CLU_000288_54_4_1; -. DR InParanoid; P24723; -. DR OMA; MTKNPNM; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P24723; 3 GO annotations based on evolutionary models. DR PhylomeDB; P24723; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P24723; -. DR Reactome; R-HSA-114508; Effects of PIP2 hydrolysis. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR SABIO-RK; P24723; -. DR SignaLink; P24723; -. DR SIGNOR; P24723; -. DR Agora; ENSG00000027075; -. DR BioGRID-ORCS; 5583; 14 hits in 1196 CRISPR screens. DR ChiTaRS; PRKCH; human. DR EvolutionaryTrace; P24723; -. DR GeneWiki; PRKCH; -. DR GenomeRNAi; 5583; -. DR Pharos; P24723; Tchem. DR PRO; PR:P24723; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; P24723; protein. DR Bgee; ENSG00000027075; Expressed in parotid gland and 189 other cell types or tissues. DR ExpressionAtlas; P24723; baseline and differential. DR GO; GO:0005911; C:cell-cell junction; IEA:Ensembl. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; ISS:UniProtKB. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; TAS:ProtInc. DR GO; GO:0004699; F:diacylglycerol-dependent, calcium-independent serine/threonine kinase activity; IEA:Ensembl. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0031267; F:small GTPase binding; IEA:Ensembl. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0141212; P:phospholipase C/protein kinase C signal transduction; IEA:Ensembl. DR GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:UniProtKB. DR GO; GO:0045618; P:positive regulation of keratinocyte differentiation; ISS:UniProtKB. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; ISS:UniProtKB. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; TAS:ParkinsonsUK-UCL. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:2000810; P:regulation of bicellular tight junction assembly; IMP:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR CDD; cd20835; C1_nPKC_epsilon-like_rpt1; 1. DR CDD; cd20838; C1_nPKC_epsilon-like_rpt2; 1. DR CDD; cd04014; C2_PKC_epsilon; 1. DR CDD; cd05590; STKc_nPKC_eta; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000003; Protein kinase C delta; 1. DR FunFam; 1.10.510.10:FF:000126; Protein kinase C epsilon; 1. DR FunFam; 2.60.40.150:FF:000056; Protein kinase C epsilon; 1. DR FunFam; 3.30.60.20:FF:000024; Protein kinase C epsilon; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR034665; nPKC_eta. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR027431; PKC_eta. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR014376; Prot_kin_PKC_delta. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000551; PKC_delta; 1. DR PIRSF; PIRSF501107; Protein_kin_C_eta; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cytoplasm; KW Differentiation; Kinase; Metal-binding; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..683 FT /note="Protein kinase C eta type" FT /id="PRO_0000055705" FT DOMAIN 1..118 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 355..614 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 615..683 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 171..222 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 245..295 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 320..342 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 479 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 361..369 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 384 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 28 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127, FT ECO:0007744|PubMed:23186163" FT MOD_RES 32 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000305|PubMed:16973127" FT MOD_RES 317 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P23298" FT MOD_RES 513 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000305" FT MOD_RES 656 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:34593629, FT ECO:0007744|PubMed:24275569" FT MOD_RES 675 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:34593629" FT VAR_SEQ 1..161 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056572" FT VARIANT 19 FT /note="A -> V (in dbSNP:rs55645551)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042312" FT VARIANT 65 FT /note="K -> R (in dbSNP:rs55737090)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042313" FT VARIANT 149 FT /note="R -> Q (in dbSNP:rs55848048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042314" FT VARIANT 359 FT /note="R -> Q (in dbSNP:rs55818778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042315" FT VARIANT 374 FT /note="V -> I (risk factor for ischemic stroke; increases FT autophosphorylation and kinase activity; dbSNP:rs2230500)" FT /evidence="ECO:0000269|PubMed:17206144, FT ECO:0000269|PubMed:17344846" FT /id="VAR_034604" FT VARIANT 497 FT /note="D -> Y (in dbSNP:rs11846991)" FT /id="VAR_060736" FT VARIANT 575 FT /note="T -> A (in a aLL TEL/AML1+ sample; somatic mutation; FT dbSNP:rs1378993559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042316" FT VARIANT 594 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042317" FT VARIANT 612 FT /note="P -> S (in dbSNP:rs34159231)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042318" FT VARIANT 645 FT /note="D -> V (in dbSNP:rs35561533)" FT /id="VAR_042438" FT CONFLICT 96 FT /note="Missing (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 109 FT /note="L -> R (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 110 FT /note="R -> G (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 393 FT /note="Q -> L (in Ref. 1; AAA60100)" FT /evidence="ECO:0000305" FT CONFLICT 472 FT /note="D -> E (in Ref. 7; AAB32724)" FT /evidence="ECO:0000305" FT STRAND 8..20 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 26..30 FT /evidence="ECO:0007829|PDB:2FK9" FT TURN 31..33 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 34..37 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 43..49 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 52..56 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 67..79 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 81..88 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 91..94 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 96..104 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 105..112 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 116..123 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2FK9" FT STRAND 129..137 FT /evidence="ECO:0007829|PDB:2FK9" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 355..364 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 367..374 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 375..377 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 380..387 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 388..393 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 397..409 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 410..412 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 419..424 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 426..434 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 438..440 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 441..448 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 453..472 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 482..484 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:8FP1" FT STRAND 493..495 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 518..520 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 523..526 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 534..549 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 559..568 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 600..602 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 603..605 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 606..609 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 619..623 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 646..648 FT /evidence="ECO:0007829|PDB:8FP1" FT TURN 660..662 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 663..665 FT /evidence="ECO:0007829|PDB:8FP1" FT HELIX 668..671 FT /evidence="ECO:0007829|PDB:8FP1" SQ SEQUENCE 683 AA; 77828 MW; 0A29806CE31912F2 CRC64; MSSGTMKFNG YLRVRIGEAV GLQPTRWSLR HSLFKKGHQL LDPYLTVSVD QVRVGQTSTK QKTNKPTYNE EFCANVTDGG HLELAVFHET PLGYDHFVAN CTLQFQELLR TTGASDTFEG WVDLEPEGKV FVVITLTGSF TEATLQRDRI FKHFTRKRQR AMRRRVHQIN GHKFMATYLR QPTYCSHCRE FIWGVFGKQG YQCQVCTCVV HKRCHHLIVT ACTCQNNINK VDSKIAEQRF GINIPHKFSI HNYKVPTFCD HCGSLLWGIM RQGLQCKICK MNVHIRCQAN VAPNCGVNAV ELAKTLAGMG LQPGNISPTS KLVSRSTLRR QGKESSKEGN GIGVNSSNRL GIDNFEFIRV LGKGSFGKVM LARVKETGDL YAVKVLKKDV ILQDDDVECT MTEKRILSLA RNHPFLTQLF CCFQTPDRLF FVMEFVNGGD LMFHIQKSRR FDEARARFYA AEIISALMFL HDKGIIYRDL KLDNVLLDHE GHCKLADFGM CKEGICNGVT TATFCGTPDY IAPEILQEML YGPAVDWWAM GVLLYEMLCG HAPFEAENED DLFEAILNDE VVYPTWLHED ATGILKSFMT KNPTMRLGSL TQGGEHAILR HPFFKEIDWA QLNHRQIEPP FRPRIKSRED VSNFDPDFIK EEPVLTPIDE GHLPMINQDE FRNFSYVSPE LQP // ID NEK1_HUMAN Reviewed; 1258 AA. AC Q96PY6; G5E9Z3; Q05DG5; Q14CB7; Q5H9T1; Q6PIB8; Q96SS2; Q9H6P7; Q9Y594; DT 13-AUG-2002, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-2002, sequence version 2. DT 28-JAN-2026, entry version 212. DE RecName: Full=Serine/threonine-protein kinase Nek1; DE EC=2.7.11.1 {ECO:0000269|PubMed:20230784}; DE AltName: Full=Never in mitosis A-related kinase 1; DE Short=NimA-related protein kinase 1; DE AltName: Full=Renal carcinoma antigen NY-REN-55; GN Name=NEK1; Synonyms=KIAA1901; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=11572484; DOI=10.1093/dnares/8.4.179; RA Nagase T., Kikuno R., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XXI. The RT complete sequences of 60 new cDNA clones from brain which code for large RT proteins."; RL DNA Res. 8:179-187(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT GLY-724. RC TISSUE=Uterus; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4). RC TISSUE=Bone marrow, and Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 91-1258 (ISOFORM 5), AND RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 865-1258. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 444-1258 (ISOFORM 2), AND IDENTIFICATION AS A RP RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [8] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=15604234; DOI=10.1158/0008-5472.can-04-2243; RA Polci R., Peng A., Chen P.L., Riley D.J., Chen Y.; RT "NIMA-related protein kinase 1 is involved early in the ionizing radiation- RT induced DNA damage response."; RL Cancer Res. 64:8800-8803(2004). RN [9] RP SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=18843199; DOI=10.4161/cc.7.20.6815; RA Chen Y., Chen P.L., Chen C.F., Jiang X., Riley D.J.; RT "Never-in-mitosis related kinase 1 functions in DNA damage response and RT checkpoint control."; RL Cell Cycle 7:3194-3201(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414; SER-418; SER-428; RP SER-653; SER-798; SER-834; SER-868 AND SER-881, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP FUNCTION IN PHOSPHORYLATION OF VDAC1, AND CATALYTIC ACTIVITY. RX PubMed=20230784; DOI=10.1016/j.bbrc.2010.03.077; RA Chen Y., Gaczynska M., Osmulski P., Polci R., Riley D.J.; RT "Phosphorylation by Nek1 regulates opening and closing of voltage dependent RT anion channel 1."; RL Biochem. Biophys. Res. Commun. 394:798-803(2010). RN [14] RP FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INVOLVEMENT IN RP DIGENIC SHORT-RIB THORACIC DYSPLASIA 3/6 WITH POLYDACTYLY. RX PubMed=21211617; DOI=10.1016/j.ajhg.2010.12.004; RA Thiel C., Kessler K., Giessl A., Dimmler A., Shalev S.A., von der Haar S., RA Zenker M., Zahnleiter D., Stoess H., Beinder E., Abou Jamra R., Ekici A.B., RA Schroeder-Kress N., Aigner T., Kirchner T., Reis A., Brandstaetter J.H., RA Rauch A.; RT "NEK1 mutations cause short-rib polydactyly syndrome type majewski."; RL Am. J. Hum. Genet. 88:106-114(2011). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-156; SER-428; THR-661; RP SER-664; SER-868; SER-881 AND SER-1052, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1052, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN A COMPLEX WITH RP CFAP410 AND SPATA7 BY MASS SPECTROMETRY, AND INTERACTION WITH CFAP410. RX PubMed=26167768; DOI=10.1038/ncb3201; RG UK10K Consortium; RG University of Washington Center for Mendelian Genomics; RA Wheway G., Schmidts M., Mans D.A., Szymanska K., Nguyen T.M., Racher H., RA Phelps I.G., Toedt G., Kennedy J., Wunderlich K.A., Sorusch N., RA Abdelhamed Z.A., Natarajan S., Herridge W., van Reeuwijk J., Horn N., RA Boldt K., Parry D.A., Letteboer S.J., Roosing S., Adams M., Bell S.M., RA Bond J., Higgins J., Morrison E.E., Tomlinson D.C., Slaats G.G., RA van Dam T.J., Huang L., Kessler K., Giessl A., Logan C.V., Boyle E.A., RA Shendure J., Anazi S., Aldahmesh M., Al Hazzaa S., Hegele R.A., Ober C., RA Frosk P., Mhanni A.A., Chodirker B.N., Chudley A.E., Lamont R., RA Bernier F.P., Beaulieu C.L., Gordon P., Pon R.T., Donahue C., RA Barkovich A.J., Wolf L., Toomes C., Thiel C.T., Boycott K.M., McKibbin M., RA Inglehearn C.F., Stewart F., Omran H., Huynen M.A., Sergouniotis P.I., RA Alkuraya F.S., Parboosingh J.S., Innes A.M., Willoughby C.E., Giles R.H., RA Webster A.R., Ueffing M., Blacque O., Gleeson J.G., Wolfrum U., RA Beales P.L., Gibson T., Doherty D., Mitchison H.M., Roepman R., RA Johnson C.A.; RT "An siRNA-based functional genomics screen for the identification of RT regulators of ciliogenesis and ciliopathy genes."; RL Nat. Cell Biol. 17:1074-1087(2015). RN [19] RP INVOLVEMENT IN OFD2, AND VARIANTS OFD2 THR-155 AND 409-TRP--GLU-1258 DEL. RX PubMed=27530628; DOI=10.1038/ejhg.2016.103; RA Monroe G.R., Kappen I.F., Stokman M.F., Terhal P.A., van den Boogaard M.H., RA Savelberg S.M., van der Veken L.T., van Es R.J., Lens S.M., Hengeveld R.C., RA Creton M.A., Janssen N.G., Mink van der Molen A.B., Ebbeling M.B., RA Giles R.H., Knoers N.V., van Haaften G.; RT "Compound heterozygous NEK1 variants in two siblings with oral-facial- RT digital syndrome type II (Mohr syndrome)."; RL Eur. J. Hum. Genet. 24:1752-1760(2016). RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-10; LYS-25; VAL-76; PRO-294; GLY-355; RP VAL-463; THR-598; GLY-724; ASN-745; GLU-883 AND ASN-1180. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [21] RP VARIANTS SRTD6 ARG-145 AND SER-253. RX PubMed=22499340; DOI=10.1136/jmedgenet-2011-100717; RA El Hokayem J., Huber C., Couve A., Aziza J., Baujat G., Bouvier R., RA Cavalcanti D.P., Collins F.A., Cordier M.P., Delezoide A.L., Gonzales M., RA Johnson D., Le Merrer M., Levy-Mozziconacci A., Loget P., RA Martin-Coignard D., Martinovic J., Mortier G.R., Perez M.J., Roume J., RA Scarano G., Munnich A., Cormier-Daire V.; RT "NEK1 and DYNC2H1 are both involved in short rib polydactyly Majewski type RT but not in Beemer Langer cases."; RL J. Med. Genet. 49:227-233(2012). RN [22] RP INVOLVEMENT IN ALS24, AND VARIANTS 784-ARG--GLU-1258 DEL AND RP 1008-SER--GLU-1258 DEL. RX PubMed=26945885; DOI=10.1093/brain/aww033; RA Brenner D., Mueller K., Wieland T., Weydt P., Boehm S., Lule D., RA Huebers A., Neuwirth C., Weber M., Borck G., Wahlqvist M., Danzer K.M., RA Volk A.E., Meitinger T., Strom T.M., Otto M., Kassubek J., Ludolph A.C., RA Andersen P.M., Weishaupt J.H.; RT "NEK1 mutations in familial amyotrophic lateral sclerosis."; RL Brain 139:E28-E28(2016). RN [23] RP INVOLVEMENT IN ALS24, AND VARIANTS HIS-261 AND 550-ARG--GLU-1258 DEL. RX PubMed=27455347; DOI=10.1038/ng.3626; RA Kenna K.P., van Doormaal P.T., Dekker A.M., Ticozzi N., Kenna B.J., RA Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., RA Shatunov A., Sproviero W., Smith B.N., van Es M.A., Topp S.D., Kenna A., RA Miller J.W., Fallini C., Tiloca C., McLaughlin R.L., Vance C., Troakes C., RA Colombrita C., Mora G., Calvo A., Verde F., Al-Sarraj S., King A., RA Calini D., de Belleroche J., Baas F., van der Kooi A.J., de Visser M., RA Ten Asbroek A.L., Sapp P.C., McKenna-Yasek D., Polak M., Asress S., RA Munoz-Blanco J.L., Strom T.M., Meitinger T., Morrison K.E., Lauria G., RA Williams K.L., Leigh P.N., Nicholson G.A., Blair I.P., Leblond C.S., RA Dion P.A., Rouleau G.A., Pall H., Shaw P.J., Turner M.R., Talbot K., RA Taroni F., Boylan K.B., Van Blitterswijk M., Rademakers R., RA Esteban-Perez J., Garcia-Redondo A., Van Damme P., Robberecht W., Chio A., RA Gellera C., Drepper C., Sendtner M., Ratti A., Glass J.D., Mora J.S., RA Basak N.A., Hardiman O., Ludolph A.C., Andersen P.M., Weishaupt J.H., RA Brown R.H. Jr., Al-Chalabi A., Silani V., Shaw C.E., van den Berg L.H., RA Veldink J.H., Landers J.E.; RT "NEK1 variants confer susceptibility to amyotrophic lateral sclerosis."; RL Nat. Genet. 48:1037-1042(2016). CC -!- FUNCTION: Phosphorylates serines and threonines, but also appears to CC possess tyrosine kinase activity (PubMed:20230784). Involved in DNA CC damage checkpoint control and for proper DNA damage repair CC (PubMed:20230784). In response to injury that includes DNA damage, NEK1 CC phosphorylates VDAC1 to limit mitochondrial cell death CC (PubMed:20230784). May be implicated in the control of meiosis (By CC similarity). Involved in cilium assembly (PubMed:21211617). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:20230784, CC ECO:0000269|PubMed:21211617}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:20230784}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- SUBUNIT: Binds to CBY2 (By similarity). Found in a complex with CC CFAP410, NEK1 and SPATA7 (PubMed:26167768). Interacts with CFAP410 CC (PubMed:26167768). Interacts (via Ser-1052 phosphorylated form) with CC 14-3-3 proteins (By similarity). {ECO:0000250|UniProtKB:P51954, CC ECO:0000269|PubMed:26167768}. CC -!- INTERACTION: CC Q96PY6; Q96Q42: ALS2; NbExp=2; IntAct=EBI-373615, EBI-1044902; CC Q96PY6; Q99689: FEZ1; NbExp=2; IntAct=EBI-373615, EBI-396435; CC Q96PY6; Q9UHY8: FEZ2; NbExp=2; IntAct=EBI-373615, EBI-396453; CC Q96PY6; Q5S007: LRRK2; NbExp=2; IntAct=EBI-373615, EBI-5323863; CC Q96PY6; Q04917: YWHAH; NbExp=6; IntAct=EBI-373615, EBI-306940; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15604234, CC ECO:0000305|PubMed:21211617}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome {ECO:0000250|UniProtKB:P51954}. Cytoplasm CC {ECO:0000269|PubMed:18843199}. Note=Associated with the pericentriolar CC material (PubMed:21211617). Localizes to centrosome during interphase CC and mitosis (By similarity). Translocated from cytoplasm to discrete CC nuclear foci at sites of DNA damage (PubMed:15604234). CC {ECO:0000250|UniProtKB:P51954, ECO:0000269|PubMed:15604234, CC ECO:0000269|PubMed:21211617}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q96PY6-1; Sequence=Displayed; CC Name=2; CC IsoId=Q96PY6-2; Sequence=VSP_004870; CC Name=3; CC IsoId=Q96PY6-3; Sequence=VSP_035439; CC Name=4; CC IsoId=Q96PY6-4; Sequence=VSP_035435, VSP_035436; CC Name=5; CC IsoId=Q96PY6-5; Sequence=VSP_035437, VSP_035438; CC Name=6; CC IsoId=Q96PY6-6; Sequence=VSP_035436, VSP_035439; CC -!- TISSUE SPECIFICITY: High fetal expression in the brain and kidney. CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Short-rib thoracic dysplasia 6 with or without polydactyly CC (SRTD6) [MIM:263520]: A form of short-rib thoracic dysplasia, a group CC of autosomal recessive ciliopathies that are characterized by a CC constricted thoracic cage, short ribs, shortened tubular bones, and a CC 'trident' appearance of the acetabular roof. Polydactyly is variably CC present. Non-skeletal involvement can include cleft lip/palate as well CC as anomalies of major organs such as the brain, eye, heart, kidneys, CC liver, pancreas, intestines, and genitalia. Some forms of the disease CC are lethal in the neonatal period due to respiratory insufficiency CC secondary to a severely restricted thoracic cage, whereas others are CC compatible with life. Disease spectrum encompasses Ellis-van Creveld CC syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer- CC Saldino syndrome, and short rib-polydactyly syndrome. CC {ECO:0000269|PubMed:22499340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. In some cases NEK1 CC mutations result in disease phenotype in the presence of mutations in CC DYNC2H1 indicating digenic inheritance (digenic short rib-polydactyly CC syndrome 3/6 with polydactyly) (PubMed:21211617). CC {ECO:0000269|PubMed:21211617}. CC -!- DISEASE: Amyotrophic lateral sclerosis 24 (ALS24) [MIM:617892]: A form CC of amyotrophic lateral sclerosis, a neurodegenerative disorder CC affecting upper motor neurons in the brain and lower motor neurons in CC the brain stem and spinal cord, resulting in fatal paralysis. Sensory CC abnormalities are absent. The pathologic hallmarks of the disease CC include pallor of the corticospinal tract due to loss of motor neurons, CC presence of ubiquitin-positive inclusions within surviving motor CC neurons, and deposition of pathologic aggregates. The etiology of CC amyotrophic lateral sclerosis is likely to be multifactorial, involving CC both genetic and environmental factors. The disease is inherited in 5- CC 10% of the cases. {ECO:0000269|PubMed:26945885, CC ECO:0000269|PubMed:27455347}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Orofaciodigital syndrome 2 (OFD2) [MIM:252100]: A form of CC orofaciodigital syndrome, a group of heterogeneous disorders CC characterized by malformations of the oral cavity, face and digits, and CC associated phenotypic abnormalities that lead to the delineation of CC various subtypes. OFD2 is an autosomal recessive form characterized by CC cleft lip/palate, lobulated tongue with nodules, dental anomalies, CC maxillary hypoplasia, conductive hearing loss, polydactyly, syndactyly, CC brachydactyly, and mesomelic lower limb shortening. CC {ECO:0000269|PubMed:27530628}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. NEK Ser/Thr CC protein kinase family. NIMA subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH15147.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305}; CC Sequence=BAB15207.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB55209.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB67794.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB067488; BAB67794.1; ALT_INIT; mRNA. DR EMBL; CR933642; CAI45943.1; -; mRNA. DR EMBL; AC116615; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC116621; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC084724; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471056; EAX04791.1; -; Genomic_DNA. DR EMBL; BC015147; AAH15147.1; ALT_SEQ; mRNA. DR EMBL; BC037790; AAH37790.1; -; mRNA. DR EMBL; BC114491; AAI14492.1; -; mRNA. DR EMBL; AK025658; BAB15207.1; ALT_INIT; mRNA. DR EMBL; AK027580; BAB55209.1; ALT_INIT; mRNA. DR EMBL; AF155113; AAD42879.1; -; mRNA. DR CCDS; CCDS47162.1; -. [Q96PY6-1] DR CCDS; CCDS56348.1; -. [Q96PY6-4] DR CCDS; CCDS56349.1; -. [Q96PY6-2] DR CCDS; CCDS56350.1; -. [Q96PY6-6] DR CCDS; CCDS56351.1; -. [Q96PY6-3] DR RefSeq; NP_001186326.1; NM_001199397.3. [Q96PY6-3] DR RefSeq; NP_001186327.1; NM_001199398.3. [Q96PY6-6] DR RefSeq; NP_001186328.1; NM_001199399.3. [Q96PY6-4] DR RefSeq; NP_001186329.1; NM_001199400.3. [Q96PY6-2] DR RefSeq; NP_001361347.1; NM_001374418.1. [Q96PY6-3] DR RefSeq; NP_001361348.1; NM_001374419.1. [Q96PY6-1] DR RefSeq; NP_036356.1; NM_012224.4. [Q96PY6-1] DR RefSeq; XP_011530306.1; XM_011532004.2. [Q96PY6-2] DR RefSeq; XP_047271687.1; XM_047415731.1. [Q96PY6-6] DR PDB; 4APC; X-ray; 2.10 A; A/B=1-328. DR PDB; 4B9D; X-ray; 1.90 A; A/B=1-328. DR PDBsum; 4APC; -. DR PDBsum; 4B9D; -. DR AlphaFoldDB; Q96PY6; -. DR SMR; Q96PY6; -. DR BioGRID; 110825; 92. DR CORUM; Q96PY6; -. DR FunCoup; Q96PY6; 4026. DR IntAct; Q96PY6; 63. DR MINT; Q96PY6; -. DR STRING; 9606.ENSP00000424757; -. DR BindingDB; Q96PY6; -. DR ChEMBL; CHEMBL5855; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q96PY6; -. DR GuidetoPHARMACOLOGY; 2114; -. DR GlyGen; Q96PY6; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q96PY6; -. DR PhosphoSitePlus; Q96PY6; -. DR BioMuta; NEK1; -. DR DMDM; 22256934; -. DR jPOST; Q96PY6; -. DR MassIVE; Q96PY6; -. DR PaxDb; 9606-ENSP00000424757; -. DR PeptideAtlas; Q96PY6; -. DR ProteomicsDB; 34091; -. DR ProteomicsDB; 77788; -. [Q96PY6-1] DR ProteomicsDB; 77789; -. [Q96PY6-2] DR ProteomicsDB; 77790; -. [Q96PY6-3] DR ProteomicsDB; 77791; -. [Q96PY6-4] DR ProteomicsDB; 77792; -. [Q96PY6-5] DR Pumba; Q96PY6; -. DR TopDownProteomics; Q96PY6-3; -. [Q96PY6-3] DR Antibodypedia; 28454; 148 antibodies from 27 providers. DR DNASU; 4750; -. DR Ensembl; ENST00000439128.6; ENSP00000408020.2; ENSG00000137601.19. [Q96PY6-1] DR Ensembl; ENST00000507142.6; ENSP00000424757.2; ENSG00000137601.19. [Q96PY6-3] DR Ensembl; ENST00000510533.5; ENSP00000427653.1; ENSG00000137601.19. [Q96PY6-2] DR Ensembl; ENST00000511633.5; ENSP00000423332.1; ENSG00000137601.19. [Q96PY6-6] DR Ensembl; ENST00000512193.5; ENSP00000424938.1; ENSG00000137601.19. [Q96PY6-4] DR GeneID; 4750; -. DR KEGG; hsa:4750; -. DR MANE-Select; ENST00000507142.6; ENSP00000424757.2; NM_001199397.3; NP_001186326.1. [Q96PY6-3] DR UCSC; uc003isb.3; human. [Q96PY6-1] DR AGR; HGNC:7744; -. DR ClinPGx; PA31545; -. DR CTD; 4750; -. DR DisGeNET; 4750; -. DR GeneCards; NEK1; -. DR HGNC; HGNC:7744; NEK1. DR HPA; ENSG00000137601; Low tissue specificity. DR MalaCards; NEK1; -. DR MIM; 252100; phenotype. DR MIM; 263520; phenotype. DR MIM; 604588; gene. DR MIM; 617892; phenotype. DR OpenTargets; ENSG00000137601; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 2751; Orofaciodigital syndrome type 2. DR Orphanet; 93269; Short rib-polydactyly syndrome, Majewski type. DR VEuPathDB; HostDB:ENSG00000137601; -. DR eggNOG; KOG0589; Eukaryota. DR GeneTree; ENSGT00940000158460; -. DR HOGENOM; CLU_000288_60_1_1; -. DR InParanoid; Q96PY6; -. DR OMA; ELNEEWH; -. DR OrthoDB; 248923at2759; -. DR PAN-GO; Q96PY6; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q96PY6; -. DR PathwayCommons; Q96PY6; -. DR Reactome; R-HSA-9861718; Regulation of pyruvate metabolism. DR SignaLink; Q96PY6; -. DR SIGNOR; Q96PY6; -. DR Agora; ENSG00000137601; -. DR BioGRID-ORCS; 4750; 51 hits in 1199 CRISPR screens. DR ChiTaRS; NEK1; human. DR EvolutionaryTrace; Q96PY6; -. DR GeneWiki; NEK1; -. DR GenomeRNAi; 4750; -. DR Pharos; Q96PY6; Tchem. DR PRO; PR:Q96PY6; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q96PY6; protein. DR Bgee; ENSG00000137601; Expressed in secondary oocyte and 212 other cell types or tissues. DR ExpressionAtlas; Q96PY6; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0000242; C:pericentriolar material; IDA:UniProtKB. DR GO; GO:0071889; F:14-3-3 protein binding; ISS:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016301; F:kinase activity; IMP:CACAO. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IDA:MGI. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0060271; P:cilium assembly; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:CACAO. DR CDD; cd08218; STKc_Nek1; 1. DR FunFam; 3.30.200.20:FF:000097; Probable serine/threonine-protein kinase nek1; 1. DR FunFam; 1.10.510.10:FF:000172; serine/threonine-protein kinase Nek1 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR051131; NEK_Ser/Thr_kinase_NIMA. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR44899; CAMK FAMILY PROTEIN KINASE; 1. DR PANTHER; PTHR44899:SF4; SERINE_THREONINE-PROTEIN KINASE NEK1; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Amyotrophic lateral sclerosis; KW ATP-binding; Cell cycle; Cell division; Ciliopathy; KW Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton; Kinase; Magnesium; KW Metal-binding; Mitosis; Neurodegeneration; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase. FT CHAIN 1..1258 FT /note="Serine/threonine-protein kinase Nek1" FT /id="PRO_0000086418" FT DOMAIN 4..258 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 330..360 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 578..600 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 648..669 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 685..704 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1118..1171 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 344..360 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 579..591 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 691..700 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 128 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 10..18 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 33 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 156 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 162 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000250" FT MOD_RES 414 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 418 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 428 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT MOD_RES 653 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 661 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 664 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 798 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 834 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 868 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 881 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1052 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 1126 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P51954" FT VAR_SEQ 398..422 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035435" FT VAR_SEQ 477..520 FT /note="Missing (in isoform 4 and isoform 6)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_035436" FT VAR_SEQ 478..521 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10508479" FT /id="VSP_004870" FT VAR_SEQ 522..527 FT /note="QKGQLA -> LDCDDP (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035437" FT VAR_SEQ 528..1258 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_035438" FT VAR_SEQ 555 FT /note="M -> MGILQNLAAMYGGRPSSSRGGKPRNKEEE (in isoform 3 and FT isoform 6)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_035439" FT VARIANT 10 FT /note="I -> F (in dbSNP:rs34214559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040900" FT VARIANT 25 FT /note="E -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040901" FT VARIANT 76 FT /note="L -> V (in dbSNP:rs35093214)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040902" FT VARIANT 145 FT /note="G -> R (in SRTD6; dbSNP:rs431905508)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069617" FT VARIANT 155 FT /note="S -> T (in OFD2; uncertain significance; the FT nucleotide substitution creating this missense variant may FT predominantly result in aberrant splicing, with skipping of FT exon 6 and creation of a premature stop codon, possibly FT leading to nonsense-mediated mRNA decay)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089300" FT VARIANT 253 FT /note="L -> S (in SRTD6)" FT /evidence="ECO:0000269|PubMed:22499340" FT /id="VAR_069618" FT VARIANT 261 FT /note="R -> H (risk factor for ALS24; dbSNP:rs200161705)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080694" FT VARIANT 294 FT /note="A -> P (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040903" FT VARIANT 355 FT /note="R -> G (in dbSNP:rs35763578)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040904" FT VARIANT 409..1258 FT /note="Missing (in OFD2; uncertain significance; the FT nucleotide substitution creating this nonsense variant may FT predominantly result in aberrant splicing)" FT /evidence="ECO:0000269|PubMed:27530628" FT /id="VAR_089301" FT VARIANT 463 FT /note="A -> V (in dbSNP:rs34540355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040905" FT VARIANT 550..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:27455347" FT /id="VAR_080695" FT VARIANT 598 FT /note="A -> T (in dbSNP:rs33933790)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046486" FT VARIANT 717 FT /note="N -> K (in dbSNP:rs34324114)" FT /id="VAR_061743" FT VARIANT 724 FT /note="E -> G (in dbSNP:rs34099167)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005" FT /id="VAR_051651" FT VARIANT 745 FT /note="K -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040906" FT VARIANT 784..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080696" FT VARIANT 883 FT /note="Q -> E (in dbSNP:rs6828134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046488" FT VARIANT 1008..1258 FT /note="Missing (risk factor for ALS24)" FT /evidence="ECO:0000269|PubMed:26945885" FT /id="VAR_080697" FT VARIANT 1180 FT /note="D -> N (in dbSNP:rs35503975)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_046489" FT CONFLICT 250 FT /note="N -> D (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 602 FT /note="R -> RK (in Ref. 2; CAI45943)" FT /evidence="ECO:0000305" FT CONFLICT 1232 FT /note="G -> E (in Ref. 7; AAD42879)" FT /evidence="ECO:0000305" FT STRAND 4..9 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 24..26 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 29..36 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 42..57 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 66..72 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 88..94 FT /evidence="ECO:0007829|PDB:4B9D" FT TURN 95..97 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 102..121 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 131..133 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 134..136 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:4B9D" FT STRAND 149..151 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 155..164 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 172..175 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 182..198 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 208..217 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 229..238 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 243..245 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 249..253 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 256..259 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 260..264 FT /evidence="ECO:0007829|PDB:4B9D" FT HELIX 268..275 FT /evidence="ECO:0007829|PDB:4B9D" SQ SEQUENCE 1258 AA; 142828 MW; 339C4BFA56612530 CRC64; MEKYVRLQKI GEGSFGKAIL VKSTEDGRQY VIKEINISRM SSKEREESRR EVAVLANMKH PNIVQYRESF EENGSLYIVM DYCEGGDLFK RINAQKGVLF QEDQILDWFV QICLALKHVH DRKILHRDIK SQNIFLTKDG TVQLGDFGIA RVLNSTVELA RTCIGTPYYL SPEICENKPY NNKSDIWALG CVLYELCTLK HAFEAGSMKN LVLKIISGSF PPVSLHYSYD LRSLVSQLFK RNPRDRPSVN SILEKGFIAK RIEKFLSPQL IAEEFCLKTF SKFGSQPIPA KRPASGQNSI SVMPAQKITK PAAKYGIPLA YKKYGDKKLH EKKPLQKHKQ AHQTPEKRVN TGEERRKISE EAARKRRLEF IEKEKKQKDQ IISLMKAEQM KRQEKERLER INRAREQGWR NVLSAGGSGE VKAPFLGSGG TIAPSSFSSR GQYEHYHAIF DQMQQQRAED NEAKWKREIY GRGLPERGIL PGVRPGFPYG AAGHHHFPDA DDIRKTLKRL KAVSKQANAN RQKGQLAVER AKQVEEFLQR KREAMQNKAR AEGHMVYLAR LRQIRLQNFN ERQQIKAKLR GEKKEANHSE GQEGSEEADM RRKKIESLKA HANARAAVLK EQLERKRKEA YEREKKVWEE HLVAKGVKSS DVSPPLGQHE TGGSPSKQQM RSVISVTSAL KEVGVDSSLT DTRETSEEMQ KTNNAISSKR EILRRLNENL KAQEDEKGKQ NLSDTFEINV HEDAKEHEKE KSVSSDRKKW EAGGQLVIPL DELTLDTSFS TTERHTVGEV IKLGPNGSPR RAWGKSPTDS VLKILGEAEL QLQTELLENT TIRSEISPEG EKYKPLITGE KKVQCISHEI NPSAIVDSPV ETKSPEFSEA SPQMSLKLEG NLEEPDDLET EILQEPSGTN KDESLPCTIT DVWISEEKET KETQSADRIT IQENEVSEDG VSSTVDQLSD IHIEPGTNDS QHSKCDVDKS VQPEPFFHKV VHSEHLNLVP QVQSVQCSPE ESFAFRSHSH LPPKNKNKNS LLIGLSTGLF DANNPKMLRT CSLPDLSKLF RTLMDVPTVG DVRQDNLEID EIEDENIKEG PSDSEDIVFE ETDTDLQELQ ASMEQLLREQ PGEEYSEEEE SVLKNSDVEP TANGTDVADE DDNPSSESAL NEEWHSDNSD GEIASECECD SVFNHLEELR LHLEQEMGFE KFFEVYEKIK AIHEDEDENI EICSKIVQNI LGNEHQHLYA KILHLVMADG AYQEDNDE // ID RIR2B_HUMAN Reviewed; 351 AA. AC Q7LG56; B4E2N4; Q17R22; Q75PQ6; Q75PQ7; Q75PY8; Q75PY9; Q86YE3; Q9NPD6; AC Q9NTD8; Q9NUW3; DT 21-MAR-2006, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 197. DE RecName: Full=Ribonucleoside-diphosphate reductase subunit M2 B; DE EC=1.17.4.1; DE AltName: Full=TP53-inducible ribonucleotide reductase M2 B; DE AltName: Full=p53-inducible ribonucleotide reductase small subunit 2-like protein; DE Short=p53R2; GN Name=RRM2B; Synonyms=P53R2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), FUNCTION, AND RP INDUCTION. RX PubMed=10716435; DOI=10.1038/35003506; RA Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., RA Takei Y., Nakamura Y.; RT "A ribonucleotide reductase gene involved in a p53-dependent cell-cycle RT checkpoint for DNA damage."; RL Nature 404:42-49(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5). RA Ugai H., Yokoyama K.K.; RT "Homo sapiens p53-inducible ribonucleotide reductase small subunit 2 RT splicing variants."; RL Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 1-351 (ISOFORM 6). RC TISSUE=Placenta, and Trachea; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain, and Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP FUNCTION, AND SUBUNIT. RX PubMed=11517226; DOI=10.1074/jbc.m106088200; RA Guittet O., Haakansson P., Voevodskaya N., Fridd S., Graeslund A., RA Arakawa H., Nakamura Y., Thelander L.; RT "Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro RT with the R1 protein, which is expressed both in resting cells in response RT to DNA damage and in proliferating cells."; RL J. Biol. Chem. 276:40647-40651(2001). RN [10] RP FUNCTION, SUBCELLULAR LOCATION, AND VARIANT LEU-115. RX PubMed=11719458; RA Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., RA Arakawa H.; RT "p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle RT checkpoint."; RL Cancer Res. 61:8256-8262(2001). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH TP53 AND RRM1. RX PubMed=12615712; RA Xue L., Zhou B., Liu X., Qiu W., Jin Z., Yen Y.; RT "Wild-type p53 regulates human ribonucleotide reductase by protein-protein RT interaction with p53R2 as well as hRRM2 subunits."; RL Cancer Res. 63:980-986(2003). RN [12] RP TISSUE SPECIFICITY. RX PubMed=14583450; RA Zhou B., Liu X., Mo X., Xue L., Darwish D., Qiu W., Shih J., Hwu E.B., RA Luh F., Yen Y.; RT "The human ribonucleotide reductase subunit hRRM2 complements p53R2 in RT response to UV-induced DNA repair in cells with mutant p53."; RL Cancer Res. 63:6583-6594(2003). RN [13] RP CATALYTIC ACTIVITY, AND SUBUNIT. RX PubMed=16376858; DOI=10.1016/j.bbrc.2005.12.019; RA Qiu W., Zhou B., Darwish D., Shao J., Yen Y.; RT "Characterization of enzymatic properties of human ribonucleotide reductase RT holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits."; RL Biochem. Biophys. Res. Commun. 340:428-434(2006). RN [14] RP INVOLVEMENT IN PEOA5. RX PubMed=19664747; DOI=10.1016/j.ajhg.2009.07.009; RA Tyynismaa H., Ylikallio E., Patel M., Molnar M.J., Haller R.G., RA Suomalainen A.; RT "A heterozygous truncating mutation in RRM2B causes autosomal-dominant RT progressive external ophthalmoplegia with multiple mtDNA deletions."; RL Am. J. Hum. Genet. 85:290-295(2009). RN [15] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH IRON IONS, AND RP COFACTOR. RX PubMed=19728742; DOI=10.1021/bi9001425; RA Smith P., Zhou B., Ho N., Yuan Y.C., Su L., Tsai S.C., Yen Y.; RT "2.6 A X-ray crystal structure of human p53R2, a p53-inducible RT ribonucleotide reductase."; RL Biochemistry 48:11134-11141(2009). RN [17] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 20-322 IN COMPLEX WITH IRON IONS. RG Structural genomics consortium (SGC); RT "Human ribonucleotide reductase, subunit M2 B."; RL Submitted (FEB-2009) to the PDB data bank. RN [18] RP VARIANTS MTDPS8A ARG-64; GLU-85 DEL; GLY-194; LYS-194 AND PHE-236. RX PubMed=17486094; DOI=10.1038/ng2040; RA Bourdon A., Minai L., Serre V., Jais J.-P., Sarzi E., Aubert S., RA Chretien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., RA Munnich A., Roetig A.; RT "Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase RT (p53R2), causes severe mitochondrial DNA depletion."; RL Nat. Genet. 39:776-780(2007). RN [19] RP VARIANTS MTDPS8A SER-224; ILE-282 AND VAL-317. RX PubMed=18504129; DOI=10.1016/j.nmd.2008.04.006; RA Bornstein B., Area E., Flanigan K.M., Ganesh J., Jayakar P., Swoboda K.J., RA Coku J., Naini A., Shanske S., Tanji K., Hirano M., DiMauro S.; RT "Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene."; RL Neuromuscul. Disord. 18:453-459(2008). RN [20] RP VARIANTS MTDPS8B HIS-110 AND HIS-121. RX PubMed=19667227; DOI=10.1001/archneurol.2009.139; RA Shaibani A., Shchelochkov O.A., Zhang S., Katsonis P., Lichtarge O., RA Wong L.J., Shinawi M.; RT "Mitochondrial neurogastrointestinal encephalopathy due to mutations in RT RRM2B."; RL Arch. Neurol. 66:1028-1032(2009). RN [21] RP VARIANT SER-33. RX PubMed=26741492; DOI=10.1371/journal.pgen.1005679; RA Kohda M., Tokuzawa Y., Kishita Y., Nyuzuki H., Moriyama Y., Mizuno Y., RA Hirata T., Yatsuka Y., Yamashita-Sugahara Y., Nakachi Y., Kato H., RA Okuda A., Tamaru S., Borna N.N., Banshoya K., Aigaki T., Sato-Miyata Y., RA Ohnuma K., Suzuki T., Nagao A., Maehata H., Matsuda F., Higasa K., RA Nagasaki M., Yasuda J., Yamamoto M., Fushimi T., Shimura M., RA Kaiho-Ichimoto K., Harashima H., Yamazaki T., Mori M., Murayama K., RA Ohtake A., Okazaki Y.; RT "A comprehensive genomic analysis reveals the genetic landscape of RT mitochondrial respiratory chain complex deficiencies."; RL PLoS Genet. 12:E1005679-E1005679(2016). RN [22] RP VARIANT RCDFRD ASP-262, AND INVOLVEMENT IN RCDFRD. RX PubMed=32827185; DOI=10.1002/humu.24094; RA Roberts L., Julius S., Dawlat S., Yildiz S., Rebello G., Meldau S., RA Pillay K., Esterhuizen A., Vorster A., Benefeld G., da Rocha J., RA Beighton P., Sellars S.L., Thandrayen K., Pettifor J.M., Ramesar R.S.; RT "Renal dysfunction, rod-cone dystrophy, and sensorineural hearing loss RT caused by a mutation in RRM2B."; RL Hum. Mutat. 41:1871-1876(2020). CC -!- FUNCTION: Plays a pivotal role in cell survival by repairing damaged CC DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for CC DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free CC radical center required for catalysis. Forms an active ribonucleotide CC reductase (RNR) complex with RRM1 which is expressed both in resting CC and proliferating cells in response to DNA damage. CC {ECO:0000269|PubMed:10716435, ECO:0000269|PubMed:11517226, CC ECO:0000269|PubMed:11719458}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 2'-deoxyribonucleoside 5'-diphosphate + [thioredoxin]- CC disulfide + H2O = a ribonucleoside 5'-diphosphate + [thioredoxin]- CC dithiol; Xref=Rhea:RHEA:23252, Rhea:RHEA-COMP:10698, Rhea:RHEA- CC COMP:10700, ChEBI:CHEBI:15377, ChEBI:CHEBI:29950, ChEBI:CHEBI:50058, CC ChEBI:CHEBI:57930, ChEBI:CHEBI:73316; EC=1.17.4.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10014, CC ECO:0000269|PubMed:16376858}; CC -!- COFACTOR: CC Name=Fe cation; Xref=ChEBI:CHEBI:24875; CC Evidence={ECO:0000269|PubMed:19728742}; CC Note=Binds 2 iron ions per subunit. {ECO:0000269|PubMed:19728742}; CC -!- SUBUNIT: Heterotetramer with large (RRM1) subunit. Interacts with CC p53/TP53. Interacts with RRM1 in response to DNA damage. CC {ECO:0000269|PubMed:11517226, ECO:0000269|PubMed:12615712, CC ECO:0000269|PubMed:16376858, ECO:0000269|PubMed:19728742, CC ECO:0000269|Ref.17}. CC -!- INTERACTION: CC Q7LG56; Q13315: ATM; NbExp=3; IntAct=EBI-9009083, EBI-495465; CC Q7LG56; Q00987: MDM2; NbExp=2; IntAct=EBI-9009083, EBI-389668; CC Q7LG56; O43929: ORC4; NbExp=4; IntAct=EBI-9009083, EBI-374889; CC Q7LG56; Q9H4P4: RNF41; NbExp=3; IntAct=EBI-9009083, EBI-2130266; CC Q7LG56; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-9009083, EBI-9009083; CC Q7LG56-1; Q00987: MDM2; NbExp=2; IntAct=EBI-15741413, EBI-389668; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Translocates from CC cytoplasm to nucleus in response to DNA damage. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Name=1; CC IsoId=Q7LG56-1; Sequence=Displayed; CC Name=2; Synonyms=Long form; CC IsoId=Q7LG56-2; Sequence=VSP_017670; CC Name=3; Synonyms=Short form gamma; CC IsoId=Q7LG56-3; Sequence=VSP_017669; CC Name=4; Synonyms=Short form beta; CC IsoId=Q7LG56-4; Sequence=VSP_017668; CC Name=5; Synonyms=Short form; CC IsoId=Q7LG56-5; Sequence=VSP_017671, VSP_017672; CC Name=6; CC IsoId=Q7LG56-6; Sequence=VSP_053585; CC -!- TISSUE SPECIFICITY: Widely expressed at a high level in skeletal muscle CC and at a weak level in thymus. Expressed in epithelial dysplasias and CC squamous cell carcinoma. {ECO:0000269|PubMed:14583450}. CC -!- INDUCTION: In response to DNA damage in a wild-type p53/TP53-dependent CC manner. {ECO:0000269|PubMed:10716435}. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8A (MTDPS8A) CC [MIM:612075]: A disorder due to mitochondrial dysfunction characterized CC by various combinations of neonatal hypotonia, neurological CC deterioration, respiratory distress, lactic acidosis, and renal CC tubulopathy. {ECO:0000269|PubMed:17486094, CC ECO:0000269|PubMed:18504129}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Mitochondrial DNA depletion syndrome 8B (MTDPS8B) CC [MIM:612075]: A disease due to mitochondrial dysfunction and CC characterized by ophthalmoplegia, ptosis, gastrointestinal dysmotility, CC cachexia, peripheral neuropathy. {ECO:0000269|PubMed:19667227}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Progressive external ophthalmoplegia with mitochondrial DNA CC deletions, autosomal dominant, 5 (PEOA5) [MIM:613077]: A disorder CC characterized by progressive weakness of ocular muscles and levator CC muscle of the upper eyelid. In a minority of cases, it is associated CC with skeletal myopathy, which predominantly involves axial or proximal CC muscles and which causes abnormal fatigability and even permanent CC muscle weakness. Ragged-red fibers and atrophy are found on muscle CC biopsy. A large proportion of chronic ophthalmoplegias are associated CC with other symptoms, leading to a multisystemic pattern of this CC disease. Additional symptoms are variable, and may include cataracts, CC hearing loss, sensory axonal neuropathy, ataxia, depression, CC hypogonadism, and parkinsonism. {ECO:0000269|PubMed:19664747}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Rod-cone dystrophy, sensorineural deafness, and Fanconi-type CC renal dysfunction (RCDFRD) [MIM:268315]: An autosomal recessive disease CC characterized by visual impairment due to rod-cone dystrophy, CC sensorineural hearing loss, and Fanconi-type renal dysfunction CC resulting in rickets-like skeletal changes. Death may occur in CC childhood or young adulthood due to renal failure. Disease onset is CC before age 5 years. {ECO:0000269|PubMed:32827185}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a CC premature stop codon in the mRNA, leading to nonsense-mediated mRNA CC decay. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the ribonucleoside diphosphate reductase small CC chain family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG65196.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=EAW91842.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB036063; BAA92434.1; -; mRNA. DR EMBL; AB036532; BAA92493.1; -; Genomic_DNA. DR EMBL; AB163437; BAD11774.1; -; mRNA. DR EMBL; AB163438; BAD11775.1; -; mRNA. DR EMBL; AB166669; BAD12265.1; -; mRNA. DR EMBL; AB166670; BAD12266.1; -; mRNA. DR EMBL; AB166671; BAD12267.1; -; mRNA. DR EMBL; AK001965; BAA92005.1; -; mRNA. DR EMBL; AK304354; BAG65196.1; ALT_INIT; mRNA. DR EMBL; DC308409; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AL137348; CAB70703.2; -; mRNA. DR EMBL; DQ027001; AAY29059.1; -; Genomic_DNA. DR EMBL; AP001328; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP002907; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471060; EAW91842.1; ALT_SEQ; Genomic_DNA. DR EMBL; BC042468; AAH42468.1; -; mRNA. DR EMBL; BC108261; AAI08262.1; -; mRNA. DR EMBL; BC117496; AAI17497.1; -; mRNA. DR EMBL; BC130628; AAI30629.1; -; mRNA. DR CCDS; CCDS34932.1; -. [Q7LG56-1] DR CCDS; CCDS55267.1; -. [Q7LG56-2] DR PIR; T46249; T46249. DR RefSeq; NP_001165948.1; NM_001172477.1. [Q7LG56-6] DR RefSeq; NP_001165949.1; NM_001172478.2. [Q7LG56-2] DR RefSeq; NP_056528.2; NM_015713.4. [Q7LG56-1] DR PDB; 2VUX; X-ray; 2.80 A; A/B=20-322. DR PDB; 3HF1; X-ray; 2.60 A; A/B=1-351. DR PDB; 4DJN; X-ray; 2.20 A; A/B=13-322. DR PDBsum; 2VUX; -. DR PDBsum; 3HF1; -. DR PDBsum; 4DJN; -. DR AlphaFoldDB; Q7LG56; -. DR SMR; Q7LG56; -. DR BioGRID; 119071; 74. DR ComplexPortal; CPX-369; Ribonucleoside-diphosphate reductase RR1 complex, RRM2B variant. DR CORUM; Q7LG56; -. DR DIP; DIP-24264N; -. DR DIP; DIP-48627N; -. DR FunCoup; Q7LG56; 2091. DR IntAct; Q7LG56; 34. DR STRING; 9606.ENSP00000251810; -. DR BindingDB; Q7LG56; -. DR ChEMBL; CHEMBL3301398; -. DR DrugBank; DB00242; Cladribine. DR DrugBank; DB00631; Clofarabine. DR DrugBank; DB12948; Didox. DR GlyGen; Q7LG56; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q7LG56; -. DR PhosphoSitePlus; Q7LG56; -. DR BioMuta; RRM2B; -. DR DMDM; 74727333; -. DR jPOST; Q7LG56; -. DR MassIVE; Q7LG56; -. DR PaxDb; 9606-ENSP00000251810; -. DR PeptideAtlas; Q7LG56; -. DR ProteomicsDB; 5837; -. DR ProteomicsDB; 68860; -. [Q7LG56-1] DR ProteomicsDB; 68861; -. [Q7LG56-2] DR ProteomicsDB; 68862; -. [Q7LG56-3] DR ProteomicsDB; 68863; -. [Q7LG56-4] DR ProteomicsDB; 68864; -. [Q7LG56-5] DR Pumba; Q7LG56; -. DR Antibodypedia; 3483; 343 antibodies from 38 providers. DR DNASU; 50484; -. DR Ensembl; ENST00000251810.8; ENSP00000251810.3; ENSG00000048392.14. [Q7LG56-1] DR Ensembl; ENST00000395912.6; ENSP00000379248.2; ENSG00000048392.14. [Q7LG56-2] DR Ensembl; ENST00000519317.5; ENSP00000430641.1; ENSG00000048392.14. [Q7LG56-3] DR Ensembl; ENST00000519962.5; ENSP00000429140.1; ENSG00000048392.14. [Q7LG56-4] DR Ensembl; ENST00000522394.1; ENSP00000429578.1; ENSG00000048392.14. [Q7LG56-5] DR GeneID; 50484; -. DR KEGG; hsa:50484; -. DR MANE-Select; ENST00000251810.8; ENSP00000251810.3; NM_015713.5; NP_056528.2. DR UCSC; uc003ykn.4; human. [Q7LG56-1] DR AGR; HGNC:17296; -. DR ClinPGx; PA34866; -. DR CTD; 50484; -. DR DisGeNET; 50484; -. DR GeneCards; RRM2B; -. DR GeneReviews; RRM2B; -. DR HGNC; HGNC:17296; RRM2B. DR HPA; ENSG00000048392; Low tissue specificity. DR MalaCards; RRM2B; -. DR MIM; 268315; phenotype. DR MIM; 604712; gene. DR MIM; 612075; phenotype. DR MIM; 613077; phenotype. DR OpenTargets; ENSG00000048392; -. DR Orphanet; 329336; Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy. DR Orphanet; 254892; Autosomal dominant progressive external ophthalmoplegia. DR Orphanet; 480; Kearns-Sayre syndrome. DR Orphanet; 255235; Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy. DR Orphanet; 298; Mitochondrial neurogastrointestinal encephalomyopathy. DR VEuPathDB; HostDB:ENSG00000048392; -. DR eggNOG; KOG1567; Eukaryota. DR GeneTree; ENSGT00390000013305; -. DR HOGENOM; CLU_035339_2_0_1; -. DR InParanoid; Q7LG56; -. DR OMA; LEPMFLG; -. DR OrthoDB; 10248373at2759; -. DR PAN-GO; Q7LG56; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q7LG56; -. DR BRENDA; 1.17.4.1; 2681. DR PathwayCommons; Q7LG56; -. DR Reactome; R-HSA-499943; Interconversion of nucleotide di- and triphosphates. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR SignaLink; Q7LG56; -. DR SIGNOR; Q7LG56; -. DR Agora; ENSG00000048392; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 50484; 17 hits in 1170 CRISPR screens. DR ChiTaRS; RRM2B; human. DR EvolutionaryTrace; Q7LG56; -. DR GeneWiki; RRM2B; -. DR GenomeRNAi; 50484; -. DR Pharos; Q7LG56; Tbio. DR PRO; PR:Q7LG56; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q7LG56; protein. DR Bgee; ENSG00000048392; Expressed in secondary oocyte and 188 other cell types or tissues. DR ExpressionAtlas; Q7LG56; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IEA:GOC. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005971; C:ribonucleoside-diphosphate reductase complex; ISS:ComplexPortal. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0004748; F:ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor; IBA:GO_Central. DR GO; GO:0009265; P:2'-deoxyribonucleotide biosynthetic process; IDA:ComplexPortal. DR GO; GO:0009200; P:deoxyribonucleoside triphosphate metabolic process; IEA:Ensembl. DR GO; GO:0009263; P:deoxyribonucleotide biosynthetic process; IBA:GO_Central. DR GO; GO:0006281; P:DNA repair; IDA:ComplexPortal. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; NAS:ComplexPortal. DR GO; GO:0001822; P:kidney development; IEA:Ensembl. DR GO; GO:0006264; P:mitochondrial DNA replication; IMP:ComplexPortal. DR GO; GO:1902254; P:negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0070318; P:positive regulation of G0 to G1 transition; IDA:ComplexPortal. DR GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IDA:ComplexPortal. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0014075; P:response to amine; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl. DR GO; GO:0009185; P:ribonucleoside diphosphate metabolic process; IDA:ComplexPortal. DR CDD; cd01049; RNRR2; 1. DR FunFam; 1.10.620.20:FF:000004; Ribonucleoside-diphosphate reductase subunit M2 B; 1. DR Gene3D; 1.10.620.20; Ribonucleotide Reductase, subunit A; 1. DR InterPro; IPR009078; Ferritin-like_SF. DR InterPro; IPR012348; RNR-like. DR InterPro; IPR033909; RNR_small. DR InterPro; IPR030475; RNR_small_AS. DR InterPro; IPR000358; RNR_small_fam. DR PANTHER; PTHR23409; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SMALL CHAIN; 1. DR PANTHER; PTHR23409:SF19; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE SUBUNIT M2 B; 1. DR Pfam; PF00268; Ribonuc_red_sm; 1. DR SUPFAM; SSF47240; Ferritin-like; 1. DR PROSITE; PS00368; RIBORED_SMALL; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cytoplasm; Deafness; KW Deoxyribonucleotide synthesis; Disease variant; DNA damage; DNA repair; KW Iron; Metal-binding; Neuropathy; Nucleus; Oxidoreductase; KW Primary mitochondrial disease; Progressive external ophthalmoplegia; KW Proteomics identification; Reference proteome. FT CHAIN 1..351 FT /note="Ribonucleoside-diphosphate reductase subunit M2 B" FT /id="PRO_0000228150" FT REGION 1..32 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU10014" FT BINDING 100 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 131 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 134 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="1" FT BINDING 194 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 228 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT BINDING 231 FT /ligand="Fe cation" FT /ligand_id="ChEBI:CHEBI:24875" FT /ligand_label="2" FT VAR_SEQ 1..16 FT /note="MGDPERPEAAGLDQDE -> MLLLRLPPHRSHASPLDCKLQDRCRKCYSPRS FT GQACPPALAAAWLRRCERRGGRPRGGRRKELTLGLRPARCSAPGPAKDDAWRPQAG FT (in isoform 6)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_053585" FT VAR_SEQ 17..301 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017668" FT VAR_SEQ 17..228 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017669" FT VAR_SEQ 17..68 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017670" FT VAR_SEQ 42..43 FT /note="FV -> SF (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017671" FT VAR_SEQ 44..351 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|Ref.2" FT /id="VSP_017672" FT VARIANT 33 FT /note="P -> S (found in a patient with combined respiratory FT complex deficiencies, muscle weakness and hearing loss; FT uncertain significance; dbSNP:rs387906892)" FT /evidence="ECO:0000269|PubMed:26741492" FT /id="VAR_076280" FT VARIANT 64 FT /note="W -> R (in MTDPS8A; dbSNP:rs515726182)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046217" FT VARIANT 85 FT /note="Missing (in MTDPS8A; dbSNP:rs515726184)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046218" FT VARIANT 110 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607025)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065122" FT VARIANT 115 FT /note="V -> L (in colorectal adenocarcinomas cell line; FT loss of ribonucleotide reductase activity)" FT /evidence="ECO:0000269|PubMed:11719458" FT /id="VAR_025699" FT VARIANT 121 FT /note="R -> H (in MTDPS8B; dbSNP:rs267607024)" FT /evidence="ECO:0000269|PubMed:19667227" FT /id="VAR_065123" FT VARIANT 194 FT /note="E -> G (in MTDPS8A; dbSNP:rs515726191)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046219" FT VARIANT 194 FT /note="E -> K (in MTDPS8A; dbSNP:rs121918308)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046220" FT VARIANT 224 FT /note="I -> S (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726196)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046221" FT VARIANT 236 FT /note="C -> F (in MTDPS8A; dbSNP:rs121918309)" FT /evidence="ECO:0000269|PubMed:17486094" FT /id="VAR_046222" FT VARIANT 262 FT /note="E -> D (in RCDFRD; dbSNP:rs1810682433)" FT /evidence="ECO:0000269|PubMed:32827185" FT /id="VAR_086956" FT VARIANT 282 FT /note="M -> I (in MTDPS8A; without tubulopathy; FT dbSNP:rs182614164)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046223" FT VARIANT 317 FT /note="L -> V (in MTDPS8A; without tubulopathy; FT dbSNP:rs515726198)" FT /evidence="ECO:0000269|PubMed:18504129" FT /id="VAR_046224" FT CONFLICT 277 FT /note="M -> V (in Ref. 3; BAA92005)" FT /evidence="ECO:0000305" FT HELIX 29..31 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 33..35 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 37..39 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 42..44 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 50..61 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 66..68 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 74..78 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 83..109 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 111..114 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 118..145 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 149..156 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 158..161 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 163..177 FT /evidence="ECO:0007829|PDB:4DJN" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 183..195 FT /evidence="ECO:0007829|PDB:4DJN" FT TURN 196..198 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 199..210 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 215..240 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 248..267 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 272..275 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 279..296 FT /evidence="ECO:0007829|PDB:4DJN" FT HELIX 310..312 FT /evidence="ECO:0007829|PDB:4DJN" SQ SEQUENCE 351 AA; 40737 MW; 6D008687EEF40994 CRC64; MGDPERPEAA GLDQDERSSS DTNESEIKSN EEPLLRKSSR RFVIFPIQYP DIWKMYKQAQ ASFWTAEEVD LSKDLPHWNK LKADEKYFIS HILAFFAASD GIVNENLVER FSQEVQVPEA RCFYGFQILI ENVHSEMYSL LIDTYIRDPK KREFLFNAIE TMPYVKKKAD WALRWIADRK STFGERVVAF AAVEGVFFSG SFAAIFWLKK RGLMPGLTFS NELISRDEGL HCDFACLMFQ YLVNKPSEER VREIIVDAVK IEQEFLTEAL PVGLIGMNCI LMKQYIEFVA DRLLVELGFS KVFQAENPFD FMENISLEGK TNFFEKRVSE YQRFAVMAET TDNVFTLDAD F // ID WNK1_HUMAN Reviewed; 2382 AA. AC Q9H4A3; A1L4B0; C5HTZ5; C5HTZ6; C5HTZ7; H6WZW3; O15052; P54963; Q4VBX9; AC Q6IFS5; Q86WL5; Q8N673; Q96CZ6; Q9P1S9; DT 02-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=Serine/threonine-protein kinase WNK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913}; DE AltName: Full=Erythrocyte 65 kDa protein; DE Short=p65; DE AltName: Full=Kinase deficient protein; DE AltName: Full=Protein kinase lysine-deficient 1 {ECO:0000312|HGNC:HGNC:14540}; DE AltName: Full=Protein kinase with no lysine 1 {ECO:0000303|PubMed:11571656}; DE Short=hWNK1; GN Name=WNK1 {ECO:0000303|PubMed:11571656, ECO:0000312|HGNC:HGNC:14540}; GN Synonyms=HSN2 {ECO:0000303|PubMed:15060842}, KDP, GN KIAA0344 {ECO:0000312|EMBL:BAA20802.2}, GN PRKWNK1 {ECO:0000312|HGNC:HGNC:14540}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606 {ECO:0000312|EMBL:CAC15059.1}; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, CHROMOSOMAL RP LOCATION, AND VARIANTS PRO-1056; SER-1506 AND ILE-1808. RC TISSUE=Heart {ECO:0000312|EMBL:CAC15059.1}; RX PubMed=11571656; DOI=10.1038/sj.onc.1204726; RA Verissimo F., Jordan P.; RT "WNK kinases, a novel protein kinase subfamily in multi-cellular RT organisms."; RL Oncogene 20:5562-5569(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Neuron; RX PubMed=22701532; DOI=10.1371/journal.pone.0037751; RA Vidal-Petiot E., Cheval L., Faugeroux J., Malard T., Doucet A., RA Jeunemaitre X., Hadchouel J.; RT "A new methodology for quantification of alternatively spliced exons RT reveals a highly tissue-specific expression pattern of WNK1 isoforms."; RL PLoS ONE 7:E37751-E37751(2012). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-1056; SER-1506 AND RP ILE-1808. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-668 (ISOFORMS 1/2), FUNCTION, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=10660600; DOI=10.1074/jbc.275.6.4311; RA Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J., Morris J.D.H.; RT "PSK, a novel STE20-like kinase derived from prostatic carcinoma that RT activates the JNK MAPK pathway and regulates actin cytoskeletal RT organisation."; RL J. Biol. Chem. 275:4311-4322(2000). RN [6] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-2382 (ISOFORM 2), AND VARIANTS RP PRO-1056 AND SER-1506. RC TISSUE=Brain {ECO:0000312|EMBL:BAA20802.2}; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [7] {ECO:0000305} RP SEQUENCE REVISION TO N-TERMINUS. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [8] RP PROTEIN SEQUENCE OF 163-175, AND GLYCOSYLATION. RX PubMed=2507249; DOI=10.1002/9780470513828.ch7; RA Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G.; RT "Nucleoplasmic and cytoplasmic glycoproteins."; RL Ciba Found. Symp. 145:102-118(1989). RN [9] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (N-TERMINUS OF ISOFORM 3), ALTERNATIVE RP PROMOTER USAGE, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY. RC TISSUE=Kidney {ECO:0000269|PubMed:14645531}; RX PubMed=14645531; DOI=10.1128/mcb.23.24.9208-9221.2003; RA Delaloy C., Lu J., Houot A.-M., Disse-Nicodeme S., Gasc J.-M., Corvol P., RA Jeunemaitre X.; RT "Multiple promoters in the WNK1 gene: one controls expression of a kidney- RT specific kinase-defective isoform."; RL Mol. Cell. Biol. 23:9208-9221(2003). RN [10] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1/4/5). RC TISSUE=Placenta {ECO:0000269|PubMed:15489334}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP IDENTIFICATION (ISOFORMS 4/5), AND INVOLVEMENT IN HSAN2A. RX PubMed=15060842; DOI=10.1086/420795; RA Lafreniere R.G., MacDonald M.L.E., Dube M.-P., MacFarlane J., RA O'Driscoll M., Brais B., Meilleur S., Brinkman R.R., Dadivas O., Pape T., RA Platon C., Radomski C., Risler J., Thompson J., Guerra-Escobio A.-M., RA Davar G., Breakefield X.O., Pimstone S.N., Green R., Pryse-Phillips W., RA Goldberg Y.P., Younghusband H.B., Hayden M.R., Sherrington R., RA Rouleau G.A., Samuels M.E.; RT "Identification of a novel gene (HSN2) causing hereditary sensory and RT autonomic neuropathy type II through the study of Canadian genetic RT isolates."; RL Am. J. Hum. Genet. 74:1064-1073(2004). RN [12] {ECO:0000305} RP INVOLVEMENT IN PHA2C. RX PubMed=11498583; DOI=10.1126/science.1062844; RA Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., RA Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W., RA Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H., RA Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P.; RT "Human hypertension caused by mutations in WNK kinases."; RL Science 293:1107-1112(2001). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-382. RX PubMed=15883153; DOI=10.1074/jbc.m502598200; RA Lenertz L.Y., Lee B.H., Min X., Xu B.E., Wedin K., Earnest S., RA Goldsmith E.J., Cobb M.H.; RT "Properties of WNK1 and implications for other family members."; RL J. Biol. Chem. 280:26653-26658(2005). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, ACTIVITY REGULATION, DOMAIN, RP PHOSPHORYLATION AT SER-382, AND MUTAGENESIS OF LYS-233; ASP-368; SER-382; RP PHE-1258; PHE-1860; PHE-1946 AND PHE-1958. RX PubMed=16263722; DOI=10.1074/jbc.m510042200; RA Moriguchi T., Urushiyama S., Hisamoto N., Iemura S., Uchida S., Natsume T., RA Matsumoto K., Shibuya H.; RT "WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters RT via the STE20-related kinases, SPAK and OSR1."; RL J. Biol. Chem. 280:42685-42693(2005). RN [15] RP INVOLVEMENT IN HSAN2A. RX PubMed=15911806; DOI=10.1212/01.wnl.0000161849.29944.43; RA Roddier K., Thomas T., Marleau G., Gagnon A.M., Dicaire M.J., St Denis A., RA Gosselin I., Sarrazin A.M., Larbrisseau A., Lambert M., Vanasse M., RA Gaudet D., Rouleau G.A., Brais B.; RT "Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in RT French Canadians."; RL Neurology 64:1762-1767(2005). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2002 AND SER-2032, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [18] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT RP SER-382, AND MUTAGENESIS OF SER-382. RX PubMed=16832045; DOI=10.1073/pnas.0604607103; RA Anselmo A.N., Earnest S., Chen W., Juang Y.C., Kim S.C., Zhao Y., RA Cobb M.H.; RT "WNK1 and OSR1 regulate the Na+, K+, 2Cl- cotransporter in HeLa cells."; RL Proc. Natl. Acad. Sci. U.S.A. 103:10883-10888(2006). RN [19] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT SER-15; SER-167; SER-382; THR-1848; SER-1261; SER-2012; RP SER-2029; SER-2032 AND SER-2372, AND MUTAGENESIS OF ASP-368 AND SER-382. RX PubMed=17190791; DOI=10.1083/jcb.200605093; RA Zagorska A., Pozo-Guisado E., Boudeau J., Vitari A.C., Rafiqi F.H., RA Thastrup J., Deak M., Campbell D.G., Morrice N.A., Prescott A.R., RA Alessi D.R.; RT "Regulation of activity and localization of the WNK1 protein kinase by RT hyperosmotic stress."; RL J. Cell Biol. 176:89-100(2007). RN [20] RP ALTERNATIVE SPLICING (ISOFORMS 4 AND 5), AND INVOLVEMENT IN HSAN2A. RX PubMed=18521183; DOI=10.1172/jci34088; RA Shekarabi M., Girard N., Riviere J.B., Dion P., Houle M., Toulouse A., RA Lafreniere R.G., Vercauteren F., Hince P., Laganiere J., Rochefort D., RA Faivre L., Samuels M., Rouleau G.A.; RT "Mutations in the nervous system--specific HSN2 exon of WNK1 cause RT hereditary sensory neuropathy type II."; RL J. Clin. Invest. 118:2496-2505(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-2011; RP SER-2012; SER-2027; SER-2029 AND SER-2032, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [24] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY RP REGULATION. RX PubMed=19739668; DOI=10.1021/bi900666n; RA Yagi Y.I., Abe K., Ikebukuro K., Sode K.; RT "Kinetic mechanism and inhibitor characterization of WNK1 kinase."; RL Biochemistry 48:10255-10266(2009). RN [25] RP FUNCTION. RX PubMed=19665974; DOI=10.1016/j.cell.2009.05.031; RA Rinehart J., Maksimova Y.D., Tanis J.E., Stone K.L., Hodson C.A., Zhang J., RA Risinger M., Pan W., Wu D., Colangelo C.M., Forbush B., Joiner C.H., RA Gulcicek E.E., Gallagher P.G., Lifton R.P.; RT "Sites of regulated phosphorylation that control K-Cl cotransporter RT activity."; RL Cell 138:525-536(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-1978; RP SER-2032 AND SER-2121, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21321328; DOI=10.1242/jcs.077230; RA Richardson C., Sakamoto K., de los Heros P., Deak M., Campbell D.G., RA Prescott A.R., Alessi D.R.; RT "Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and RT -independent pathways."; RL J. Cell Sci. 124:789-800(2011). RN [30] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21220314; DOI=10.1073/pnas.1018567108; RA Tu S.W., Bugde A., Luby-Phelps K., Cobb M.H.; RT "WNK1 is required for mitosis and abscission."; RL Proc. Natl. Acad. Sci. U.S.A. 108:1385-1390(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2027; SER-2029 AND SER-2032, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF VAL-318. RX PubMed=22989884; DOI=10.1074/jbc.m112.398750; RA Sengupta S., Tu S.W., Wedin K., Earnest S., Stippec S., Luby-Phelps K., RA Cobb M.H.; RT "Interactions with WNK (with no lysine) family members regulate oxidative RT stress response 1 and ion co-transporter activity."; RL J. Biol. Chem. 287:37868-37879(2012). RN [33] RP UBIQUITINATION BY KLHL2. RX PubMed=23838290; DOI=10.1016/j.bbrc.2013.06.104; RA Takahashi D., Mori T., Wakabayashi M., Mori Y., Susa K., Zeniya M., RA Sohara E., Rai T., Sasaki S., Uchida S.; RT "KLHL2 interacts with and ubiquitinates WNK kinases."; RL Biochem. Biophys. Res. Commun. 437:457-462(2013). RN [34] RP UBIQUITINATION. RX PubMed=23387299; DOI=10.1042/bj20121903; RA Ohta A., Schumacher F.R., Mehellou Y., Johnson C., Knebel A., RA Macartney T.J., Wood N.T., Alessi D.R., Kurz T.; RT "The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome RT interacts with and ubiquitylates WNK isoforms: disease-causing mutations in RT KLHL3 and WNK4 disrupt interaction."; RL Biochem. J. 451:111-122(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-167; SER-174; RP SER-1261; SER-2029; SER-2032; SER-2370 AND SER-2372, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP UBIQUITINATION. RX PubMed=23576762; DOI=10.1073/pnas.1304592110; RA Shibata S., Zhang J., Puthumana J., Stone K.L., Lifton R.P.; RT "Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via RT ubiquitination and degradation of WNK4."; RL Proc. Natl. Acad. Sci. U.S.A. 110:7838-7843(2013). RN [37] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167; SER-174; SER-1978 AND RP SER-2027, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [38] RP FUNCTION. RX PubMed=25362046; DOI=10.1073/pnas.1419057111; RA Dbouk H.A., Weil L.M., Perera G.K., Dellinger M.T., Pearson G., RA Brekken R.A., Cobb M.H.; RT "Actions of the protein kinase WNK1 on endothelial cells are differentially RT mediated by its substrate kinases OSR1 and SPAK."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15999-16004(2014). RN [39] RP FUNCTION. RX PubMed=25477473; DOI=10.1152/ajprenal.00612.2014; RA Roy A., Goodman J.H., Begum G., Donnelly B.F., Pittman G., Weinman E.J., RA Sun D., Subramanya A.R.; RT "Generation of WNK1 knockout cell lines by CRISPR/Cas-mediated genome RT editing."; RL Am. J. Physiol. 308:F366-F376(2015). RN [40] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH UVRAG. RX PubMed=27911840; DOI=10.1073/pnas.1617649113; RA Gallolu Kankanamalage S., Lee A.Y., Wichaidit C., Lorente-Rodriguez A., RA Shah A.M., Stippec S., Whitehurst A.W., Cobb M.H.; RT "Multistep regulation of autophagy by WNK1."; RL Proc. Natl. Acad. Sci. U.S.A. 113:14342-14347(2016). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=29196535; DOI=10.1101/gad.303677.117; RA Volanakis A., Kamieniarz-Gdula K., Schlackow M., Proudfoot N.J.; RT "WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export RT with transcription."; RL Genes Dev. 31:2175-2185(2017). RN [42] RP MUTAGENESIS OF GLY-1255 AND ARG-1257. RX PubMed=29581290; DOI=10.1073/pnas.1802339115; RA Taylor C.A. IV, An S.W., Kankanamalage S.G., Stippec S., Earnest S., RA Trivedi A.T., Yang J.Z., Mirzaei H., Huang C.L., Cobb M.H.; RT "OSR1 regulates a subset of inward rectifier potassium channels via a RT binding motif variant."; RL Proc. Natl. Acad. Sci. U.S.A. 115:3840-3845(2018). RN [43] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-378 AND SER-382. RX PubMed=31656913; DOI=10.1021/acsomega.9b02187; RA Jonniya N.A., Sk M.F., Kar P.; RT "Investigating phosphorylation-induced conformational changes in WNK1 RT kinase by molecular dynamics simulations."; RL ACS Omega 4:17404-17416(2019). RN [44] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-382. RX PubMed=34289367; DOI=10.1016/j.celrep.2021.109416; RA Schiapparelli P., Pirman N.L., Mohler K., Miranda-Herrera P.A., Zarco N., RA Kilic O., Miller C., Shah S.R., Rogulina S., Hungerford W., Abriola L., RA Hoyer D., Turk B.E., Guerrero-Cazares H., Isaacs F.J., RA Quinones-Hinojosa A., Levchenko A., Rinehart J.; RT "Phosphorylated WNK kinase networks in recoded bacteria recapitulate RT physiological function."; RL Cell Rep. 36:109416-109416(2021). RN [45] RP FUNCTION, INTERACTION WITH EMC2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP PHE-2246; ASP-2248; ASP-2249; LEU-2250; HIS-2251; LEU-2253; TRP-2257 AND RP ASP-2260. RX PubMed=33964204; DOI=10.1016/j.molcel.2021.04.013; RA Pleiner T., Hazu M., Tomaleri G.P., Januszyk K., Oania R.S., RA Sweredoski M.J., Moradian A., Guna A., Voorhees R.M.; RT "WNK1 is an assembly factor for the human ER membrane protein complex."; RL Mol. Cell 81:2693-2704(2021). RN [46] RP FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND DOMAIN. RX PubMed=36318922; DOI=10.1016/j.cell.2022.09.042; RA Boyd-Shiwarski C.R., Shiwarski D.J., Griffiths S.E., Beacham R.T., RA Norrell L., Morrison D.E., Wang J., Mann J., Tennant W., Anderson E.N., RA Franks J., Calderon M., Connolly K.A., Cheema M.U., Weaver C.J., RA Nkashama L.J., Weckerly C.C., Querry K.E., Pandey U.B., Donnelly C.J., RA Sun D., Rodan A.R., Subramanya A.R.; RT "WNK kinases sense molecular crowding and rescue cell volume via phase RT separation."; RL Cell 185:4488-4506(2022). RN [47] RP FUNCTION, INTERACTION WITH SGK1, INTERACTION WITH THE MTORC2 COMPLEX, AND RP MUTAGENESIS OF LYS-233. RX PubMed=36373794; DOI=10.1242/jcs.260313; RA Saha B., Leite-Dellova D.C.A., Demko J., Soerensen M.V., Takagi E., RA Gleason C.E., Shabbir W., Pearce D.; RT "WNK1 is a chloride-stimulated scaffold that regulates mTORC2 activity and RT ion transport."; RL J. Cell Sci. 135:0-0(2022). RN [48] {ECO:0007744|PDB:4PWN} RP X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 210-482. RX PubMed=24803536; DOI=10.1126/scisignal.2005050; RA Piala A.T., Moon T.M., Akella R., He H., Cobb M.H., Goldsmith E.J.; RT "Chloride sensing by WNK1 involves inhibition of autophosphorylation."; RL Sci. Signal. 7:RA41-RA41(2014). RN [49] {ECO:0007744|PDB:5TF9} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP AND RP ALLOSTERIC INHIBITOR. RX PubMed=27712055; DOI=10.1021/acschembio.6b00511; RA Yamada K., Zhang J.H., Xie X., Reinhardt J., Xie A.Q., LaSala D., Kohls D., RA Yowe D., Burdick D., Yoshisue H., Wakai H., Schmidt I., Gunawan J., RA Yasoshima K., Yue Q.K., Kato M., Mogi M., Idamakanti N., Kreder N., RA Drueckes P., Pandey P., Kawanami T., Huang W., Yagi Y.I., Deng Z., RA Park H.M.; RT "Discovery and characterization of allosteric WNK kinase inhibitors."; RL ACS Chem. Biol. 11:3338-3346(2016). RN [50] {ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP RP ANALOG AND ALLOSTERIC INHIBITOR. RX PubMed=28771350; DOI=10.1021/acs.jmedchem.7b00708; RA Yamada K., Levell J., Yoon T., Kohls D., Yowe D., Rigel D.F., Imase H., RA Yuan J., Yasoshima K., DiPetrillo K., Monovich L., Xu L., Zhu M., Kato M., RA Jain M., Idamakanti N., Taslimi P., Kawanami T., Argikar U.A., RA Kunjathoor V., Xie X., Yagi Y.I., Iwaki Y., Robinson Z., Park H.M.; RT "Optimization of allosteric With-No-Lysine (WNK) kinase inhibitors and RT efficacy in rodent hypertension models."; RL J. Med. Chem. 60:7099-7107(2017). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-1199 AND GLU-1799. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] THR-141; VAL-149; GLN-419; THR-509; RP GLY-527; ILE-665; ALA-674; ARG-823; VAL-1546; GLU-1799; ILE-1808; LEU-1823; RP HIS-1957; CYS-2190; LEU-2362 AND TRP-2380. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase component of the WNK1- CC SPAK/OSR1 kinase cascade, which acts as a key regulator of blood CC pressure and regulatory volume increase by promoting ion influx CC (PubMed:15883153, PubMed:17190791, PubMed:31656913, PubMed:34289367, CC PubMed:36318922). WNK1 mediates regulatory volume increase in response CC to hyperosmotic stress by acting as a molecular crowding sensor, which CC senses cell shrinkage and mediates formation of a membraneless CC compartment by undergoing liquid-liquid phase separation CC (PubMed:36318922). The membraneless compartment concentrates WNK1 with CC its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK1-dependent CC phosphorylation and activation of downstream kinases OXSR1/OSR1 and CC STK39/SPAK (PubMed:15883153, PubMed:16263722, PubMed:17190791, CC PubMed:19739668, PubMed:21321328, PubMed:22989884, PubMed:25477473, CC PubMed:34289367, PubMed:36318922). Following activation, OXSR1/OSR1 and CC STK39/SPAK catalyze phosphorylation of ion cotransporters CC SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A5/KCC2 and SLC12A6/KCC3, regulating CC their activity (PubMed:16263722, PubMed:21321328). Phosphorylation of CC Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their CC activation and ion influx; simultaneously, phosphorylation of K-Cl CC cotransporters SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, CC blocking ion efflux (PubMed:19665974, PubMed:21321328). Also acts as a CC regulator of angiogenesis in endothelial cells via activation of CC OXSR1/OSR1 and STK39/SPAK: activation of OXSR1/OSR1 regulates CC chemotaxis and invasion, while STK39/SPAK regulates endothelial cell CC proliferation (PubMed:25362046). Also acts independently of the WNK1- CC SPAK/OSR1 kinase cascade by catalyzing phosphorylation of other CC substrates, such as SYT2, PCF11 and NEDD4L (PubMed:29196535). Mediates CC phosphorylation of SYT2, regulating SYT2 association with phospholipids CC and membrane-binding (By similarity). Regulates mRNA export in the CC nucleus by mediating phosphorylation of PCF11, thereby decreasing the CC association between PCF11 and POLR2A/RNA polymerase II and promoting CC mRNA export to the cytoplasm (PubMed:29196535). Acts as a negative CC regulator of autophagy (PubMed:27911840). Required for the abscission CC step during mitosis, independently of the WNK1-SPAK/OSR1 kinase cascade CC (PubMed:21220314). May also play a role in actin cytoskeletal CC reorganization (PubMed:10660600). Also acts as a scaffold protein CC independently of its protein kinase activity: negatively regulates cell CC membrane localization of various transporters and channels, such as CC SLC4A4, SLC26A6, SLC26A9, TRPV4 and CFTR (By similarity). Involved in CC the regulation of epithelial Na(+) channel (ENaC) by promoting CC activation of SGK1 in a kinase-independent manner: probably acts as a CC scaffold protein that promotes the recruitment of SGK1 to the mTORC2 CC complex in response to chloride, leading to mTORC2-dependent CC phosphorylation and activation of SGK1 (PubMed:36373794). Acts as an CC assembly factor for the ER membrane protein complex independently of CC its protein kinase activity: associates with EMC2 in the cytoplasm via CC its amphipathic alpha-helix, and prevents EMC2 ubiquitination and CC subsequent degradation, thereby promoting EMC2 stabilization CC (PubMed:33964204). {ECO:0000250|UniProtKB:P83741, CC ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19665974, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:22989884, CC ECO:0000269|PubMed:25362046, ECO:0000269|PubMed:25477473, CC ECO:0000269|PubMed:27911840, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913, ECO:0000269|PubMed:33964204, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922, CC ECO:0000269|PubMed:36373794}. CC -!- FUNCTION: [Isoform 3]: Kinase-defective isoform specifically expressed CC in kidney, which acts as a dominant-negative regulator of the longer CC isoform 1 (PubMed:14645531). Does not directly inhibit WNK4 and has no CC direct effect on sodium and chloride ion transport (By similarity). CC Down-regulates sodium-chloride cotransporter activity indirectly by CC inhibiting isoform 1, it associates with isoform 1 and attenuates its CC kinase activity (By similarity). In kidney, may play an important role CC regulating sodium and potassium balance (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:14645531}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:19739668, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:29196535}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10660600}; CC -!- ACTIVITY REGULATION: Activated in response to hyperosmotic stress: cell CC shrinkage promotes formation of a membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK CC (PubMed:36318922). Activation requires autophosphorylation of Ser-382 CC and, to a lower extent, Ser-378 (PubMed:15883153, PubMed:16263722, CC PubMed:16832045, PubMed:17190791, PubMed:31656913, PubMed:34289367). CC Autophosphorylation and subsequent activation is inhibited by increases CC in intracellular ionic strength: Cl(-) potently inhibits WNK1 kinase CC activity via direct binding (By similarity). Also inhibited by K(+) CC ions (By similarity). Inhibited by small compounds staurosporine, CC tyrphostin 47, as well as Src tyrosine kinase inhibitors PP1 and PP2 CC (PubMed:19739668). {ECO:0000250|UniProtKB:Q9JIH7, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.0 uM for ATP {ECO:0000269|PubMed:19739668}; CC KM=68.4 uM for a OXSR1/OSR1 peptide {ECO:0000269|PubMed:19739668}; CC -!- SUBUNIT: Interacts with WNK3 (By similarity). Interacts with WNK4; CC inhibiting the activity of WNK4 (By similarity). Interacts with SGK1; CC promoting its activation (PubMed:36373794). Associates with the mTORC2 CC complex (PubMed:36373794). Interacts with UVRAG (PubMed:27911840). CC Interacts (via amphipathic alpha-helix region) with EMC2; promoting the CC ER membrane protein complex assembly (PubMed:33964204). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36373794}. CC -!- SUBUNIT: [Isoform 3]: Interacts with isoform 1; inhibiting isoform 1 CC activity. {ECO:0000250|UniProtKB:Q9JIH7}. CC -!- INTERACTION: CC Q9H4A3; O95747: OXSR1; NbExp=9; IntAct=EBI-457907, EBI-620853; CC Q9H4A3; P62136: PPP1CA; NbExp=2; IntAct=EBI-457907, EBI-357253; CC Q9H4A3; P31947: SFN; NbExp=4; IntAct=EBI-457907, EBI-476295; CC Q9H4A3; P62258: YWHAE; NbExp=7; IntAct=EBI-457907, EBI-356498; CC Q9H4A3; P61981: YWHAG; NbExp=7; IntAct=EBI-457907, EBI-359832; CC Q9H4A3; P63104: YWHAZ; NbExp=3; IntAct=EBI-457907, EBI-347088; CC Q9H4A3; P29101: Syt2; Xeno; NbExp=2; IntAct=EBI-457907, EBI-458017; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:22989884, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36318922}. Nucleus CC {ECO:0000269|PubMed:29196535}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:21220314}. Note=Mediates formation and localizes to CC cytoplasmic membraneless compartment in response to hyperosmotic stress CC (PubMed:36318922). Also localizes to the nucleus (PubMed:29196535). CC Localizes to the mitotic spindle during mitosis (PubMed:21220314). CC {ECO:0000269|PubMed:21220314, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:36318922}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=6; CC Comment=WNK1 is a complex 33-exons gene, in total 9 WNK1 exons are CC alternatively spliced, some expressed in a tissue-specific manner. CC Additional isoforms seems to exist.; CC Name=1; Synonyms=L-WNK1 {ECO:0000303|PubMed:22701532}; CC IsoId=Q9H4A3-1; Sequence=Displayed; CC Name=2 {ECO:0000303|PubMed:9205841}; CC IsoId=Q9H4A3-2; Sequence=VSP_040269, VSP_050638; CC Name=3; Synonyms=KS-WNK1, Kidney-Specific; CC IsoId=Q9H4A3-4; Sequence=VSP_050634, VSP_050637; CC Name=4; Synonyms=Brain and spinal cord variant; CC IsoId=Q9H4A3-5; Sequence=VSP_040268; CC Name=5; Synonyms=Dorsal root ganglia and sciatic nerve variant, DRG and CC sciatic nerve variant; CC IsoId=Q9H4A3-6; Sequence=VSP_040267, VSP_040270; CC Name=6; CC IsoId=Q9H4A3-7; Sequence=VSP_040267, VSP_053767; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels observed in CC the testis, heart, kidney and skeletal muscle. CC {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:11571656, CC ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Strong expression in dorsal root CC ganglia and spinal cord. {ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 3]: This isoform is kidney-specific and CC specifically expressed in the distal convoluted tubule (DCT) and CC connecting tubule (CNT) of the nephron. {ECO:0000269|PubMed:14645531}. CC -!- DOMAIN: Disordered regions undergo liquid-liquid phase separation CC (LLPS) for the formation of a cytoplasmic membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK. CC {ECO:0000269|PubMed:36318922}. CC -!- DOMAIN: The RFXV motifs mediate recognition with downstream kinases CC OXSR1/OSR1 and STK39/SPAK. {ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:22989884}. CC -!- PTM: Autophosphorylated at Ser-378 and Ser-382, promoting its activity CC (PubMed:15883153, PubMed:16263722, PubMed:16832045, PubMed:17190791, CC PubMed:31656913, PubMed:34289367). Autophosphorylation at Ser-382 is CC inhibited by intracellular calcium (By similarity). Phosphorylation at CC Thr-60 increases ability to activate SGK1 (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367}. CC -!- PTM: Ubiquitinated by the BCR(KLHL3) complex, leading to its CC degradation (PubMed:23387299, PubMed:23576762). Also ubiquitinated by CC the BCR(KLHL2) complex (PubMed:23838290). {ECO:0000269|PubMed:23387299, CC ECO:0000269|PubMed:23576762, ECO:0000269|PubMed:23838290}. CC -!- PTM: May be O-glycosylated. {ECO:0000269|PubMed:2507249}. CC -!- DISEASE: Pseudohypoaldosteronism 2C (PHA2C) [MIM:614492]: An autosomal CC dominant disorder characterized by severe hypertension, hyperkalemia, CC hyperchloremia, mild hyperchloremic metabolic acidosis in some cases, CC and correction of physiologic abnormalities by thiazide diuretics. CC {ECO:0000269|PubMed:11498583}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 2A (HSAN2A) CC [MIM:201300]: A form of hereditary sensory and autonomic neuropathy, a CC genetically and clinically heterogeneous group of disorders CC characterized by degeneration of dorsal root and autonomic ganglion CC cells, and by sensory and/or autonomic abnormalities. HSAN2A is an CC autosomal recessive disorder characterized by impairment of pain, CC temperature and touch sensation, onset of symptoms in infancy or early CC childhood, occurrence of distal extremity pathologies (paronychia, CC whitlows, ulcers, and Charcot joints), frequent amputations, sensory CC loss that affects all modalities of sensation (lower and upper limbs CC and perhaps the trunk as well), absence or diminution of tendon CC reflexes (usually in all limbs), minimal autonomic dysfunction, absence CC of sensory nerve action potentials, and virtual absence of myelinated CC fibers with decreased numbers of unmyelinated fibers in sural nerves. CC {ECO:0000269|PubMed:15060842, ECO:0000269|PubMed:15911806, CC ECO:0000269|PubMed:18521183}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 4]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for CC catalysis, including the lysine involved in ATP binding, are either not CC conserved or differ compared to the residues described in other kinase CC family proteins. {ECO:0000305|PubMed:27712055}. CC -!- CAUTION: HSN2 was originally thought to be an intronless gene lying CC within a WNK1 gene intron. It has been shown to be a nervous system- CC specific exon of WNK1 included in isoform 4 and isoform 5 CC (PubMed:18521183). {ECO:0000305|PubMed:18521183}. CC -!- CAUTION: It is uncertain whether Met-1 or Met-214 is the initiator in CC isoform 4 and isoform 5. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF31483.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305}; CC Sequence=AAI30468.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI30470.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=DAA04494.1; Type=Erroneous gene model prediction; Note=Includes 3' and 3' intronic sequences.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ296290; CAC15059.1; -; mRNA. DR EMBL; JQ358908; AEY99342.1; -; mRNA. DR EMBL; FJ515833; ACS13726.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13727.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13728.1; -; Genomic_DNA. DR EMBL; AC004765; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AF061944; AAF31483.1; ALT_SEQ; mRNA. DR EMBL; AB002342; BAA20802.2; -; mRNA. DR EMBL; AY231477; AAO46160.1; -; mRNA. DR EMBL; BC013629; AAH13629.2; -; mRNA. DR EMBL; BC130467; AAI30468.1; ALT_SEQ; mRNA. DR EMBL; BC130469; AAI30470.1; ALT_SEQ; mRNA. DR EMBL; BK004108; DAA04494.1; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS73419.1; -. [Q9H4A3-5] DR CCDS; CCDS8506.1; -. [Q9H4A3-1] DR RefSeq; NP_001171914.1; NM_001184985.2. [Q9H4A3-6] DR RefSeq; NP_055638.2; NM_014823.2. DR RefSeq; NP_061852.3; NM_018979.4. [Q9H4A3-1] DR RefSeq; NP_998820.3; NM_213655.5. [Q9H4A3-5] DR RefSeq; XP_016875326.1; XM_017019837.1. DR RefSeq; XP_016875327.1; XM_017019838.2. [Q9H4A3-2] DR PDB; 4PWN; X-ray; 1.84 A; A=210-482. DR PDB; 5TF9; X-ray; 2.50 A; A/B=206-483. DR PDB; 5WDY; X-ray; 2.46 A; A/B=206-483. DR PDB; 5WE8; X-ray; 2.01 A; A/B=206-483. DR PDB; 6FBK; X-ray; 1.74 A; P=1247-1269. DR PDBsum; 4PWN; -. DR PDBsum; 5TF9; -. DR PDBsum; 5WDY; -. DR PDBsum; 5WE8; -. DR PDBsum; 6FBK; -. DR AlphaFoldDB; Q9H4A3; -. DR BMRB; Q9H4A3; -. DR SMR; Q9H4A3; -. DR BioGRID; 122403; 141. DR CORUM; Q9H4A3; -. DR DIP; DIP-32648N; -. DR ELM; Q9H4A3; -. DR FunCoup; Q9H4A3; 2655. DR IntAct; Q9H4A3; 121. DR MINT; Q9H4A3; -. DR STRING; 9606.ENSP00000341292; -. DR BindingDB; Q9H4A3; -. DR ChEMBL; CHEMBL1075173; -. DR GuidetoPHARMACOLOGY; 2280; -. DR MoonDB; Q9H4A3; Predicted. DR TCDB; 8.A.23.1.69; the basigin (basigin) family. DR GlyConnect; 484; 1 O-GlcNAc glycan. DR GlyCosmos; Q9H4A3; 38 sites, 2 glycans. DR GlyGen; Q9H4A3; 67 sites, 2 O-linked glycans (64 sites). DR iPTMnet; Q9H4A3; -. DR MetOSite; Q9H4A3; -. DR PhosphoSitePlus; Q9H4A3; -. DR BioMuta; WNK1; -. DR DMDM; 296453029; -. DR jPOST; Q9H4A3; -. DR MassIVE; Q9H4A3; -. DR PeptideAtlas; Q9H4A3; -. DR ProteomicsDB; 80804; -. [Q9H4A3-1] DR ProteomicsDB; 80805; -. [Q9H4A3-2] DR ProteomicsDB; 80806; -. [Q9H4A3-4] DR ProteomicsDB; 80807; -. [Q9H4A3-5] DR ProteomicsDB; 80808; -. [Q9H4A3-6] DR Pumba; Q9H4A3; -. DR Antibodypedia; 22083; 602 antibodies from 42 providers. DR DNASU; 65125; -. DR Ensembl; ENST00000315939.11; ENSP00000313059.6; ENSG00000060237.20. [Q9H4A3-1] DR Ensembl; ENST00000340908.9; ENSP00000341292.5; ENSG00000060237.20. [Q9H4A3-5] DR Ensembl; ENST00000530271.6; ENSP00000433548.3; ENSG00000060237.20. [Q9H4A3-7] DR Ensembl; ENST00000537687.5; ENSP00000444465.1; ENSG00000060237.20. [Q9H4A3-6] DR Ensembl; ENST00000675631.1; ENSP00000502415.1; ENSG00000060237.20. [Q9H4A3-4] DR GeneID; 65125; -. DR KEGG; hsa:65125; -. DR MANE-Select; ENST00000315939.11; ENSP00000313059.6; NM_018979.4; NP_061852.3. DR UCSC; uc001qio.4; human. [Q9H4A3-1] DR AGR; HGNC:14540; -. DR CIViC; 65125; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33782; -. DR CTD; 65125; -. DR DisGeNET; 65125; -. DR GeneCards; WNK1; -. DR GeneReviews; WNK1; -. DR HGNC; HGNC:14540; WNK1. DR HPA; ENSG00000060237; Low tissue specificity. DR MalaCards; WNK1; -. DR MIM; 201300; phenotype. DR MIM; 605232; gene. DR MIM; 614492; phenotype. DR OpenTargets; ENSG00000060237; -. DR Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2. DR Orphanet; 88940; Pseudohypoaldosteronism type 2C. DR VEuPathDB; HostDB:ENSG00000060237; -. DR eggNOG; KOG0584; Eukaryota. DR GeneTree; ENSGT00940000155474; -. DR InParanoid; Q9H4A3; -. DR OMA; PEPNGMT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q9H4A3; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q9H4A3; -. DR PathwayCommons; Q9H4A3; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR SignaLink; Q9H4A3; -. DR SIGNOR; Q9H4A3; -. DR Agora; ENSG00000060237; -. DR BioGRID-ORCS; 65125; 582 hits in 1210 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; WNK1; human. DR EvolutionaryTrace; Q9H4A3; -. DR GeneWiki; WNK1; -. DR GenomeRNAi; 65125; -. DR Pharos; Q9H4A3; Tchem. DR PRO; PR:Q9H4A3; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9H4A3; protein. DR Bgee; ENSG00000060237; Expressed in medial globus pallidus and 204 other cell types or tissues. DR ExpressionAtlas; Q9H4A3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043232; C:intracellular membraneless organelle; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:ParkinsonsUK-UCL. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0019902; F:phosphatase binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006884; P:cell volume homeostasis; IDA:UniProtKB. DR GO; GO:0071474; P:cellular hyperosmotic response; IDA:UniProtKB. DR GO; GO:1990869; P:cellular response to chemokine; IMP:BHF-UCL. DR GO; GO:0038116; P:chemokine (C-C motif) ligand 21 signaling pathway; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IBA:GO_Central. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0030644; P:intracellular chloride ion homeostasis; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0097022; P:lymphocyte migration into lymph node; ISS:BHF-UCL. DR GO; GO:0140694; P:membraneless organelle assembly; IDA:UniProtKB. DR GO; GO:0055080; P:monoatomic cation homeostasis; ISS:UniProtKB. DR GO; GO:0006811; P:monoatomic ion transport; ISS:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB. DR GO; GO:0033633; P:negative regulation of cell-cell adhesion mediated by integrin; IMP:BHF-UCL. DR GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0090188; P:negative regulation of pancreatic juice secretion; IEA:Ensembl. DR GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; ISS:UniProtKB. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IMP:BHF-UCL. DR GO; GO:0010766; P:negative regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0048666; P:neuron development; NAS:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:FlyBase. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; IDA:UniProtKB. DR GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:BHF-UCL. DR GO; GO:1904595; P:positive regulation of termination of RNA polymerase II transcription; IDA:UniProtKB. DR GO; GO:0055075; P:potassium ion homeostasis; IEA:Ensembl. DR GO; GO:0045050; P:protein insertion into ER membrane by stop-transfer membrane-anchor sequence; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; IMP:ARUK-UCL. DR GO; GO:0010793; P:regulation of mRNA export from nucleus; IDA:UniProtKB. DR GO; GO:1902305; P:regulation of sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:ParkinsonsUK-UCL. DR GO; GO:0035725; P:sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:BHF-UCL. DR CDD; cd14030; STKc_WNK1; 1. DR FunFam; 3.10.20.90:FF:000007; Serine/threonine-protein kinase WNK1 isoform 1; 1. DR FunFam; 1.10.510.10:FF:000006; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.10.20.90:FF:000012; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000494; serine/threonine-protein kinase WNK2 isoform X2; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR056865; CCTL2_WNK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024678; Kinase_OSR1/WNK_CCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050588; WNK_Ser-Thr_kinase. DR PANTHER; PTHR13902; SERINE/THREONINE-PROTEIN KINASE WNK WITH NO LYSINE -RELATED; 1. DR Pfam; PF24889; CCTL2_WNK; 1. DR Pfam; PF12202; OSR1_C; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Chloride; Cytoplasm; Cytoskeleton; Direct protein sequencing; KW Glycoprotein; Kinase; Neurodegeneration; Neuropathy; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..2382 FT /note="Serine/threonine-protein kinase WNK1" FT /id="PRO_0000086819" FT DOMAIN 221..479 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..81 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 95..203 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 488..555 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT REGION 573..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 628..638 FT /note="Interaction with KLHL3" FT /evidence="ECO:0000250|UniProtKB:Q96J92" FT REGION 1018..1041 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1053..1119 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1457..1476 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1733..1790 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1948 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1994..2069 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2101..2196 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2241..2261 FT /note="Amphipathic alpha-helix" FT /evidence="ECO:0000269|PubMed:33964204" FT REGION 2332..2352 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1257..1260 FT /note="RFXV motif 1" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1859..1862 FT /note="RFXV motif 2" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1945..1948 FT /note="RFXV motif 3" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1957..1960 FT /note="RFXV motif 4" FT /evidence="ECO:0000269|PubMed:16263722" FT COMPBIAS 50..66 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 95..108 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 125..153 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 573..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..614 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 615..625 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..689 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 709..779 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1025..1041 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1053..1077 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1080..1090 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1098..1119 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1457..1467 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1733..1745 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1869..1884 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1887..1905 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1927..1940 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1994..2003 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2035..2062 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2122..2134 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2135..2145 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2146..2167 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2175..2196 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 368 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:16263722" FT BINDING 231 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 283 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 299 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 301..304 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 351 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 369 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 371 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 15 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 19 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 60 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 167 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 174 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 378 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:31656913" FT MOD_RES 382 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15883153, FT ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, FT ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, FT ECO:0000269|PubMed:34289367" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 1848 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 1978 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 2002 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983" FT MOD_RES 2011 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2012 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2027 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 2029 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2032 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2121 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2286 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2372 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..407 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050634" FT VAR_SEQ 408..437 FT /note="FGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDIKKKDFCSVFVIINSH FT CCCCPQKDCINE (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050637" FT VAR_SEQ 713 FT /note="V -> VPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQR FT RKSTSFLEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQV FT HPMFEPSQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSS FT PMKQIPEQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTD FT ATRLKFHPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQV FT AVDLNQEELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSS FT QITSSDPSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLT FT ASFSSGGSALHPQ (in isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_040267" FT VAR_SEQ 714..1037 FT /note="AQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHF FT LPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTA FT AIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVL FT YQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVES FT NLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLE -> PRRGRSMSVCVPIFLLLPL FT CPASLPVLFHPTASTVCTSFSFPPPDCPEETFAEKLSKALESVLPMHSASQRKHRRSSL FT PSLFVSTPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQRRKSTSF FT LEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQVHPMFEP FT SQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSSPMKQIP FT EQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTDATRLKF FT HPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQVAVDLNQ FT EELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSSQITSSD FT PSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLTASFSSG FT GSALHPQAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQ (in isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_040268" FT VAR_SEQ 740 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_040269" FT VAR_SEQ 792..1037 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_050638" FT VAR_SEQ 792..944 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_040270" FT VAR_SEQ 2215 FT /note="G -> GCAKFNCASEQVTFKPGGRRTRFLRKMVKKVCPCNQLCR (in FT isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_053767" FT VARIANT 141 FT /note="A -> T (in dbSNP:rs11554421)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041309" FT VARIANT 149 FT /note="A -> V (in dbSNP:rs34880640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041310" FT VARIANT 419 FT /note="E -> Q (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041311" FT VARIANT 509 FT /note="I -> T (in dbSNP:rs34728563)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041312" FT VARIANT 527 FT /note="D -> G (in dbSNP:rs34408667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041313" FT VARIANT 665 FT /note="T -> I (in dbSNP:rs2286007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019992" FT VARIANT 674 FT /note="T -> A (in dbSNP:rs11833299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041314" FT VARIANT 823 FT /note="H -> R (in dbSNP:rs56015776)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041315" FT VARIANT 1056 FT /note="T -> P (in dbSNP:rs956868)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059033" FT VARIANT 1199 FT /note="E -> G (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035640" FT VARIANT 1506 FT /note="C -> S (in dbSNP:rs7955371)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059034" FT VARIANT 1546 FT /note="A -> V (in dbSNP:rs56351358)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041316" FT VARIANT 1799 FT /note="Q -> E (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035641" FT VARIANT 1808 FT /note="M -> I (in dbSNP:rs12828016)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_041317" FT VARIANT 1823 FT /note="P -> L (in dbSNP:rs17755373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041318" FT VARIANT 1957 FT /note="R -> H (in dbSNP:rs36083875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041319" FT VARIANT 2190 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041320" FT VARIANT 2362 FT /note="F -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041321" FT VARIANT 2380 FT /note="R -> W (in dbSNP:rs56262445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041322" FT MUTAGEN 233 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity. Does not affect ability to activate SGK1." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:36373794" FT MUTAGEN 318 FT /note="V->E: Does not affect ability to phosphorylate FT OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:22989884" FT MUTAGEN 368 FT /note="D->A: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:17190791" FT MUTAGEN 382 FT /note="S->A: Decreased autophosphorylation, preventing FT activation of the serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791" FT MUTAGEN 1255 FT /note="G->R,N,D,C,Q,H,I,L,K,M,F,P,S,T,W,Y,V: Does not FT affect binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1257 FT /note="R->A,N,C,E,Q,H,I,L,K,M,F,S,T,W,Y,V: Does not affect FT binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1258 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1860. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1860, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1860 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1258. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1946 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1958. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1257, FT A-1860 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1958 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1946. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1860 and A-1946." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 2246 FT /note="F->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2248 FT /note="D->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2249 FT /note="D->A,K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2250 FT /note="Missing: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2251 FT /note="H->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2253 FT /note="L->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2257 FT /note="W->K,L,A: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2260 FT /note="D->A,K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT CONFLICT 164 FT /note="R -> S (in Ref. 8; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1836 FT /note="Missing (in Ref. 6; BAA20802)" FT /evidence="ECO:0000305" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 216..218 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 220..228 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 231..240 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 241..244 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 245..252 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 266..273 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 291..295 FT /evidence="ECO:0007829|PDB:5WDY" FT STRAND 297..302 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 309..316 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 321..340 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 355..358 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 359..362 FT /evidence="ECO:0007829|PDB:5WE8" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 377..380 FT /evidence="ECO:0007829|PDB:5WE8" FT HELIX 392..396 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 402..417 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 421..424 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 428..435 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 442..446 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 450..459 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 470..474 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 1248..1251 FT /evidence="ECO:0007829|PDB:6FBK" FT STRAND 1257..1261 FT /evidence="ECO:0007829|PDB:6FBK" SQ SEQUENCE 2382 AA; 250794 MW; 426785F98A452A0A CRC64; MSGGAAEKQS STPGSLFLSP PAPAPKNGSS SDSSVGEKLG AAAADAVTGR TEEYRRRRHT MDKDSRGAAA TTTTTEHRFF RRSVICDSNA TALELPGLPL SLPQPSIPAA VPQSAPPEPH REETVTATAT SQVAQQPPAA AAPGEQAVAG PAPSTVPSST SKDRPVSQPS LVGSKEEPPP ARSGSGGGSA KEPQEERSQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KKKQEESSLK QQVEQSSASQ TGIKQLPSAS TGIPTASTTS ASVSTQVEPE EPEADQHQQL QYQQPSISVL SDGTVDSGQG SSVFTESRVS SQQTVSYGSQ HEQAHSTGTV PGHIPSTVQA QSQPHGVYPP SSVAQGQSQG QPSSSSLTGV SSSQPIQHPQ QQQGIQQTAP PQQTVQYSLS QTSTSSEATT AQPVSQPQAP QVLPQVSAGK QLPVSQPVPT IQGEPQIPVA TQPSVVPVHS GAHFLPVGQP LPTPLLPQYP VSQIPISTPH VSTAQTGFSS LPITMAAGIT QPLLTLASSA TTAAIPGVST VVPSQLPTLL QPVTQLPSQV HPQLLQPAVQ SMGIPANLGQ AAEVPLSSGD VLYQGFPPRL PPQYPGDSNI APSSNVASVC IHSTVLSPPM PTEVLATPGY FPTVVQPYVE SNLLVPMGGV GGQVQVSQPG GSLAQAPTTS SQQAVLESTQ GVSQVAPAEP VAVAQTQATQ PTTLASSVDS AHSDVASGMS DGNENVPSSS GRHEGRTTKR HYRKSVRSRS RHEKTSRPKL RILNVSNKGD RVVECQLETH NRKMVTFKFD LDGDNPEEIA TIMVNNDFIL AIERESFVDQ VREIIEKADE MLSEDVSVEP EGDQGLESLQ GKDDYGFSGS QKLEGEFKQP IPASSMPQQI GIPTSSLTQV VHSAGRRFIV SPVPESRLRE SKVFPSEITD TVAASTAQSP GMNLSHSASS LSLQQAFSEL RRAQMTEGPN TAPPNFSHTG PTFPVVPPFL SSIAGVPTTA AATAPVPATS SPPNDISTSV IQSEVTVPTE EGIAGVATST GVVTSGGLPI PPVSESPVLS SVVSSITIPA VVSISTTSPS LQVPTSTSEI VVSSTALYPS VTVSATSASA GGSTATPGPK PPAVVSQQAA GSTTVGATLT SVSTTTSFPS TASQLCIQLS SSTSTPTLAE TVVVSAHSLD KTSHSSTTGL AFSLSAPSSS SSPGAGVSSY ISQPGGLHPL VIPSVIASTP ILPQAAGPTS TPLLPQVPSI PPLVQPVANV PAVQQTLIHS QPQPALLPNQ PHTHCPEVDS DTQPKAPGID DIKTLEEKLR SLFSEHSSSG AQHASVSLET SLVIESTVTP GIPTTAVAPS KLLTSTTSTC LPPTNLPLGT VALPVTPVVT PGQVSTPVST TTSGVKPGTA PSKPPLTKAP VLPVGTELPA GTLPSEQLPP FPGPSLTQSQ QPLEDLDAQL RRTLSPEMIT VTSAVGPVSM AAPTAITEAG TQPQKGVSQV KEGPVLATSS GAGVFKMGRF QVSVAADGAQ KEGKNKSEDA KSVHFESSTS ESSVLSSSSP ESTLVKPEPN GITIPGISSD VPESAHKTTA SEAKSDTGQP TKVGRFQVTT TANKVGRFSV SKTEDKITDT KKEGPVASPP FMDLEQAVLP AVIPKKEKPE LSEPSHLNGP SSDPEAAFLS RDVDDGSGSP HSPHQLSSKS LPSQNLSQSL SNSFNSSYMS SDNESDIEDE DLKLELRRLR DKHLKEIQDL QSRQKHEIES LYTKLGKVPP AVIIPPAAPL SGRRRRPTKS KGSKSSRSSS LGNKSPQLSG NLSGQSAASV LHPQQTLHPP GNIPESGQNQ LLQPLKPSPS SDNLYSAFTS DGAISVPSLS APGQGTSSTN TVGATVNSQA AQAQPPAMTS SRKGTFTDDL HKLVDNWARD AMNLSGRRGS KGHMNYEGPG MARKFSAPGQ LCISMTSNLG GSAPISAASA TSLGHFTKSM CPPQQYGFPA TPFGAQWSGT GGPAPQPLGQ FQPVGTASLQ NFNISNLQKS ISNPPGSNLR TT //